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CHAPTER I 
REDUCTION OF AROMATIC AND ALIPHATIC NITRO COMPOUNDS USING 
DISSOLVED METAL REDUCTION PROCESSES 
 
Introduction 
 Tandem reactions are often referred as ‘multistep one-pot syntheses’.1  The term 
tandem reaction involves breaking and forming of several bonds in a single tep sequence 
to generate complex molecules with a high degree of stereoselectivity.2   The terms 
‘tandem’, ‘cascade’, ‘one-pot’, ‘zipper’, ‘iterative’, one-flask’, ‘sequential’ and ‘domino’ 
are used as synonyms for this class of reactions.     
The advantages of tandem reactions include: (1) all the transformati n occur in 
the same flask in a single laboratory operations; (2) economically less waste and fewer 
byproducts are generated by the use of a tandem reaction sequenc ; and (3) the process of 
purification becomes much simpler by avoiding the isolation of intermediates.  
 The use of tandem reactions initiated by the reduction of nitroaromatics has 
provided an efficient route to a variety of heterocyclic system.  The synthesis involves 
the reduction of the nitro group which reacts in situ with other reactive functional groups 
present in the substrate to give the heterocyclic ring system.     
The tandem reduction of a nitroaromatic substrate can be done by two meth ds, 
catalytic hydrogenation or dissolving metal reduction.   In the casof dissolving metal 
reductions,the nitro group undergoes reduction in the presence of metals such a Fe or Zn
 2
under different acid conditions such as with acetic acid, hydrochlori acid or sulphuric 
acid.  The nitro groups undergo reduction, followed by reaction with other functional 
groups present in the molecule to provide various nitrogen heterocycles.  The product of 
the cyclization depends on the functional group that reacts with the reduced nitro and can 
include aldehydes, ketones and esters as well as α,β-unsaturated carbonyl group. 
 In the present work, the reduction of an aromatic nitro group, followed by 
cyclization of the resulting aromatic nitrogen with an aldehydes, k tones, esters or α,β-
unsaturated carbonyl groups (Michael acceptors) present in the molecule, resulted in 
cyclization to a nitrogen heterocycle.3   
Dissolving Metal Reduction of Nitro Compounds 
 Dissolving metal reductions, discovered nearly 140 years ago, were among the 
first reductions performed on organic compounds.   The reduction of nitro to amine was 
first discovered by Bechamp4 in 1854 using iron and acetic acid.  After three years, 
Perkin5 applied this technique in the commercial production of aniline and also found that 
hydrochloric acid can be used instead of acetic acid in this reduction process.   
 These metal reduction processes are most widely used in the reduction of polar 
compounds and in selective reduction of specific types of bonds.  The reduction of nitro 
compounds by iron under acidic conditions is one such reaction that is still mportant 
today.  In addition to being an inexpensive reagent, iron is very mild and selective for the 
nitro group.  Other functional groups in the compound are seldom affected when 




Mechanism of Reduction 
 Reduction is defined as the acceptance of electrons.  In dissolving metal
reductions, electrons are transferred from the surface of the metal to the organic molecule 
being reduced.  The radical ion that is produced is then rapidly protonated under the 
(normally) acidic conditions.  The process is repeated one more time until the reduction is 
complete.  The hydrogen gas emitted during the course of reaction of the metal with the 
acid does not contribute to the reduction process but sometimes leads to si e reactions.  
The coupling of radicals will result if acidic conditions or a protic solvent is not used in 
the reaction.   
Balanced Equation 
 
 A balanced equation and the mechanism for the reduction of nitro benzene by iron 
in acid are shown above.  The mechanism starts with the transfer of an electron to the 
double bonded nitrogen of the nitro group from iron.  This results in the formation of a 
radical anion, which is protonated by the acidic medium.  Once the protonation occurs, a 
second electron is transferred from the iron to the nitrogen.  Further addition of another 
proton, followed by elimination of water, gives the nitroso intermediat.   The same 
sequence is repeated again to get the hydroxylamine.  Finally, two more electrons are 
added to break the N-O bond to give anions of the two products, which are protonated in 
the acidic medium to give aniline and water.  This whole process consumes 3 atoms of 
iron (2 e- from each, 6 e- total) and 6 protons for each nitro group.   Generally, a large 










Early Examples of Ring Closures using Dissolved Metal Reduction Process 
 Bunce and coworkers6 prepared 1,2,3,4-tetrahydroquinolines by using a tandem 
reduction-Michael addition process.  In this process, the ethyl(E)-3-methyl-4-((2-
nitrophenyl)amino)-2-butenoate (1) was reacted with iron and acetic acid over a period of 
30 minutes to give ethyl (±)-2-methyl-1,2,3,4-tetrahydroquinoxaline-2-acetate (2).  The 
mechanism involves the reduction of nitro group to an amine, which then undergoes 
Michael addition to the pendent acrylate in a favorable pathway to give the 
tetrahydroquinoline. 
 
        
 
 
                
             Figure 1.1.  Dissolved metal reduction followed by Michael cyclization 
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The second example involved the formation of dibenzo-fused nitrogen 
heterocycles by a tandem reduction-lactamization process.7  These dibenzodiazepinone 
compounds are found to have potent antiarrhythmic defibrillatory activity.8  In this 
process methyl-2-[(2-nitrophenyl)amino]benzoate (3) reacted to give 5,10-dihydro-1H-
dibenzo[b,e][1,4]diazepin-11-one (4) using Fe and acetic acid.  The same reaction using 
catalytic condition such as 5% Pd/C in ethanol gave a reduced amine but could not 





    Figure 1.2.  Tandem reduction-lactamization reduction using iron and acetic acid 
     
 The tandem reaction process was extended to include a reduction-addition-
elimination sequence for the preparation of 2-alkyl-1H-indole-3-carboxylate esters (6).9  
These indole-3-carboxylic acid derivatives are known to have significat biological 
activity10 and are valuable building blocks in the synthesis of various drugs.11 
In one example, ethyl (2Z)-3-hydroxy-2-(2-nitrophenyl)-2-butenoate (5) 
underwent ring closure by direct treatment with 6 equivalents of iron powder in glacial 
acetic acid at 115 ºC to give 6 in 82% yield.   This treatment resulted in the reduction of 
the nitroarene to the aniline followed by Michael addition to the unsatrated ester to yield 
the final compound via elimination of water.  Another mechanistic possibility could 
involve the addition of the aniline nitrogen to the carbonyl (keto form) under acidic 
 6
conditions, followed by a loss of water molecule.  The final cyclization in this reaction is 






 Figure 1.3.  Dissolved metal lactamization process to form indole rings 
 
A recent use of tandem reduction-cyclization sequence is used in the preparation 
of spirooxindoles,12 such as 7 using iron and acetic acid.  Spirooxindoles are known to be 
anti-inflammatory agents.13  These compound can be prepared using spiroimides as a 
source of starting material.  Spiroimides are one such compounds which contains the 
spirooxindole core ring systems and attributes to the presence of pentacyclic spiro-










                              Figure 1.4.  Structure of spirooxindole ring 
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       In an example, nitro imide 8 was converted to the spiro compound 9 using iron and 






           Figure 1.5.  Formation of spiroimide 
  
In this tandem reduction sequence, the nitro was first reduced to an amine which then 
reacted with the ester moiety to close the spiroimide compound.  
A new improved scaleable process to prepare 1,3,4,12a-tetrahydro-11H-[1,4]-
oxanio[3,4-c][1,4]benzodiazepine-6,12-dione (11) using iron and acetic acid was 
developed by Stefanick and coworkers.14  In this application, the target compound was 
obtained in a pure form in 85% yield without the need for chromatographic purification.  










Di Santo and coworkers16 developed a new synthetic procedure to obtain 2H-
pyrrolo[3,4-c]quinolines (12).  These ring systems are used as lead structures for 






Figure 1.7.  Structure of 2H-pyrrolo[3,4-c]quinolines 
 
In the process of preparing target 14, one of the steps involved the tandem 
reduction of a nitro group, from 13 using iron and acetic acid.  The product was obtained 





              Figure 1.8.  Synthesis of 2H-pyrrolo[3,4-c]quinoline-4(5H)-one 
 
Pyrroloquinoxaline 15 represents an important class of compounds in a wide 






    
Figure 1.9.  Structure of pyrroloquinoxaline 
  
Grivas and Edin19 discovered a new method to synthesize pyrroloquinoxalines 
using a selenadiazoloindole 17 as an intermediate.  This intermediate was the first of its 
kind to be discovered.  In the presence of iron and acetic acid at 100 ºC enamine 16 
underwent ring closure to give selenadiazoloindole 17 in 55% yield.  Initially, the nitro 
group was converted to amine which then underwent ring closure by displacing the 
dimethylamino group.   
       
   
 
Figure 1.10.  Synthesis of selenadiazoloindole 
 
Another interesting reaction that used iron and acetic acid was the preparation of 
imidazo[5,1-d]pyrrolo[1,2-b][1,2,5]benzothiadiazepine-9,9-dioxide (18), developed by 
Artico and coworkers.20  These novel sulfur containing tetracyclic benzodiazepines have 














Figure 1.11.  Structure of imidazo[5,1-d] pyrrolo[1,2-b][1,2,5]benzothiadiazepine-9,9-
dioxide 
 
In the course of preparing this drug, one of the intermediates involved a tandem 
intramolecular ring closure to form imine 20 from intramolecular condensation of 
aromatic nitro aldehyde 19.  This ring closure was achieved by the use of iron and acetic 





              Figure 1.12.  Tandem reduction-cyclization of a nitro with an aldehyde 
                 
Vanelle and coworkers22 discovered bioactive family of bicyclic 2-pyridones for 
the treatment of central nervous system disorders.  Thiazolopyridine 22 is one such 
bicyclic 2-pyridone which is biologically very active.  In this case, nitrothiazole 21 was 
treated with iron and acetic acid at 115 ºC over a period of 30 minutes to give 
thiazolopyridone 22.  The same reaction was tried under different hydrogenation 
 11
conditions but resulted in a very poor yield.  These conditions resulted in a 90% yield of 
the lactam is highly pure form. 
 
Figure 1.13.  Synthesis of thiazolopyridone ring 
  
Syntheses of various heterocyclic compounds were accomplished in the pas by 
the use of iron and acetic acid on various Baylis-Hillman adducts.  Baylis-Hillman is an 
organic reaction in which aldehydes react with variety of activated alkenes in the 
presence of tertiary bicyclic amines to give multifunctional products.  These heterocycles 
are present as a framework in numerous structures which are precursors to natural 
products or pharmaceutical agents.   
 Basavaish and coworkers23 reported the synthesis of substituted γ-lactam 24 
which was obtained from the acetate derivative of a Baylis-Hillman adduct e.g. (23).  In 
this reaction, the adduct acetate underwent reductive cyclization in the presence of iron 
and acetic acid to give the γ-lactam in a moderate yield of 54%. 
     
               
 
 
              Figure 1.14.  Synthesis of γ-lactams using iron and acetic acid 
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Another interesting, one-pot sequence was developed by Basvaish and 
coworkers24 for the synthesis of 3-benzoquinoline 26 using Baylis-Hillman alcohol 25 
along with iron and acetic acid.  The reaction mechanism involves the easy 
transformation of an acyclic nitrogen and a cyclic oxygen into another important  
  
   
 
 
                             Figure 1.15.  Formation of a 3-benzoylquinoline 
 
structural framework containing cyclic nitrogen along with acycli oxygen by a 
reduction-addition-elimination process. 
Batra and coworkers25 developed a convenient, practical approach to the synthesis 
of imidazo[2,1-b]quinazolin-2-ones (28) using a Baylis-Hillman derivative 27 along with 
iron powder and acetic acid.  The method involves a sequential reduction of the nitro 
group and addition of the resulting amine to the cyano group to give the heterocyclic ring 
system. 
 














                       Figure 1.16.  Formation of imidazo[2,1-b]quinazolin-2-ones 
 
Bathadoss26 recently reported the synthesis of (E)-3-arylidene-2,3 
dihydrobenzo[b][1,4]-oxazepin-4(5H)-one 29 using a modified Baylis-Hillman adduct 
28.  Iron and acetic acid promoted the key step by in situ reduction of the nitro group to  










Use of Iron and Acetic Acid without Ring Closures 
The use of iron and acetic acid in the preparation of a drug candidate has been 
reported by Berlin and coworkers27 in the synthesis of heteroarotinoids.  Heteroarotinoids 
are a class of modified synthetic retinoids.  They are structural arotinoids which contain 
one aryl moiety in the molecular framework.  These heteroarotinoids demonstrate 
promising inhibitory activities towards various cancer cells. N-(3,4-Dihydro-2,2,4,4-
tetramethyl-2H-1-benzothiopyran-6-yl)-N’-(4-nitrophenyl)thiourea (30) is one such 
heteroarotinoid and which is scheduled for human clinical studies for the treatment of 





Figure 1.18.  N-(3,4-Dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-6-yl)-N’-(4-
nitrophenyl)thiourea  
 
The key step in the synthesis of this drug is the conversion of 2,2,4,4-tetramethyl-
6-nitrothiochroman (31) to  2,2,4,4-tetramethylthiochroman-6-amine (32).  In this 
example, the nitro derivative 31 was heated at 85 ºC in the presence of iron and acetic 
acid in ethanol to give 3 in a yield of 50% with minimum side reactions.  Other methods 





           
 
 
Figure 1.19.  Reduction of a nitrothiochroman to an aminothiochroman 
  
       An effective way to synthesize amino-substituted naphthalene 33 for the treatment of 
breast cancer was developed by Shi and coworkers.28  Quinolines are known for their 
diverse biological activity, especially their antimalarial and anticancer properties.29  







               Figure 1.20.  Structure of an amino substituted napthalene 
 
           In this synthesis, one of the intermediate steps was the conversio of an 1-nitro 
naphthalene compound 34 to amine 35.  For this conversion, iron and acetic acid was 

















Figure 1.21.  Conversion of an aromatic nitro compound to an amine using iron and    
acetic acid 
 
ether functions or damaging the benzylic C-F bonds of the trifluoromethyl group 
           Geisler and coworkers29 developed an efficient synthesis of 11β-(4-aminophenyl) 
spiro[estr-4-ene-17β,2’(5’H)-furan]3,5’-dione which is an 19-nor steroid exhibiting 
progesterone antagonistic activity.  In this procedure, the precursor nitroaromatic 36 was 
converted to the target amine 37 in 45% yield via the use of iron and acetic acid with 
ethyl acetate as a co-solvent at 80 ºC. 
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1,2,3,9-TETRAHYDRO-4H-CARBAZOL-4-ONE AND 8,9-DIPYRIDO- 




 Earlier studies from this laboratory1 and by others2 described the synthesis of 
substituted indoles from 2-nitrobenzyl ketone derivatives by a tandem reduction-
cycloaromatization reaction.  The current project sought to assemble more complex rings 
using this strategy.  In particular, we have developed a route to 1,2,3,9-tetrahydro-4H-
carbazol-4-one and 8,9-dihydropyrido[1,2-a]indol-6(7H)-one through a common 
intermediate 1H-indole-2-butanoic acid.  We have further found that the tetrahydro-4H-
carbazol-4-one can be prepared in one step by a tandem reduction-cy l aromatization-
acylation sequence.  The 1,2,3,9-tetrahydro-4H-carbazol-4-one is a building block for the 
synthesis of alkaloids3 as well as the core ring system in current drugs used for the 
treatment of cancer,4 HIV,5 congestive heart failure6 and emesis brought on by 
chemotherapy7; the 8,9-dihydropyrido[1,2-a]indol-6(7H)-one  system has been studied 
for the treatment of ischemic disorders8 and vomiting resulting from cancer treatment.9 
 Several other approaches have been reported for this ring system.  The Fischer 
indole synthesis, by far the simplest, uses phenyhydrazine but provides at most a 50% 
yield.10  Other routes include C4 oxidation of tetrahydrocarbazole,11 base promoted 
cyclization of 2-(2-trifluoroacetamidophenyl)-2-cyclohexene-1-one,12 copper(I)
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mediated13 or photochemical14 arylation of N-substituted enaminones and several 
different palladium catalyzed coupling reactions.15  Our synthesis requires several steps, 
but permits reasonable structural variation and does not require excessively hazardous 
reagents or expensive catalysts.  We have also found that other saturated ring homologues 
of the tetrahydro-4H-carbazol-4-one system are accessible using this strategy. 
Results and Discussion 
 Our cyclization studies required the preparation of a series of 1H-indole-2-
alkanecarboxylic acids.  Our synthesis began with Meldrum’s acid16 and commercially 
available methyl (ω-chlorocarbonyl)alkane carboxylate derivatives 1a-c (Figure 2.1).  
Acylation of Meldrum’s acid in the presence of pyridine, followed by refluxing in tert-
butyl alcohol, gave the tert-butyl methyl 3-oxoalkanedicarboxylic esters 2a-c in 68-76% 
yields.17  Deprotonation of 2a-c with sodium hydride in anhydrous N,N-dimethyl- 
formamide and reaction with 2-fluoro-1-nitrobenzene at 55-60 ºC afforded the 
nucleophilic aromatic substitution products 3a-c in yields ranging from 60-70%.1,2  
Subsequent exposure of 3a-c to trifluoroacetic acid in the presence of triethylsilane18 
resulted in tert-butyl ester cleavage and decarboxylation to provide nitro keto ester 4a-c 
in 92-94% yields.    
Treatment of 4a-c with iron powder in acetic acid then intitated a tandem 
reduction-cycloaromatization reaction ot furnish 1H-indole-2-alkanecarboxylic esters 5a-
c in 90-95%.1  Finally, basic hydrolysis of 5a-c provided acids 6a-c in 90-96% yields.  
Treatment of 6a-c with 2.0-6.0 equivalents of p-toluenesulfonic acid in refluxing toluene 
resulted in a Friedel-Crafts like ring closure of the acid to C3 of the indole moiety to 
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yield 7a-c in 67-80% yields (Figure 2.2).  Refluxing 6b in toluene without the added p-

















Figure 2.1.  Syntheis of indole carboxylic acid derivatives 
 
with 6a or 6c, reflecting the additional strain and entropy effects involved in closing a 
five- or a seven membered rings.  Acids 6a and 6c could be lactamized, however, using 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride19 in the presence of 
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excess 4-dimethylaminopyridine.20  Numerous other conditions21 failed to give the 
desired lactams.  This appears to be the first report to use N-(3-dimethylaminopropyl)-N’-
ethyl carbodiimide with 4-dimethylaminopyridine for lactam closure.  The function of the 
base in this reaction appears to be two fold.  First it neutralizes the hydrochloride salt of 
the carbodiimide and, secondly, it scavenges the proton from the cyclized amide.  The 







   
 
      Figure 2.2.  Cyclization methods to give carbazole and lactam rings 
 
Remarkably, it was found that treatment of 4b with iron in concentrated 
hydrochloric acid yielded 7b in 92% yield by a tandem process involving a reduction-
cycloaromatization-acylation sequence.  Attempts to cyclize 6a and 6c under the same 
conditions afforded significantly lower yields, and the product mixtures were more 




Mechanistically, reduction of the aromatic nitro group is followed by 
cycloaromatization to the indole system as previously observed.1,2  Under strong acid 
conditions, however, the methyl ester is cyclized onto the C3 position of the indole.  This 
most likely occurs by protonation of the ester carbonyl, attack by the electron-rich indole 
double bond to the carbonyl carbon, followed by methanol elimination and 
rearomatization (see Figure 2.3).  The closure of acids 6a to 6c-7a and 7c should be  
         
          Figure 2.3.  Mechanism for tetrahydrocarbazole ring system 
 
analogous to the conversion of 10 to 7b with loss of water in the penultimate step.  
Finally, the lactamization reactions proceed via the expected cyclocondensation 




































 We have developed an alternative approach to the synthesis of the title 
compounds from 1H-indole-2-butanoic acid (6b) prepared by a tandem reduction 
cycloaromatization process using iron in acetic acid.  Heating th s acid 6b in the presence 
of p-toluenesulfonic acid in refluxing toluene affords 1,2,3,9-tetrahydro-4H-carbazol-4-
on (7b), while heating in toluene with no added acid afforded 8,9-dihydropyrido[1,2-
a]indol-6(7H)-one (8b).  Interestingly, a high yield of 7b can be achieved directly from 
4b via a reduction-cycloaromatization acylation reaction promoted by iron in 
concentrated hydrochloric acid.  Analogous systems incorporating five- and seven- 
membered fused cycloalkanones can be prepared by treatment of 6a and 6c with p-
toluenesulfonic acid in refluxing toluene.  However, direct conversion of 4a and 4c with 
iron in concentrated hydrochloric acid gives complex mixtures containig only small 
amounts of 7a and 7c.  Cyclization of 6a and 6c to the lactams requires treatment with N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride in the presence of excess 
4-dimethylaminopyridine.  The reaction permits reasonable structural variation and 
furnished the products in high yield without toxic reagents or expensive catalysts. 
Experimental Section 
 N,N-Dimethylformamide, from a freshly opened bottle, was dried over 4 Å
molecular sieves under nitrogen and transferred by syringe into reactions where it was 
used.  The acid chlorides were used as received.  The HCl (2 M and 6 M), NaHCO3 
(saturated), and NaCl (saturated) employed in various procedures refer to aqueous 
solutions.  All reactions were run under N2 in oven-dried glassware.   
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Evaporation of solvents was accomplished in vacuo via the use of a Buchi 
Rotovapor RE-111® and a Brinkman B-169 water aspirator unless otherwise specified.  
For those intermediates that were liquids and required distillation for purification, 
vacuum distillation was employed using a Welch® ChemstarTM 1402N vacuum pump.  
Reactions were monitored by thin layer chromatography on silica gel GF plates (Analtech 
21521).  Preparative separations were performed using flash column chromatography22 
on silica gel (grade 62, 60-200 mesh) mixed with ultraviolet-active phosphor (Sorbent 
Technologies UV-5) or thin layer chromatography on 20-cm × 20-cm silica gel GF plates 
(Analtech 02015).  Band elution, for both methods, was monitored using a hand held 
ultraviolet lamp.  Hexanes used in chromatography had a boiling range of 65-70 ºC.  
Melting points of all solids were uncorrected and taken on a MelTemp purchased from 
Laboratory Devices, Cambridge, MA 02139.  Infrared spectra were taken on a Varian 
800 FT-IR (Scimitar series) run as thin films on sodium chloride disks and were 
referenced to polystyrene.  Unless otherwise indicated, 1H and 13C nuclear magnetic 
resonance spectra were measured in deuteriochloroform at 300 MHz and 75 MHz, 
respectively, on a Varian 300 MHz unit and were referenced to internal tetramethylsilane; 
coupling constants (J) are reported in Hertz 
Representative Procedure for the Preparation of tert-Butyl Methyl 3-
Oxoalkyldicarboxylic Esters: tert-Butyl Methyl 3-Oxohexanediate (2a). 
 The procedure of Yonemitsu and co-workers was used.18  A 250-mL, two-necked, 
round-bottomed flask equipped with a magnetic stirrer, a condenser and a nitrogen inlet, 
was charged with 7.00 g (48.6 mmoles) of Meldrum’s acid along with 7.68 g (97.2 
mmoles) of pyridine in 50 mL of dichloromethane.  A solution of 7.68 g (51.0 mmoles) 
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of 1a in 10 mL of dichloromethane was added after 5 minutes and the solution was stirred 
at 0 ºC.  Stirring was continued at 0 ºC for 30 minutes and at 22 ºC for 1 hour.  The crude 
reaction mixture was washed with 2 N hydrochloric acid (3 × 150 mL) to remove the 
excess pyridine, and the solution was dried (magnesium sulfate) and concentrated under 
vacuum.  The resulting oil was dissolved in 50 mL of tert-butyl alcohol and refluxed for 
3 hours.  The crude reaction mixture was concentrated under vacuum, and the compound 
was distilled under high vacuum to give 8.20 g (78%, containing some enol) of the keto 
diester as a colorless oil, bp 85-110 ºC (0.5 mm Hg).  IR:  1737, 1717 cm-1; 1H NMR: δ 
3.68 (s, 3H), 3.41 (s, 2H), 2.87 (t, 2H, J = 6.6), 2.62 (t, 2H, J = 6.6), 1.47 (s, 9H); 13C 
NMR: δ 201.4, 172.8, 166.2, 81.9, 51.7, 50.4, 37.2, 27.8 (3C), 27.5. 
tert-Butyl Methyl 3-oxoheptanedioate (2b).  This compound (9.00 g, 81% containing 
some enol) was isolated as a colorless oil, bp 110-130 ºC (0.5 mm Hg).  IR: 1738, 1716 
cm-1; 1H NMR: δ 3.67 (s, 3H), 3.35 (s, 2H), 2.62 (t, 2H, J = 7.0), 2.36 (t, 2H, J = 7.2), 
1.92 (quintet, 2H, J = 7.1), 1.47 (s, 9H); 13C NMR: δ 202.5, 173.5, 166.4, 82.0, 51.5, 
50.5, 41.6, 32.7, 27.9 (3C), 18.5.  
tert-Butyl Methyl 3-Oxooctanedioate (2c).  This compound (8.50 g, 68% containing 
some enol) was isolated as a colorless oil, bp 125-140 ºC (0.5 mm Hg).  IR: 1735, 1716 
 cm-1; 1H NMR: δ 3.67 (s, 3H), 3.35 (s, 2H), 2.56 (distorted t, 2H, J = 6.7), 2.33 (distorted 
t, 2H, J = 6.7), 1.63 (m, 4H), 1.47 (s, 9H); 13C NMR: δ 202.8, 173.7, 166.4, 81.9, 51.5, 




Representative Procedre for the Nucleophilic Aromatic Substitutions: tert- Butyl 
Methyl 2-(2-Nitrophenyl)-3-oxohexanedioate (3a): 
 A modification of the procedure described by Bunce and co-workers was used.1  
A 250-mL, three-necked, round-bottomed flask, equipped with magnetic stirr ng, a reflux 
condenser and a nitrogen inlet, was charged with 1.9 g of NaH in a 60% mineral oil 
suspension.  The solid was washed with hexane (3 × 25 mL) to remove the mineral oil, 
and the remaining 1.36 g (56.7 mmol) of NaH was suspended in 20 mL of dry N,N-
dimethyl formamide.  Stirring was initated and a solution of  4.00 g (28.4 mmoles) of 2-
fluoro-1-nitrobenzene in  25 mL of dimethylformamide was added, followed by a 
solution of 6.35 g (29.7 mmoles) of 2a in 5 mL of dimethylformamide.  The reaction 
mixture was heated to 60 ºC and stirred for 48 hours, then added to 50 mL of saturated 
ammonium chloride and the mixture was extracted with ether (3 × 150 mL).  The 
combined organic extracts were washed with saturated sodium chloride (1 × 100 mL), 
dried (magnesium sulfate) and concentrated under vacuum.  The crude product was 
purified by flash chromatography on a 50-cm × 2-cm silica gel column eluted with 10% 
ether in hexanes to give 6.65 g (18.9 mmoles 66% containing some enol) of 3a as a 
yellow oil.  IR: 1736, 1640, 1613, 1520, 1351 cm-1; 1H NMR: δ 7.98 (dd, 1H, J = 8.0, 
1.2), 7.58 (td, 1H, J = 7.6, 1.4), 7.46 (td, 1H, J = 7.9, 1.6), 7.33 (dd, 1H, J = 7.6, 1.4),  
5.28 (s, 1H), 3.64 (s, 3H), 2.50 (m, 4H), 1.32 (s, 9H); 13C NMR: δ 200.4, 172.7, 170.6, 
149.7, 133.7, 132.6, 130.1, 128.3, 124.5, 82.6, 61.3, 51.7, 37.4, 29.8, 27.8 (3C). 
tert-Butyl Methyl 2-(2-Nitrophenyl)-3-oxoheptanedioate (3b).  This compound (6.00 
g, 72%, containing some enol) was isolated as a yellow oil.  IR: 1738, 645, 1526, 1394, 
1352 cm-1; 1H NMR: δ 7.98 (dd, 1H, J = 8.0, 1.2), 7.57 (td, 1H, J = 7.6, 1.4), 7.45 (td, 1H, 
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J = 7.9, 1.4), 7.25 (dd, 1H, J = 7.6, 1.4), 5.25 (s, 1H), 3.57 (s, 3H), 2.25 (m, 4H), 1.88 (m, 
2H), 1.33 (s, 9H); 13C NMR: δ 200.8, 172.7, 170.7, 149.7, 133.7, 132.8, 130.1, 128.4, 
124.3, 82.6, 61.3, 51.8, 37.4, 29.9, 28.0, 27.8 (3C). 
tert-Butyl Methyl 2-(2-Nitrophenyl)-3-oxooctanedioate (3c).  The compound (4.20 g, 
62%, containing some enol) was isolated as a yellow oil.  IR: 1735, 1643, 1615, 1524, 
1352 cm-1; 1H NMR: δ 7.98 (dd, 1H, J = 8.0, 1.3), 7.56 (td, 1H, J = 7.5, 1.4), 7.45 (td, 1H, 
J = 7.9, 1.6), 7.25 (dd, 1H, J = 7.7, 1.4), 5.26 (s, 1H), 3.63 (s, 3H), 2.21 (m, 2H), 2.12 (m, 
2H), 1.57 (m, 4H), 1.24 (s, 9H); 13C NMR: δ 201.8, 173.7, 170.7, 149.7, 133.7, 132.5, 
130.5, 128.8, 124.3, 82.4, 61.0, 51.5, 33.6, 32.5, 27.8 (3C), 25.7, 24.3. 
Representative Procedure for tert-Butyl Ester Cleavage and Decarboxylation:  
Methyl 5-(2-Nitrophenyl)-4-oxopentanoate (4a). 
 The procedure of Mehta and co-workers was used.17  A 250-mL three-necked 
round-bottomed flask, equipped with magnetic stirring, a reflux condenser a d a nitrogen 
inlet, was charged with a solution of 5.20 g (14.8 mmoles) of 3a in 50 mL of 
dichloromethane to which were added 27.6 g (18.0 mL, 242 mmoles) of trifluoroacetic 
acid and 4.88 g (6.70 mL, 421 mmoles) of triethylsilane.  The mixture was stirred for 1 
hour and then concentrated under high vacuum to give 3.50 g (94%) of 4a as light yellow 
oil which was used without further purification.  IR: 1735, 1722, 1525, 1351 cm-1; 1H 
NMR: δ 8.11 (dd, 1H, J = 8.0, 1.1), 7.60 (td, 1H, J = 7.7, 1.3), 7.46 (td, 1H, J = 7.9, 1.5), 
7.31 (dd, 1H, J = 7.7, 1.1), 4.16 (s, 2H), 3.67 (s, 3H), 2.93 (t, 2H, J = 6.5), 2.65 (t, 2H, J = 
6.5); 13C NMR: δ 204.0, 173.1, 148.5, 133.7, 133.6, 130.1, 128.5, 125.2, 51.8, 47.8, 37.1, 
27.8. 
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Methyl 6-(2-Nitrophenyl)-5-oxohexanoate (4b).  This compound (3.46 g, 92%) was 
isolated as a light yellow oil and was used without further purificat on. IR: 1729, 1525, 
1346 cm-1; 1H NMR: δ 8.11 (dd, 1H, J = 8.0, 1,1), 7.59 (td, 1H, J = 7.7, 1.5), 7.46 (td, 1H, 
J = 7.9, 1.5), 7.28 (dd, 1H, J = 7.7, 1.1), 4.09 (s, 2H), 3.68 (s, 3H), 2.70 (t, 2H, J = 7.1), 
2.38 (t, 2H, J = 7.1), 1.96 (quintet, 2H, J = 7.1); 13C NMR: δ 204.9, 173.6, 148.6, 133.6 
(2C), 130.2, 128.4, 125.2, 51.6, 47.9, 41.4, 32.9, 18.7. 
Methyl 7-(2-Nitrophenyl)-6-oxoheptanoate (4c).  This compound (1.45 g, 92%) was 
isolated as a light yellow oil and used without further purification.  IR: 1727, 1528, 1352 
cm-1; 1H NMR: δ 8.10 (dd, 1H, J = 8.2, 1.3), 7.59 (td, 1H, J = 7.5, 1.3), 7.46 (td, 1H, J = 
8.1, 1.5), 7.27 (dd, 1H, J = 7.6, 1.1), 4.10 (s, 2H), 3.67 (s, 3H), 2.62 (distorted, t, 2H, J = 
6.8), 2.34 (distorted, t, 2H, J = 6.8), 1.67 (m, 4H); 13C NMR: δ 205.2, 173.8, 148.6, 133.5 
(2C), 130.3, 128.3, 125.2, 51.5, 47.8, 42.2, 33.7, 24.3, 22.9. 
Representative Procedure for Reductive Cyclization to the 1H-Indoles: Methyl 1H-
Indole-2-propanate (5a).  The procedure of Bunce and coworkers1 was used.  Into a 25-
mL three-necked round-bottomed flask, equipped with magnetic stirring, a reflux 
condenser and a nitrogen inlet, was placed a mixture of 1.50 g (5.98 mmoles) of 4a, 25 
mL of acetic acid and 2.00 g (6.00 eq, 35.9 mmoles) of iron powder (>100 mesh).  The 
mixture was heated with stirring at 115 ºC (oil bath) until thin layer chromatography 
indicated complete consumption of the starting material (ca 30 minutes).  The crude 
reaction mixture was cooled, transferred to a separatory funnel containing 50 mL of water 
and extracted with ether (3 × 100 mL).  The combined ether layers were washed with 
water (1 × 100 mL), saturated sodium bicarbonate (3 × 150 mL), saturated sodium 
chloride (1 × 100 mL), then dried (magnesium sulfate) and concentratd under vacuum to 
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give a brown solid.  Recrystallization from hexanes gave 1.10 g (91%) of 5a as a tan 
solid, mp 97-98 ºC (lit23 mp 97-98 ºC).  IR: 3357, 1720 cm-1; 1H NMR: δ 8.47 (br s, 1H), 
7.52 (dd, 1H, J = 7.9, 0.6), 7.31 (dq, 1H. J = 8.0, 0.9), 7.12 (td, 1H, J = 7.9, 1.3), 7.06 (td, 
1H, J = 7.9, 1.1), 6.24 (dd, 1H, J = 2.0, 0.9), 3.72 (s, 3H), 3.08 (t, 2H, J = 6.7), 2.73 (t, 
2H, J = 6.7); 13C NMR: δ 174.3, 138.1, 136.0, 128.4, 121.3, 119.9, 119.6, 110.5, 99.8, 
51.9, 33.9, 23.1. 
Methyl 1H-Indole-2-butanoate (5b). This compound (1.15 g, 95%) was isolated as a tan 
solid, mp 69-71 ºC.  IR: 3392, 1718 cm-1; 1H NMR: δ 8.06 (br s, 1H), 7.52 (d, 1H, J = 
7.6), 7.30 (d, 1H, J = 6.0), 7.08 (m, 2H), 6.25 (s, 1H), 3.66 (s, 3H), 2.81 (t, 2H, J = 7.2),  
2.40 (t, 2H, J = 7.2), 2.04 (m, 2H); 13C NMR: δ 173.9, 138.4, 128.8, 121.1, 119.8, 119.6, 
110.3, 100.0, 51.6, 33.1, 30.0, 27.3, 24.5. 
Methyl 1H-Indole-2-pentanoate (5c).  This compound (1.10 g, 90%) was isolated as a 
tan solid, mp. 121-124 ºC.  IR: 3353, 1719 cm-1; 1H NMR: δ 7.98 (br, s, 1H), 7.52 (d, 1H, 
J = 6.8), 7.28 (d, 1H, J = 8.0), 7.08 (m, 2H), 6.24 (s, 1H), 3.67 (s, 3H), 2.76 (t, 2H, J = 
7.2), 2.37 (t, 2H, J = 3.6), 1.76 (m, 4H); 13C NMR: δ 174.2, 139.3, 136.0, 128.9, 121.2, 
119.6, 119.8, 110.5, 99.8, 51.7, 33.9, 28.7, 28.0, 24.6. 
Representative Procedure for the Ester Hydrolysis: 1H-Indole-2-propanic Acid (6a). 
 A 25-mL three-necked round-bottomed flask, equipped with magnetic stirr ng, a 
reflux condenser and a nitrogen inlet, was charged with a mixture of 1.00 g (4.93 
mmoles) of 5a in 2 mL of dioxane along with 15.0 mL of a 1.0 M aqueous solution of 
sodium hydroxide.  The mixture was stirred for 1 hour.  The solution was then 
concentrated to one-half volume under vacuum, acidified with 3 M hydrochloric acid and 
extracted with ether (3 × 100 mL).  The combined ether layers wee ashed with 
 32
saturated sodium chloride (1 × 150 mL), then dried (magnesium sulfate) and concentrated 
under vacuum.  The crude product was purified by flash chromatography on a 15-cm × 2-
cm silica gel column eluted with 50% ether in hexanes to give 0.85 g (91%) of 6a as 
white solid, mp 165-167 ºC (lit24 mp 167 ºC).  IR: 3462-2300, 3392, 1701 cm-1.  1H 
NMR: δ 9.87 (br, s, 1H), 8.26 (br s, 1H), 7.52 (dd, 1H, J = 7.7, 1.3), 7.30 (dd, 1H, J = 8.0, 
0.9), 7.13 (td, 1H, J = 7.7, 1.3), 7.07 (td, 1H, J = 7.9, 1.1), 6.26 (dd, 1H, J = 1.9, 0.8), 3.08 
(t, 1H, J = 6.8), 2.81 (t, 2H, J = 6.8);  13C NMR: δ 178.4, 137.6, 135.5, 128.4, 121.4, 
119.9, 119.7, 110.5, 99.9, 33.6, 22.9. 
1H-Indole-2-butanoic Acid (6b).  This compound (0.31 g, 85%) was isolated as a white 
solid, mp 114-115 ºC.  IR: 3252-2348, 3386, 1700 cm-1.  1H NMR: δ 10.85 (br s, 1H),  
7.95 (br s, 1H), 7.52 (dd, 1H, J = 7.7, 0.7), 7.29 (dd, 1H, J = 8.0, 0.9), 7.12 (td, 1H, J = 
7.9, 1.3), 7.07 (td, 1H, J = 7.7, 1.1), 6.27 (dd, 1H, J = 2.0, 0.8), 2.83 (t, 2H, J = 7.3), 2.45 
(t, 2H, J = 7.3), 2.06 (quintet, 2H, J = 7.3);  13C NMR: δ 179.2, 138.1, 135.9, 128.7, 
121.2, 119.9, 119.7, 110.4, 100.1, 33.0, 27.3, 24.2. 
1H-Indole-2-pentanoic Acid (6c).  This compound (0.90 g, 96%) was isolated as a white 
solid, mp 145-147 ºC.  IR: 3425-2350, 3384, 1700 cm-1.  1H NMR: δ 10.50 (s, 1H), 7.92 
(br s, 1H), 7.52 (d, 1H, J = 6.8), 7.30 (d, 1H, J = 8.0), 7.10 (m, 2H), 6.24 (s, 1H), 2.80 (t, 
2H, J = 6.8), 2.42 (t, 2H, J = 7.2), 1.76 (m, 4H);  13C NMR:  δ 178.4, 138.9, 135.7, 128.7, 
121.0, 119.7, 119.6, 110.2, 99.7, 33.4, 28.4, 27.8, 24.1. 
Representative Procedure for the Acylation Reactions: 3,4-Dihydrocyclo-
pent[b]indol-1(2H)-one (7a). 
 A 500-mL, one-necked, round-bottomed flask, equipped with magnetic stirr ng, a 
reflux condenser and a nitrogen inlet, was charged with a solution of 200 mg (1.06 
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mmoles) of 6a in 10 mL of toluene.  The mixture was heated to reflux and 200 mg of p-
toluenesulfonic acid was slowly added through the top of the condenser.  Aft  1 hour at 
reflux, a second 200-mg portion of p-toluenesulfonic acid monohydrate (total 400 mg, 
2.00 eq, 2.10 mmoles) was added, and refluxing was continued for a total of 12 hours.  
The resulting solution was cooled, added to water (50 mL) and extracted with ether (3 × 
100 mL).  The ether layer was washed with saturated sodium bicarbonate (3 × 150 mL) 
and sodium chloride (1 × 100 mL), then dried (magnesium sulfate) and co centrated 
under vacuum.  The crude product was purified by flash chromatography on a 20-cm × 2-
cm silica gel column eluted with 10% ether in hexanes to give 136 mg (75%) of pure 7a.  
IR: 3371, 1648 cm-1;  1H NMR (dimethyl sulfoxide-d6): δ 12.0 (br, s, 1H), 7.67 (d, 1H, J 
= 7.5), 7.45 (d, 1H, J = 8.0), 7.22 (td, 1H, J = 7.7, 1.3), 7.16 (td, 1H, J = 7.7, 1.3), 3.08 
(m, 2H), 2.82 (m, 2H);  13C NMR: δ 194.7, 167.7, 142.2, 129.8, 127.6, 122.9, 121.5, 
119.4, 112.6, 40.6, 21.0. 
1,2,3,9-Tetrahydro-4H-carbazol-4-one (7b).  This compound was prepared from 150 
mg (0.74 moles) of 6b using a modified procedure.  In this case, 844 mg (4.44 mmoles, 
6.0 eq) of p-toluenesulfonic acid monohydrate was required, and this acid was added in 
2.0-eq portions at one hour intervals during the first three hours of the twelve hour reflux 
period.  Product 7b (120 mg, 88%) was isolated as an off-white solid, mp 225-228 ºC 
(dec) (lit11 mp 219-221 ºC).  IR: 3368, 1588, 1566 cm-1; 1H NMR (dimethyl sulphoxide-
d6): δ 11.7 (br, s, 1H), 7.99 (d, 1H, J = 7.5), 7.46 (dd, 1H, J = 7.8, 1.1), 7.25 (td, 1H, J = 
7.7, 1.2),  7.19 (td, 1H, J = 7.7, 1.2), 2.99 (t, 2H, J = 6.3), 2.42 (t, 2H), J = 6.4), 2.13 
(quintet, 2H, J = 6.4); 13C NMR (dimethyl sulfoxide-d6): 192.1, 148.4, 134.1, 122.7, 
122.2, 120.5, 120.2, 108.8, 106.5, 37.7, 22.9, 20.4. 
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6,7,8,9-Tetrahydrocyclohept[b]indol-10(5H)-one (7c).  This compound was prepared 
as described for 7b using 203 mg (0.93 mmoles) of 6c to give 133 mg (72%) of 7c as a 
tan solid, mp 217-218 ºC.  (lit11 mp 220-221 ºC).  IR: 3365, 1718 cm-1; 1H NMR 
(dimethyl sulfoxide-d6): δ 11.7 (br s, 1H), 8.14 (dd, 1H, J = 7.4, 1.4), 7.34 (dd, 1H, J = 
7.9, 1.3), 7.12 (m, 2H), 3.10 (t, 2H, J = 6.3), 2.64 (m, 2H), 1.93 (quintet, 2H, J = 6.4),  
1.83 (m, 2H);  13C NMR (dimethyl sulfoxide-d6): δ 196.4, 149.0, 135.0, 127.3, 122.2, 
121.2, 120.9, 113.7, 110.9, 42.7, 27.0, 24.3, 21.8. 
Direct Preparation of 7b from 4b.  A 100-mL single-necked round-bottomed flask, 
equipped with a reflux condenser (N2 inlet) and a magnetic stirrer, was charged with 200 
mg (0.75 mmoles) of 4b and 8 mL of concentrated hydrochloric acid.  The mixture was 
heated to 80 ºC (oil bath), and 126 mg (3.00 eq, 2.25 mmoles) of Fe powder (>100 mesh) 
was added.  The reaction was refluxed at 110 ºC until thin layer chromatography 
indicated complete consumption of starting material (ca 20 minutes).  The mixture was 
cooled, added to 15 mL of water and extracted with ether (3 × 50 mL).  The combined 
ether layers were washed with saturated sodium chloride (1 × 50 mL), dried (magnesium 
sulfate) and concentrated under vacuum.  The resulting solid was flash chromatographed 
on a 20-cm × 2-cm silica gel column eluted with increasing concentrations of ether in 
hexanes to give 128 mg (92%) of 7b.  The physical properties and spectral data matched 
those reported above. 
Representative Procedure for Five- and Seven-Membered Lactam Formation: 1,2-
Dihydro-3H-pyrrolo[1,2-a]indol-3-one (8a).  A 100-mL one-necked round-bottomed 
flask, equipped with magnetic stirring, a reflux condenser and a nitrogen inlet, was 
charged with 100 mg (0.53 mmoles) of 6a in 5 mL of dichloromethane along with 103 
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mg (0.85 mmoles, 1.6 eq) of 4-dimethylaminopyridine.  The mixture was stirred for 10 
minutes to give a clear light brown solution.  To this solution was added 101 mg (0.53 
mmoles, 1.0 eq) of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride and 
the reaction mixture was stirred at room temperature for 24 hours.  The crude reaction 
mixture was washed with water (1 × 20 mL), 1 M hydrochloric acid (1 × 25 mL), 
saturated sodium bicarbonate (1 × 25 mL) and saturated sodium chloride (1 × 25 mL), 
then dried (magnesium sulfate) and concentrated under vacuum.  The resulting semisolid 
was purified by preparative thin layer chromatography eluted with 60% ether in hexanes 
to give 72 mg (80%) of the lactam as a light tan solid, mp 148-151 ºC (lit25 mp 151-153 
ºC). IR: 1731 cm-1; 1H NMR: δ 8.07 (m, 1H), 7.48 (m, 1H), 7.25 (m, 2H), 6.27 (s, 1H), 
3.14 (A of ABm, 2H), 3.08 (B of ABm, 2H); 13C NMR: δ 171.6, 143.6, 135.3, 130.4, 
124.0, 123.2, 120.5, 113.5, 100.3, 34.9, 19.6. 
8,9-Dihydropyrido[1,2-a]indol-6(7H)-one (8b).  This compound was prepared by 
dissolving 100 mg (0.493 mmoles) of 6b in 15 mL of dry toluene and refluxing the 
mixture for 36 hours.  The solvent was evaporated to dryness under vacuum.  The crude 
product was purified by preparative thin layer chromatography on a 20-cm × 20-cm silica 
gel GF plate using 50% ether in hexanes to give 82 mg (90%) of a 8b as a white solid, 
mp 78-79 ºC (lit24 mp 79-81 ºC).  IR: 1690 cm-1; 1H NMR: δ 8.44 (dd, 1H, J = 8.1, 0.9), 
7.45 (dd, 1H, J = 6.8, 1.6), 7.25 (m, 2H), 6.31 (s, 1H), 2.97 (td, 2H, J = 6.8, 1.2), 2.78 (t, 
2H, J = 6.4), 2.07 (quintet, 2H, J = 6.4);  13C NMR: δ 169.4, 138.1, 134.8, 129.7, 124.0, 
123.9, 119.6, 116.3, 104.8, 34.4, 23.8, 21.4. 
7,8,9,10-Tetrahydro-6H-azepino[1,2-a]indol-6-one (8c).  This compound was prepared 
as described for 8a on an 80 mg (0.37 mmole) scale to give 60 mg (81%) of the lactam as 
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a white solid, mp 172-175 ºC.  IR: 1692 cm-1; 1H NMR: δ 8.42 (dm, 1H, J = 7.9), 7.46 
(dm, 1H, J = 7.3), 7.32-7.20 (complex, 2H), 6.36 (s, 1H), 3.06 (t, 2H, J = 5.9), 2.94 
(distorted, t, 2H, J = 5.8), 1.94 (m, 4H);  13C NMR: δ 173.8, 139.5, 136.9, 129.6, 124.1, 
123.5, 119.5, 116.3, 107.9, 35.9, 25.8, 23.7, 20.8. 
References and Notes 
1. Bunce, R. A.; Randall, M. H.; Applegate, K. G. Org. Prep. Proceed. Int. 2002, 
34, 493. 
2. Augustine, R.; Gustavsen, A. J.; Wanat, S. F.; Pattison, I. C.; Houghton, K. S.; 
Koletat, G.  J. Org. Chem. 1973, 38, 2004. 
3. Scott, T. L.; Soderberg, B. C. G. Tetrahedron 2003, 59, 6323. 
4. Sissoumma, D.; Maingot, L.; Collet, S.; Guigant, A.  J Org. Chem. 2006, 22, 
8384. 
5. Li, X.; Vince, R. Bioorg & Med. Chem. 2006, 14, 2942. 
6. [a] Kohno, T.; Yoshikawa, T.; Yoshizawa, A.; Nakamura, I.; Anzai, T.; Satoh, T.; 
Ogawa, S.  Cardiovascular Drugs and Therapy 2005, 19, 347.  [b] Romeo, G.; 
Materia, L.; Pittala, V.; Modica, M.; Salerno, L.; Siracusa, M.; Russo, F.l 
Minneman, K. P. Bioorg. & Med. Chem. 2006, 14, 5211. 
7. [a] Elz, S.; Heil, W. L. Bioorg & Med. Chem. Lett. 1995, 5, 667. [b] Scott, T. L.; 
Soderberg, B. C. G. Tetrahedron  Lett. 2002, 43, 1621. 
8. Kato, M.; Ito, K.; Takasugi, H. European Patent EP 451538 1991; Chem Abstr. 
1992, 116, 207822. 
 37
9. [a] Kato, M.; Ito, K.; Nishino, S.; Yamakuni, H.; Takasugi, H. Chem. Pharm. 
Bull. 1994, 42, 2546. [b] Kato, M.; Nishino, S.; Ito, K.; Takasugi, H. Chem. 
Pharm. Bull. 1995, 43, 1346. 
10. [a] Czeski, B. A.; Wheeler, W. J. Label Compd. Radiopharm. 2005, 48, 407. [b] 
Clemo, G, R.; Felton, D. G. I. J. Chem. Soc. 1951, 700. 
11.  Oikawa, Y.; Yonemitsu, O. J. Org. Chem. 1977, 42, 1213. 
12. [a] Wender, P. A.; White, A. W. Tetrahedron 1983, 39, 3767. [b] For a related 
approach, see Kudzma, L. V. Synthesis 2003, 1661. 
13. [a] Osuka, A.; Mori, Y.; Suzuki, H. Chem Lett. 1982, 2031. [b] Yan, S.; Wu, H.; 
Wu, N.; Jiang, Y. Synlett 2007, 2699. 
14.  Iida, H.; Yuasa, Y.; Kibayashi, C. J Org. Chem. 1979, 44, 123. 
15. [a] Scott, T. L.; Burke, N.; Carrero-Martinez, G.; Soderberg, B. C. G. 
Tetrahedron 2007, 63, 1183. [b] Soresen, U. S.; Pombo-Villar, E. Helv. Chim. 
Acta 2004, 87, 82. [c] Wang, H.-M.; Chou, H.-L; Chen, L-C. J. Chin. Chem. Soc. 
(Taipei) 1995, 42, 593. [d] Mori, M.; Uozumi, Y.; Sibasaki, M. Heterocycles 
1992, 33, 819. [e] Sakamoto, S.; Nagano, T.; Kondo, Y.; Yamanaka, H. Synthesis 
1990, 215. 
16. Davidson, D.; Bernhard, S. A. J Am. Chem. Soc. 1948, 70, 3426. 
17. Mehta, A.; Jaouhari, R.; Benson, T. J.; Douglas, K. T. Tetrahedron Lett. 1992, 33, 
5441. 
18. [a] Oikawa, Y.; Sugano, K.; Yonemitsu, O. J. Org. Chem. 1978, 43, 2087. [b] 
Oikawa, Y.; Sugano, K.; Yonemitsu, O. rganic Syntheses; Wiley-Interscience,        
New York, NY; Coll. Vol. VII, pp 359-361. 
 38
19. [a] Sheehan, J. C.; Cruickshank, P. A.; Boshart, G. L. J. Org. Chem. 1961, 26, 
2525. [b] Kopple, K. D.; Nitecki, D. E. J. Am. Chem. Soc. 1962, 84, 4457. 
20. The use of a larger excess of 4-(dimethylamino)pyridine promotes side reactions 
that generate more complex product mixtures. 
21. Several other reagent combinations were explored for the lactamization reaction. 
[a] N-(3-Dimethylaminopropyl)-N’-ethyl carbodiimide alone: ref 18b. [b] N-(3-
Dimethylaminopropyl)-N’-ethyl carbodiimide with 1-hydroxybenzotriazole: 
Harigawa, D.; Neya, M.; Miyazaki, Y.; Hemmi, K.; Hashimoto, M. J. Chem. Soc., 
Chem Commun. 1984, 1676. [c] Polymer-bound N-benzyl-N’-
Cyclohexylcarbodiimide: LeBas, M.-D. H.; McKinley, N. F.; Hogan, A. –M. L.; 
O’Shea, D. F. J. Comb. Chem. 2005, 7, 503.  N,N’-Dicyclohexylcarbodiimide 
appeared to promote lactam formation, but N,N’-dicyclohexylurea and excess 
carbodiimide but could not be removed from the products.  All reactions were run 
in dichloromethane; each was tried with added triethylamine and 4-
dimethylaminopyridine. 
22. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923. 
23. Mohri, K.; Oikawa, Y.; Hirao, K.; Yonemitsu, O. Heterocycles 1982, 19, 515. 
24. Julia, M.; Bagot, J. Bull Soc Chim Fr. 1964, 1924. 





DIVERGENT REACTIVITY IN TANDEM REDUCTION-MICHAEL RING 




 The reductive cyclization of 2-nitrobenzyl ketones under dissolving metal 
conditions is a well established route to indoles.1,2  Earlier work from our laboratory 
reported a tandem reduction-Michael addition variant of this reaction as a route to 
1,2,3,4-tetrahydroquinoline-2-acetic esters,3 and we have recently utilized this reaction to 
synthesize 1,2,3,9-tetrahydro-4H-carbazole-4-one.4  In the current investigation, we 
sought to expand the scope of the tandem reduction-Michael sequence to access
functionalized, linear-fused tricyclic systems.  For this study, we prepared six- and five-
membered cyclic enones, substituted at C4 by a methyl ester and a 2-nitrobenzyl group, 
and subjected each to mild reduction using iron in acetic acid.  To our surprise, divergent 
reactivity was observed from the cyclohexenone and cyclopentenone substrates resulting 
in two relatively uncommon ring systems.  In addition, a mechanistically novel 
competitive ester reduction process was observed.  Thus, we wish to report our findings 
in this area.   
Results and Discussion 
 The syntheses of the cyclization substates are summarized in Figure 3.1.  
Ketoester 3 was prepared from 1,3-cyclohexanedione (1) by Lewis acid-catalyzed enol
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ether formation to give 2,5 followed by kinetic deprotonation6 and subsequent reaction 
with methyl cyanoformate7.  In this case methyl cyanoformate gave better yields of the 
ketoester than methyl chloroformate with easier purification of the product.  Ketoester 6 















Figure 3.1.  Synthesis of Cyclization Substrates 
 
Alkylation of 5 and 6 with 2-nitrobenzyl bromide9 using potassium carbonate and 
catalytic 18-crown-6 in acetonitrile under anhydrous conditions10 gave products 7 and 8, 
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respectively.  Reduction of the enone carbonyls in 7 and 8 with sodium borohydride in 
the presence of cerium(III) chloride,11 followed by treatment with aqueous acid, resulted 
in 1,3-carbonyl transposition to give substrates 9 and 10.   
The results of this reduction-cyclization study are outlined in Figure 3.2.  In each 













Figure 3.2.  Ring cyclization and its derivatization 
 
For cyclohexenone 9, the expected reduction-Michael addition was not observed, but 
instead, reduction of the nitro group was followed by addition of the aniline nitrogen to 
the ester to give the spiro-fused 3,4-dihydro-2(1H)-quinolinone derivative 11 (95%) 
yield.  For cyclopentenone 10, the reduction-Michael sequence proceeded as planned but 
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was accompanied by reduction of the ester to afford alcohol 12 in 76% yield.  Extended 
reaction times (4 hours) led to further acylation of the primary alcohol in 12 to give 13.   
 
Figure 3.3.  Molecular structure of compound 14, with thermal ellipsoids drawn at the 
50% probability level.  Hydrogen atoms on C10 and on the aromatic rings have been 
removed for clarity. 
The cis stereochemistry of the ring junction was confirmed by single crystal X-ray 
analysis of the N-benzoyl derivative 14 derived from 13 (Figure 3.3). 
Examination of molecular models provides some insight into the observed 
difference in reactivity.  Following reduction of the nitro function n 9, alignment of the 
amino group for addition to the enone would result in steric repulsion between the C5 
methylene of the cyclohexenone ring and the aromatic ring as in A (Figure 3.4).  Rotation 
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about the benzylic bond to minimize this interaction would then lead to conformation B, 
which is more prone to react at the ester carbonyl.  By comparison, similar steric 
interference is not present in cyclopentenone 10.  Furthermore, the five-membered cyclic 
enone should be more reactive due to strain.  Eclipsing interactions that develop in the 
five-membered ring of 12 during addition should not significantly deter cyclization since 
the starting enone also possesses considerable torsional strain.  The eclipsing in the 






Figure 3.4.  Steric repulsion of the six membered cyclohexenone ring 
 
The preference for the cis stereochemistry of the ring junction in 12 is in accord 
with both strain and stereoelectronic considerations.  The cis-fused stereochemistry 
would be expected based on strain arguments, with the cis-fused ring junction preferred 
over the more strained trans.12  Stereoelectronically, it is well established the cis-fused 
isomer is strongly favored in nucleophilic ring closures on pre-existing rings via an axial 
attack that permits a chair-like transition state.13  Although, a true chair transition state is 
not possible due to the aromatic sp2 carbons, pseudoaxial attack would still be expected to 













The reduction of the ester group in 10 is also an interesting observation.  The 
reduction is analogous to the classical Bouveault-Blanc reaction14 but would not be 
expected to occur with iron as the electron source.15  In our substrates, the α,β-
unsaturated ketone is the functional group most susceptible to reduction nder dissolving 
metal conditions,16 and it is reasonable that this moiety is the key to reducing the ester. 
 To explore this process without interference from the amino group, methyl (±)-1-
benzyl-4-oxo-2-cyclohexene-1-carboxylate (15) and methyl (±)-1-benzyl-4-oxo-2-
cyclopentene-1-carboxylate (16) were prepared using the same method described for the 
nitro-bearing substrates above.  Treatment of 15 with iron in acetic acid for 24 hours 
yielded a 33:67 mixture (by NMR) of starting material 15 and the double bond reduction 
product 17.  This ratio varied little with longer reaction times or increased amounts of 
iron.  A similar reaction of 16 gave more interesting results, and the reaction was 
considerably faster.  Exposure of 16 to iron in refluxing acetic acid gave nearly complete 
conversion to alcohol 20 in 15 minutes.  Prolonged treatment (2 hours) under the same 
conditions gave a 67:33 mixture (by NMR) of 20:22, as the acetates, in 95% yield.  These 
results are summarized in Figure 3.5. 
Mechanistically, reduction of 15 and 16 is initiated by protonation of the enone 
carbonyls followed by addition of two electrons to each conjugated system16 to give of 
anions 23 and 24, respectively (Figure 3.6).  In 23, the six-membered ring is 
conformationally flexible making the ester at C4 less accessible to attack by the anionic 












Figure 3.5.  Cyclization of the substrate in the absence of nitro group 
Substrate                time (hours)                    15                 17                  19                   21 
15(n = 2)                      24                              33                 67      0                    0 
                                                                       16               18                  20                   22
16(n = 1)                    0.25                             10[b]             0                    72 [b]          trace 
                                   2                                    0                  0                    67 [c]         33 [c] 
[a] Percentage listed are from the 1H NMR.  [b] Isolated yields.  [c] Products detected 
were the acetates of the indicated alcohols. 
structure 24, the C3 anion is closer to the C4 ester, and cyclization occurs to afford the 
strained cyclopropanone hemiketal 25.  Under the acidic conditions of the reaction, 25 
would undergo rapid proton and enol assisted three-ring opening,17 as in 26, followed by 
loss of methanol to give aldehyde 27.   Further reduction of 27 would then afford alcohol 
20 and, eventually, 22.  
 The systems resulting from these ring closures have minimal precedent in the 



















recovered 15 (n = 2)
recovered 16 (n = 1)
15 (n = 2)
16 (n = 1)
17 (n = 2)
18 (n = 1)
19 (n = 2)
20 (n = 1)
21 (n = 2)
22 (n = 1)
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some antidepressants,18 but spiro-fused compounds have not been extensively 
investigated.19  The 2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b] quinoline system has been 
reported20 and is known to exhibit some antipsychotic activity,21 but structures with the 








Figure 3.6.  Mechanism of the benzylic substrate 
 
Conclusion 
 Divergent behavior has been observed in the dissolving metal reduction-Michael 
reaction of two substrated differing only in the size of the ring incorporating the Michael  
acceptor.  The disparate reaction pathways can be attributed to differences in stain and 
steric environment of the enone acceptor as well as the alignment of the reacting 
functionality in the two systems.  The reaction is clean and offers an efficient route to a 
relatively rare ring skeleton from each substrate.  The reduction of the ester functionality 
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in the five-membered ring substrate is novel and likely involved participa on of the 
enone moiety. 
Experimental Section 
 Commercial reagents and solvents were used as received.  Tetrahydrofuran was 
dried over potassium hydroxide pellets and distilled from lithium aluminium hydride 
prior to use.  The hydrochloric acid (3 M), ammonium chloride (saturated), sodium 
bicarbonate (saturated) and sodium chloride (saturated) used in workup procedures refer 
to aqueous solutions.  All reactions were run under dry nitrogen in oven-dried glassware.  
Reactions were monitored by thin layer chromatography on silica gel GF plates (Analtech 
21521).  Preparative separations were performed using flash column chromatography22 
on silica gel (grade 62, 60-200 mesh) mixed with ultraviolet-active phosphor (Sorbent 
Technologies 5) or thin layer chromatography on 20-cm × 20-cm silica gel GF plates 
(Analtech 02015); band elution was monitored using a hand held ultraviolet lamp.  
Hexanes used in chromatography had a boiling range of 65-70 ºC.  Melting points of all 
solids were uncorrected and taken on a MelTemp purchased from Laboratory Devices, 
Cambridge, MA 02139.   Infrared spectra were run as thin films on sodium chloride 
disks.  1H and 13C Nuclear magnetic resonance spectra were measured in 
deuteriochloroform at 300 MHz and 75 MHz, respectively, on a Varian 300 MHz unit 
and were referenced to internal tetramethylsilane; coupling constants (J) are reported in 
Hertz. 
3-Methoxy-2-cyclohexen-1-one (2).  The procedure of Sabitha and coworkers5 was 
modified.  A mixture of 20.0 g of silica gel (Alfa-Aesar, 220-440 mesh) and 3.60 g (9.60 
mmoles) of cerium(III) chloride heptahydrate in 60 mL of dry acetonitrile was stirred for 
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12 hours at 22 ºC.  The acetonitirle was removed under vacuum, and a solution of 5.00 g 
(44.6 mmoles) of 1 in 20 mL of methanol was added.  The mixture was stirred for 72 
hours at 22 ºC and filtered with ethyl acetate.  The filtrate was concentrated under 
reduced pressure and the crude product was purified by flash chromatography on a 30-cm 
× 2.5-cm silica gel column eluted with 50% ethyl acetate in hexan s to give 3.70 g (90%) 
of 2 as a colorless oil. IR: 1671, 1645, 1605 cm-1; 1H NMR: δ 5.37 (s, 1H), 3.70 (s, 3H), 
2.42 (t, 2H, J = 6.4), 2.35 (t, 2H, J = 6.9), 1.98 (quintet, 2H, J = 6.6); 13C NMR: δ 199.4, 
178.4, 102.1, 55.4, 36.5, 28.6, 21.0. 
Methyl (±)-4-Methoxy-2-oxo-3-cyclohexene-1-carboxylate (3).  To a stirred solution of 
2.88 g (4.00 mL, 28.6 mmoles) of diisopropylamine in 30.0 mL of tetrahydrofuran at -78 
ºC, was slowly added 17.0 mL of 1.75 M n-butyllithium in hexanes (30.0 mmoles). After 
30 minutes, a solution of 3.00 g (23.8 mmoles) of 2 in 20.0 mL of tetrahydrofuran was 
added dropwise and stirring was continued at -78 ºC for 30 minutes.  A solution of 3.40 g 
(40.0 mmoles) of methyl cyanoformate in 10 mL of tetrahydrofuran was then added 
dropwise and the reaction was stirred for 1 hour at -78 ºC.  The reaction mixture was 
slowly warmed to 22 ºC, stirred for 30 minutes, cautiously added to saturated ammonium 
chloride (50 mL) and extracted with ether (3 × 100 mL).  The ether extracts were washed 
with saturated sodium bicarbonate (1 × 100 mL), water (1 × 100 mL) and s turated 
sodium chloride (1 × 100 mL), then dried (magnesium sulfate) and concentrated under 
vacuum.  The crude product was purified by flash chromatography on a 100-cm × 2.5-cm 
silica gel column eluted with 30% ethyl acetate in hexanes to give 0.60 g (20%) of 2 and 
3.20 g (73%) of 3.  The yield of 3 was 91% based on recovered starting material.  IR: 
1740, 1656, 1606 cm-1;  1H NMR: δ 5.41 (s, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 3.35 (dd, 1H, 
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J = 9.2, 5.3), 2.57 (m, 1H), 2.46 (m, 1H), 2.36 (m, 1H), 2.17 (m, 1H); 13C NMR: δ 193.5, 
178.4, 170.6, 101.6, 55.8, 52.2, 52.0, 27.0, 24.0. 
Trimethyl ( E)-3-Methoxy-3-butene-1,1,4-tricarboxylate (5):    This compound was 
prepared by the method of Fuchs and McGarrity.8  To a stirred solution of 6.60 g (50.0 
mmol) of dimethyl malonate in 25 mL of dry N,N-dimethyl formamide was added 2.78 g 
(50.0 mmol) of sodium methoxide, and the solution was stirred at room temperature for 
10 minutes.   After 10 minutes, 4.16 g (25.0 mmol) of methyl (E)-4-chloro-3-methoxy-2-
butenoate (4) was added and stirring was continued for 2 hours.  The solvent was distilled 
off at 45 ºC/15 mm, and the residue was mixed with in 25 mL of dichloromethane and 25 
mL of water.  The aqueous layer was acidified with 15 mL of 30% HCl.  The combined 
aqueous and organic layer was transferred into a separatory funnel, a d the 
dichloromethane layer was separated.  The organic layer was further washed with water 
(1 × 25 mL), saturated sodium chloride (1 × 25 mL), dried over magnesium sulfate and 
concentrated under vacuum to give a colorless liquid.  The liquid was further distilled at 
180 ºC /15 mm to give  5 (78%).   The spectral data matched with those reported.   
Methyl (±)-4-Methoxy-2-oxo-3-cyclopentene-1-carboxylate (6).  Exactly 1.4 g (61.3 
mmol) of sodium was added into a 100-mL, three necked round-bottomed flask, equipped 
with an additional funnel, a reflux condenser and a magnetic stir bar, containing 70 mL of 
dry methanol.   The reaction mixture was heated at 60 ºC under nitrogen atmosphere for 
30 minutes and 8.0 g (30.0 mmol) of trimethyl (E)-methoxy-3-butene-1,1,4-
tricarboxylate (5) was added dropwise to the reaction mixture under hot conditions.  After 
stirring for 4 hours at reflux, the reaction mixture was cooled to room temperature, and 
4.0 mL of acetic acid was added.  The methanol layer was concentrated under vacuum.  
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The crude residue was dissolved in 50 mL of dichloromethane and washed wit  water (1 
× 50 mL), and saturated sodium chloride (1 × 50 mL), then dried (magnesium sulfate) 
and concentrated under vacuum to give a colorless liquid.  The liquid was purified by 
distilling at 116-117 ºC/5 mm to give a colorless liquid 6 (82 %).  The physical and 
spectral data matched those reported.   
Representative Procedure for Alkylation of 3 with 2-Nitrobenzyl Bromide: Methyl 
(±)-4-Methoxy-1-(2-nitrobenzyl)-2-oxo-3-cyclohexene-1-carboxylate (7):  The general 
procedure of Makosza and Tyrala10 was used.  A 100-mL three-necked round-bottomed 
flask, equipped with an addition funnel, a reflux condenser and a magnetic stir bar, was 
charged with a 35 mL of dry acetonitrile, 4.87 g (35.2 mmoles) of anhydrous pota sium 
carbonate and 10 mg of 18-crown-6.  Stirring was initiated, and a solution of 2.16 g (11.7 
mmoles) of 3 in 10 mL of acetonitrile was added dropwise at 22 ºC.  The resulting blue 
solution was stirred for 10 minutes, and a solution of 2.80 g (13.0 mmoles) of 2-
nitrobenzyl bromide9 in 10 mL of acetonitrile was added dropwise.  The reaction was 
refluxed for 18 hours at which time thin layer chromatography indicated complete 
consumption of 3.  The crude reaction mixture was cooled, diluted with ether, vacuum 
filtered and concentrated under vacuum.  The resulting dark yellow oil as purified by 
flash chromatography on a 100-cm × 2.5-cm silica gel column eluted wi h 20-30% ether 
in hexanes to give 3.30 g (88%) of 7 as a light yellow oil.  IR: 1729, 1660, 1609, 1526, 
1384, 1350 cm-1;  1H NMR: δ 7.82 (dd, 1H, J  =  8.2, 6.6), 7.47 (td, 1H, J = 7.5, 1.5), 7.36 
(td, 1H, J = 7.9, 1.6), 7.35 (d, 1H, J = 7.0), 5.41 (d, 1H, J = 1.5), 3.87 (d, 1H, J = 14.1), 
3.68 (s, 3H), 3.67 (s, 3H), 1.77 (m, 1H); 13C NMR: δ 193.9, 177.7, 171.1, 150.9, 133.4, 
133.3, 131.5, 127.9, 124.7, 101.9, 57.0, 55.8, 52.7, 34.7, 28.3, 26.3.  
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Methyl (±)-4-Methoxy-1-(2-Nitrobenzyl)-2-oxo-3-cyclopentene-1-carboxylate (8).  
This compound (3.00 g, 84%) was obtained as a light yellow oil.  IR: 1740, 1699, 1596, 
1526, 1359 cm-1; 1H NMR: δ 7.86 (dd, 1H, J = 8.1, 1.5), 7.47 (td, 1H, J = 7.5, 1.5), 7.38 
(td, 1H, J = 7.9, 1.6), 7.35 (dd, 1H, J = 7.7, 1.5), 5.26 (t, 1H, J = 1.1), 3.80 (s, 3H), 3.75 
(d, 1H, J = 14.6), 3.75 (s, 3H), 3.52 (d, 1H, J = 14.6), 3.17 (dd, 1H, J = 17.9, 1.1), 2.48 
(dd, 1H, J = 17.9, 1.1);  13C NMR: δ 200.3, 191.0, 170.8, 150.5, 132.7, 132.2, 131.4, 
128.0, 124.7, 102.0, 59.8, 59.1, 53.1, 37.0, 33.7. 
Representative Procedure for 1,3-Carbonyl Transposition: Methyl (±)-1-(2-
Nitrobenzyl)-4-oxo-2-cyclohexene-1-carboxylate (9).   The procedure of Luche was 
modified.11  A 250-mL three-necked round-bottomed flask, equipped with a reflux 
condenser and a magnetic stir bar, was charged with 20 mL of methanol followed by 4.60 
g (12.4 mmoles) of cerium(III) chloride heptahydrate.  The mixture was stirred for 10 
minutes, and a solution of 2.50 g (7.84 mmoles) of 5 in 10 mL of methanol was added 
dropwise.  After 5 minutes, 1.25 g (32.9 mmoles) of sodium borohydride was added in 
small portions over a period of 20 minutes.  [Caution!  Frothing is a problem if the added 
portions of sodium borohydride are too large.].  The reaction mixture was stirred for 15 
minutes at which time 12 mL of 3 M hydrochloric acid was added.  After 20 minutes, the 
mixture was concentrated under vacuum to one-third its volume and extract d with ether 
(3 × 75 mL).  The combined ether extracts were washed with water (3 × 50 mL) and 
saturated sodium chloride (1 × 50 mL), then dried (magnesium sulfate) and concentrated 
under vacuum.  The resulting dark brown liquid was purified by flash chromatography on 
a 50-cm × 2.5-cm silica gel column eluted with 20-30% ether in hexanes to give 1.78 g 
(79%) of 9 as thick yellow oil.  IR: 1732, 1685, 1609, 1528, 1351 cm-1; 1H NMR: δ 7.92 
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(dd, 1H, J = 8.1, 1.5), 7.55 (td, 1H, J = 7.5, 1.3), 7.43 (td, 1H, J = 8.1, 1.5), 7.27 (dd, 1H, 
J = 7.7, 1.5), 6.82 (d, 1H, J = 10.4), 6.02 (d, 1H, J = 10.4), 3.70 (s, 3H), 3.66 (d, 1H, J = 
13.8), 3.50 (d, 1H, J = 13.8), 2.45 (m, 2H), 2.36 (m, 1H), 2.06 (m, 1H);  13C NMR: δ 
197.8, 172.8, 50.2, 149.0, 133.0, 132.7, 130.3, 129.7, 128.5, 125.2, 52.8, 48.6, 39.5, 34.4, 
30.9. 
Methyl (±)-1-(2-Nitrobenzyl)-4-oxo-2-cyclopentene-1-carboxylate (10).  This 
compound (1.65 g, 73%) was obtained as yellow crystals, mp 103-105 ºC.  IR: 1712, 
1679, 1608, 1526, 1352 cm-1;  1H NMR:  δ 7.86 (dd, 1H, J = 8.2, 1.3), 7.52 (td, 1H, J = 
7.5, 1.3), 7.47 (d, 1H, J = 5.7), 7.39 (td, 1H, J = 8.1, 1.5), 7.29 (dd, 1H, J = 13.7), 3.17 (d, 
1H, J = 13.7), 2.36 (d, 1H, J = 18.7), 2.18 (d, 1H, J = 18.7);  13C NMR: δ 208.7, 167.3 
(2C), 150.1, 134.9, 133.4, 132.6, 131.2, 128.1, 125.0, 67.7, 52.3, 42.6, 36.5. 
(±)1’,4’-Dihydrospiro[2-cyclohexene-1’-3(2’H)-quinoline]-2’,4-dione (11).  The 
procedure of Bunce and co-workers was used.1  A 50-mL three necked round-bottomed 
flask, equipped with a reflux condenser and a magnetic stir bar, was charged with a 
mixture of 500 mg (1.73 mmoles) of 9, 7.25 mL of acetic acid and 773 mg (13.8 mmoles, 
8.0 eq) of iron powder (>100 mesh).  The reaction mixture was heated with stirring at 115 
ºC (oil bath) until thin layer chromatography indicated complete consumption of the 
starting material (ca 30 minutes).  The reaction mixture was cooled, diluted with 50 mL 
of water and extracted with ether (3 × 50 mL).  The combined ether layers were washed 
with water (1 × 50 mL), saturated sodium bicarbonate (3 × 50 mL), saturated sodium 
chloride (1 × 50 mL), then dried (magnesium sulfate) and concentrated under vacuum to 
give 373 mg (95%) of 11 as a pale white solid, mp 212-215 ºC.  IR: 3195, 1667 cm-1;  1H 
NMR: δ 8.69 (br, s, 1H), 7.21 (complex, 2H), 7.05 (td, 1H, J = 7.5, 1.3), 6.82 (obscured, 
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1H), 6.81 (d, 1H, J = 10.3), 6.14 (d, 1H, J = 10.3), 3.13 (d, 1H, J = 15.9), 2.99 (d, 1H, J = 
15.9), 2.73 (ddd, 1H, J = 17.1, 8.4, 4.9), 2.49 (ddd, 1H, J = 17.1, 8.4, 4.9), 2.34 (ddd, 1H, 
J = 13.4, 8.4, 4.9), 1.98 (ddd, 1H, J = 13.4, 8.4, 4.9);  13C NMR: δ 198.2, 172.1, 148.9, 
136.1, 130.7, 128.6, 128.2, 123.7, 121.1, 115.1, 42.6, 36.6, 33.6, 29.4. 
(±)-(3aR*,9aR*)-9a-Hydroxymethyl-1,3,3a,4,9,9a-hexahydro-2H-cyclopenta[b]- 
quinoline-2-one (12).  The procedure used to prepare 11 was followed using 200 mg 
(0.73 mmoles) of 10 and 325 mg (5.84 mmoles) of iron powder in 12 mL of acetic acid.  
After 30 minutes at 115 ºC, workup and preparative thin layer chromatography using 
40% ether in hexanes gave 120 mg (76%) of 12 as a light yellow oil.  IR: 3395, 1733   
cm-1;  1H NMR: δ 7.01 (td, 1H, J = 7.3, 1.2), 6.98 (dd, 1H, J = 7.5, 0.8), 6.64 (td, 1H, J = 
7.3, 1.2), 6.48 (dd, 1H, J = 7.9, 0.8), 3.92 (br s, 1H), 3.94 (t, 1H, J = 6.4), 3.59 (d, 1H, J = 
10.9), 3.55 (d, 1H, J = 16.7), 2.37 (d, 1H, J = 18.7), 2.17 (dd, 1H, J = 18.7, 1.6), 2.20 (m, 
1H);  13C NMR:  δ 216.6, 141.7, 129.6, 127.4, 117.5, 117.4, 113.4, 66.6, 52.0, 46.4, 45.9, 
41.3, 31.3.  This reaction also gave 26 mg (14%) of compound 13. 
(±)-(3aR*,9aR*)-9a-Acetoxymethyl-1,3,3a,4,9,9a-hexahydro-2H-cyclopenta[b]- 
quinolin-2-one (13).   The procedure used to prepare 9 was followed using 500 mg (1.82 
mmoles) of 10 and 812 mg (14.6 mmoles) of iron powder in 30 mL of acetic acid.  After
4 hours at 115 oC, workup and flash chromatography on a 25-cm × 2-cm silica gel 
column eluted with 15% ether in hexanes gave 400 mg (85%) of 14 as a tan oil.  IR: 
3394, 1740 cm-1;  1H NMR: δ 7.05 (m, 2H), 6.66 (td, 1H, J = 7.5, 1.3), 6.50 (dd, 1H, J = 
7.8, 0.8), 4.10 (br s, 1H), 4.08 (d, 1H, J = 11.4), 4.02 (d, 1H, J = 11.4), 3.92 (t, 1H, J = 
6.4), 2.80 (d, 1H, J = 16.5), 2.70 (d, 1H, J = 16.5), 2.70 (m, 1H), 2.27 (m, 2H), 2.21 (dd, 
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1H, J = 5.4, 1.1), 2.06 (s, 3H);  13C NMR: δ 214.9, 170.8, 141.4, 129.7, 127.6, 117.7, 
116.8, 113.5, 67.6, 52.4, 46.3, 46.0, 39.6, 31.5, 20.8. 
(±)-(3aR*,9aR*)-9a-Acetoxymethyl-4-benzoyl-1,3,3a,4,9,9a-hexahydro-2H-
cyclopenta[b]quinolin-2-one  (14).  To a stirred solution of 200 mg (0,77 mmoles) of 13 
and 85.6 mg (0.85 mmoles) of triethylamine in 20 mL of dichloromethane was slowly 
added a solution of 120 mg (0.85 mmoles) of benzoyl chloride in 1 mL of 
dichloromethane over a period of 5 minutes.  The reaction mixture was stirred at 22 ºC 
for 2 hours at which time thin layer chromatography confirmed the absence of starting 
material.  The reaction mixture was poured into cold water, and the dic loromethane 
layer was separated.  The organic phase was washed with cold water (2 × 20 mL), dried 
(magnesium sulfate) and concentrated under vacuum.  The resulting res due was passed 
through a small plug of silica gel with 30% ether in hexanes to give 260 mg (93%) of 14 
as a light yellow solid, mp 108-110 ºC.  IR: 1744, 1643 cm-1;  1H NMR: δ 7.38-7.21 
(complex, 6H), 7.07 (td, 1H, J = 7.5, 1.1), 6.93 (t, 1H, J = 7.5), 6.49 (d, 1H, J = 7.9), 5.19 
(dd, 1H, J = 9.0, 4.4), 4.28 (d, 1H, J = 10.9), 4.20 (d, 1H, J = 10.9), 3.04 (ddd, 1H, J = 
19.4, 9.0, 1.8), 2.94 (d, 1H, J = 14.1), 2.73 (d, 1H, J = 14.1), 2.29 (ddd, 1H, J = 19.4, 4.4, 
1.8), 2.20 (dd, 1H, J = 18.5, 1.8), 2.10 (s, 3H), 2.06 (dd, 1H, J = 18.5, 1.8);  13C NMR: δ 
214.1, 170.7, 169.8, 138.1, 134.8, 130.8, 130.6, 129.1, 129.0, 128.1, 127.4, 126.9, 126.1, 
171.1, 57.4, 48.0, 45.6, 45.2, 34.6, 20.7. 
X-Ray Crystallographic Analysis of 14.  Flat, elongated rods of 14 were obtained by 
slow diffusion of pentane into an ether solution of the compound.  A sample measuring 
0.4 × 0.4 × 0.1 mm, which was cut from a longer rod, was immersed in polyisobutylene 
and placed in a nylon loop under a nitrogen cold stream. The X-ray intensity data were 
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measured at 115(2) K on a Bruker SMART Apex II diffractometer.  Graphite-
monochromated Mo-Kα radiation (λ = 0.71073 Å, fine-focus sealed tube) was used with 
the CCD detector placed 6.0 cm from the sample.  Data frames were collected in a series 
of  φ and ω scans with 0.5 º scan widths and 30 second exposure times.  Data integr tion  
employed the Bruker SAINT software package.23  Data were corrected for absorption 
effects using the multi-scan technique (SADABS).24  The structure was solved by direct 
methods and refined by full-matrix least-squares of F2 using the Bruker SHELXTL 
software suite.25  Non-hydrogen atoms were assigned anisotropic temperature factors.  
Hydrogen atoms were placed in calculated positions based on the geometry at carbon 
(riding model).  Refined formula: C22H21NO4, M = 363.40, monoclinic, space group 
P21/n, a = 11.1983(2) Å, b = 8.18310(10) Å, c = 19.7453(3) Å, β = 101.7010(10)º, U = 
1771.80(5) Å3, Z = 4, Dc = 1.362 g cm
-1, µ = 0.094 mm-1, T = 115(2) K, 2θmax = 50.6 º, 
completeness to 2θmax = 100.0%, 13372 total reflections, 3227 independent (Rint = 
0.0248), 2619 observed [I>2σ(I)].  Final R1 [I>2σ(I) ] = 0.0336, wR2 (all data) = 0.0833, 
largest difference peak and hole 0.225 and -0.194 eÅ-3.  CCDC 692896 contains the 
supplementary crystallographic data for compound 14.  These data can be obtained free 
of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Methyl (±)-1-Benzyl-4-oxo- 2-cyclohexene-1-carboxylate (15).  The procedure used to 
prepare 7 was followed using 1.08 g (5.85 mmoles) of 3 and 1.11 g (6.5 mmoles) of 
benzyl bromide.  Following flash chromatography, 1.52 g (95%) of methyl (± )-1-benzyl-
4-methoxy-2-oxo-3-cyclohexene-1-carboxylate was isolated as a white solid, mp 68-70 
ºC.  IR: 1729, 1660, 1610 cm-1;  1H NMR: δ 7.28-7.17 (complex, 3H), 7.14 (m, 2H), 5.41 
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(d, 1H, J = 1.2), 3.71 (s, 3H), 3.66 (s, 3H), 3.32 (d, 1H, J = 13.7), 3.23 (d, 1H, J = 13.7), 
2.63 (m, 1H), 2.29 (m, 2H), 1.80 (m, 1H);  13C NMR: δ 194.4, 177.8, 171.5, 136.5, 130.4, 
128.1, 126.7, 101.9, 56.9, 55.7, 52.4, 40.0, 28.1, 26.3. 
Reduction and carbonyl transposition was carried out as described for the 
preparation of 9 was followed using 1.52 g (5.56 mmoles) of the benzylated product from 
above.  Following flash chromatography, 1.22 g (90%) of 15 was isolated as a colorless 
oil.  IR: 1732, 1681 cm-1;  1H NMR: δ 7.32-7.22 (complex, 3H), 7.09 (dd, 1H, J = 7.8, 
1.8), 6.95 (d, 1H, J = 10.3), 6.02 (d, 1H, J = 10.3), 3.69 (s, 3H), 3.08 (s, 2H), 2.47 (m, 
2H), 2.40 (m, 1H), 2.07 (m, 1H);  13C NMR: δ 198.3, 173.2, 150.3, 135.4, 129.8, 129.2, 
128.4, 127.2, 52.3, 49.0, 44.5, 34.5, 30.5. 
Methyl (±)-1-Benzyl-4-oxo-2-cyclopentene-1-carboxylate (16).  The procedure used to 
prepare 7 was followed using 0.99 g (5.85 mmoles) of 6 and 1.11 g (6.50 mmoles of 
benzyl bromide.  Following flash chromatography, 1.46 g (96%) of methyl (±)-1-benzyl-
4-methoxy-2-oxo-3-cyclopentene-1-carboxylate was isolated as whitesol d, mp 96-98 ºC.  
IR:  1741, 1699, 1597 cm-1;  1H NMR: δ 7.27-7.17 (complex, 3H), 7.13 (m, 2H), 5.18 (s, 
1H), 3.76 (2s, 6H), 3.30 (d, 1H, J = 14.1), 3.25 (d, 1H, J = 14.1), 3.11 (dd, 1H, J = 17.7, 
1.0), 2.61 (dd, 1H, J = 17.7, 1.0);  13C NMR: δ 200.6, 190.3, 171.0, 136.2. 130.0, 128.2,  
126.9, 102.3, 60.1, 59.0, 52.9, 39.1, 36.5. 
 Reduction and carbonyl transposition was carried out as described for the 
preparation of 9 was followed using 1.46 g (5.62 mmoles) of the benzylated product from 
above.  Following flash chromatography, 1.16 g (90%) of 16 was isolated as colorless oil.  
IR: 1710, 1677 cm-1;  1H NMR: δ 7.54 (d, 1H, J = 5.7), 7.32-7.20 (complex, 3H), 7.13 
(m, 2H), 6.14 (d, 1H, J = 5.7), 3.62 (s, 3H), 2.97 (d, 1H, J = 13.3), 2.84 (d, 1H, J = 13.3), 
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2.29 (s, 2H);  13C NMR:  δ 209.0, 168.2, (2C)., 136.4, 130.2, 128.3, 126.8, 67.3, 51.7, 
43.0, 41.5. 
Reduction of 15 with Iron and Acetic Acid.  Methyl 1-Benzyl-4-oxocylohexane-1-
carboxylate (17).  The procedure used to prepare 11 was followed using 500 mg (2.05 
mmoles) of 15 and 915 mg (16.4 mmoles) of iron powder in 35 mL of acetic acid.  After
24 hours, workup gave 450 mg of an inseparable 33:67 mixture of 15:17.  The spectral 
data for 17 were: IR: 1727, 1702 cm-1; 1H NMR: δ 7.36-7.27 (complex, 3H), 7.12 (m, 
2H), 3.77 (s, 3H), 2.96 (s, 2H), 2.56-2.33 (complex, 6H), 1.78 (m, 2H); 13C NMR: δ 
210.4, 174.8, 129.4, 128.1, 127.9, 126.6, 51.6, 47.5, 45.6, 38.1, 33.1.  The use of more 
iron and longer reation times failed to significantly alter this product ratio. 
Reduction of 16 with Iron and Acetic Acid: (±)-4-Benzyl-4-hydroxymethyl-2-
cyclopenten-1-one (20).  The procedure used to prepare 11 was followed using 500 mg 
(2.17 mmoles) of 16 969 mg (17.3 mmoles) of iron powder in 35 mL of acetic acid.  
After 15 minutes, workup and preparative thin layer chromatography gave 320 mg (72%) 
of 20 as a colorless oil.  IR: 3416, 1711, 1677 cm-1;  1H NMR: δ 7.53 (d, 1H, J = 5.7), 
7.30-7.21 (d, 1H, J = 10.7), 7.10 (d, 2H, J = 6.8), 6.11 (d, 1H, J = 5.7), 3.60 (d, 1H, J = 
10.7), 3.58 (d, 1H, J = 10.7), 2.96 (d, 1H, J = 13.5), 2.81 (d, 1H, J = 13.5), 2.62 (br s, 1H), 
2.29 (d, 1H, J = 18.6), 2.26 (d, 1H, J = 18.6);  13C NMR: δ 209.5, 168.7, 136.3, 134.4, 
130.1, 128.2, 126.7, 67.0, 51.8, 42.9, 41.3.   
 Upon prolonged heating for 2 hours, the reaction gave 450 mg of an inseparabl  
67:33 mixture of 20:22 as the acetates.  The spectral data for 20 (acetate) were: IR: 1743, 
1715 cm-1.  1H NMR: δ 7.46 (d, 1H, J = 5.7), 7.33-7.17 (complex, 3H), 7.09 (m, 2H), 
6.13 (d, 1H, J = 5.7), 4.17 (d, 1H, J = 10.9), 4.00 (d, 1H, J = 10.9), 2.96 (d, 1H, J = 13.7), 
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2.84 (d, 1H, J = 13.6), 2.31 (s, 2H), 2.06 (s, 3H);  13C NMR: δ 207.6, 170.6, 166.7, 135.5, 
134.6, 130.0, 128.4, 127.0, 67.7, 49.4, 43.0, 42.0, 20.7;  The spectra data for 22 (acetate) 
were  IR: 1743 cm-1;  1H NMR: δ 7.34-7.18 (complex, 3H), 7.10 (m, 2H), 3.98 (d, 1H, J = 
11.1), 3.89 (d, 1H, J = 11.1), 2.79 (s, 2H), 2.39-2.21 (complex, 2H), 2.33 (s, 2H), 2.10 (s, 
3H), 1.93 (m, 2H);  13C NMR:  δ 217.5, 170.7, 136.6, 130.0, 128.3, 126.7, 68.4, 47.0, 
43.6, 42.3, 36.3, 30.2, 20.8. 
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SYNTHESIS OF (±)-2-ARYL- AND 2-ALKYL-SUBSTITUTED 2,3-DIHYDR O-
4(1H)-QUINAZOLINONES FROM 2-NITRO- AND 2-AMINOBENZAMIDE 
 
Introduction 
 Dihydroquinazolinones are an important class of heterocycles that have expressed 
a broad range of biological activities.1  This ring system is found as the core structure in 
compounds investigated as anticancer,2 anti-inflammatory,3 anticonvulsant,4 anti-
bacterial,5 antifungal,6 anti-osteoporosis7  and diuretic8 drug candidates.  Additionally, 
several dihydroquinazolinone derivatives have been found to be potent plant growth 
regulators and herbicidal agents. 9 
We have previously utilized tandem reactions initiated by dissolving metal 
reduction of nitroarenes to prepare indole-3-carboxylic esters10 and benzo-fused 
oxepinones, diazepinones,11 and carbazoles12 as well as various linear-fused ring 
systems.13  In the current project, we have employed a tandem reduction-condensative 
cyclization strategy involving 2-nitrobenzamide (1) and an aldehyde or ketone 2 for the 
formation of 2-aryl- or 2-alkyldihydroquinazolinones 3.  This method has been further 
extended to include sequences involving additional reactions following the heterocyclic 
ring closure.  Finally, we have also found that heating 2-aminobenzamide (4) with 
aldehydes and ketones in glacial acetic acid provides the target heterocycl s cleanly and 
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in high yields. 
Earlier methods reported to prepare dihydroquinazolinones utilized 1 with aldehydes 
and ketones in the presence of titanium(IV) chloride and zinc,14 samarium iodide15 and 
samarium in the presence of iodine.16  The target compounds have also been prepared by 
condensation of 4 with aldehydes or ketones in the presence of catalysts such as 
gallium(III) triflate,17 scandium(III) triflate18 or by heating in solvents such as 
trifluoroethanol.19  Most of these reagents and catalysts are expensive and require dry box 
conditions; additionally, the reaction workup procedures are often tedious.  Alternative 
methods are available using isatoic anhydride with amines and carbonyl compounds in 
the presence of montmorillonite K-10,20 p-toluenesulfonic acid21 or Amberlyst-15 under 
microwave conditions.22  The yields reported for these methods are slightly lower and 
have been evaluated on only a limited selection of aldehydes and ketones.  To overcome 
these shortcomings, we report a method which uses inexpensive, readily available 
reagents and mild conditions that hydroquinazolinones from a wide variety of aldehydes 
and ketones.  The only general procedure that compares well with our approach involves 
the cyclization of 4 with aldehydes and ketones promoted by catalytic ammonium 
chloride in ethanol.23 
Results and Discussion 
The results of our tandem synthesis of dihydroquinazolinones from reductive cyclization 
of 1 with aldehydes and ketones are summarized in Figure 4.1.   The reaction is 
performed by reacting a 1:1 mole ratio of 2-nitrobenzamide (1) and the carbonyl 
compound 2 with 5 equivalents of iron powder in acetic acid at 115 oC for 30 minutes.  
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After quenching with water, extractive workup and recrystallization, 




















Figure 4.1.  Cyclization of aldehydes and ketones with 1 
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required.  Finally, the target heterocycles can also be prepared in comparable yields by 
reacting 2-aminobenzamide (4) with an aldehyde or ketone (1:1) in acetic acid for 30 
minutes at 115 oC or 4 hours at room temperature (see Figure 4.2). 
In the current project, we have prepared 2-aryl and 2 alkyl-substituted 
dihydroquinazolinone derivatives from both 2-nitrobenzamide (1) and 2-aminobenzamide  
















Figure 4.2.  Cyclization of aldehydes and ketones with 4 
 
(4) in acetic acid.  Starting from 1 under dissolving metal conditions, the process is 
initiated by reduction of the nitro group to give 4 (Figure 4.3).  The aniline amino group 
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the amide nitrogen to close the heterocyclic portion of the structure.  Reactions starting 
with 4 do not require added iron and proceed rapidly at reflux or more slowly at room 
temperature (see Figure 4.2).  
We have also used modified carbonyl substrates to generate more complex 
structures such as 6-9 (see Figure 4.4).  This involved reacting 1 with aldehydes and 
ketones bearing reactive functionality γ to the carbonyl function.  Cyclization of these 





                  
              Figure 4.3.  Mechanism for dihydroquinazolinone formation 
 
such that a subsequent reaction would close to a five-membered ring.  This was the only 
ring size  that successfully formed in these extended tandem sequenc s.  For example, the 
reaction of 1 with 5-chloro-2-pentanone (10) under dissolving metal conditions furnished 
tetrahydropyrrolo[1,2-a]quinazolinone (6) in 73% yield.  This reaction involved 
reduction of the nitro function and ring closure to generate the dihydroquinazolinone ring 
with a chloride leaving group δ to the aniline nitrogen.  Further reaction then occurred by 
SN2 displacement of chloride by the more reactive aniline nitrogen
24 to deliver the final 













Figure 4.4.  Preparation of more complex systems from 1 
 
fact that no hydrogenolysis of the aliphatic chloride was observed.25  Another extended 
sequence resulted when 1 was reacted with γ-keto esters such as methyl levulinate (11) 
and methyl 3-benzoylpropionate (12).  These reactions proceeded to give reduction, 
condensative ring closure and cyclization by addition-elimination of the aniline nitrogen 
with the δ ester groups to give tetrahydropyrrolo[1,2-a]quinazolin-1,5-diones 7a and 7b 
in 74% and 77% yields, respectively.26  Oxoesters with greater separation between the 
carbonyl moieties (e.g. 2g and 2h) failed to undergo the final cyclization even after 
extended refluxing for 24 hours.  In a related transformation, 1 was reduced in the 
presence of methyl 2-formylbenzoate (13)27 to produce 6,6a-dihydroisoindolo[2,1-
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a]quinazolin-5,11-dione (8)  in 72% yield.  Finally, 1 was also reacted with diphosgene 
(14) to afford 2,4(1H,3H)-quinazolinedione (9) in 86% yield. 
One extended reaction was investigated using 4 as the starting material (see Figure 
4.4).  Treatment of 4 with 11 in acetic acid with no iron at room temperature for 24 h 
gave (±)-methyl 3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (15) in 
70% yield.  Further heating of 15 in acetic acid at 115 oC for 8 hours then effected 
quantitative ring closure to 7a.  This two-step synthesis was simplified to a one-step 





Figure 4.5.  Preparation of complex system from 4  
 
Conclusion 
 We have developed an efficient one-pot syntheses for the preparation of (±)-2-
aryl- and 2-alkyl-substituted 2,3-dihydro-4(1H)-quinazolinones from 2-nitro- and 2-
aminobenzamide. The procedures utilize inexpensive reagents, mild conditions and 
simple laboratory procedures. The method furnishes high yields of the title compounds 
from a wide range of aldehydes and ketones without the need for extensive purification. 
This method can be extended to the synthesis of more complex structures by positioning 
additional functionality γ to the carbonyl of the aldehyde or ketone (δ to the aniline 
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nitrogen in the initially-formed dihydroquinazolinone), which allows subsequent 
reactions to occur. 
Experimental Section 
All reactions were run under dry nitrogen in oven-dried glassware. Reactions were 
monitored by thin layer chromatography on silica gel GF plates (Analtech 21521). 
Commercial reagents and solvents were used as received. Preparativ  separations were 
performed using flash column chromatography28 on silica gel (Grade 62, 60-200 mesh) 
mixed with ultraviolet-active phosphor (Sorbent Technologies UV-5); band elution was 
monitored using a hand held UV lamp.  Melting points were taken on a MelTemp 
purchased from Laboratory Devices, Cambridge, MA 02139 and were uncorrected.  
Infrared spectra were taken on a Varian 800 FT-IR (Scimitar series) run as thin films on 
sodium chloride disks.  Unless otherwise indicated, 1H and 13C NMR spectra were 
measured in dimethyl sulfoxide-d6 using a broadband Gemini 2000 High-Resolution 
NMR spectrometer operating at 300 MHz and 75 MHz respectively.  All the NMR 
signals were referenced to internal tetramethylsilane; coupling constants (J) are reported 
in Hz.  Low-resolution mass spectra (electron impact/direct probe) were run at 70 eV or 
30 eV as indicated.  Elemental analysis were performed by Altlantic Microlab Inc., 
Norcross, GA. 
Representative Procedure from 2-Nitrobenzamide: (±)-2-Phenyl-2,3-dihydro-4(1H)-
quinazolinone (3a). A 100-mL three-necked round-bottomed flask, equipped with 
magnetic stirring and a reflux condenser, was charged with 7 mL of acetic acid, 498 mg 
(3.00 mmoles) of 1 and 318 mg (3.00 mmoles) of benzaldehyde (2a). The flask was 
placed in an oil bath preheated to 115 oC, 840 mg (5.0 eq, 15.0 mmoles) of iron powder 
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(>100 mesh) was added, and the reaction was refluxed for 30 minutes.  The reaction was 
cooled and poured into saturated aqueous sodium chloride and extracted with ether (1 × 
50 mL) and ethyl acetate (1 × 50 mL).  The combined organic layers were washed with 
saturated aqueous sodium bicarbonate (two times) and saturated aqueous sodium chloride 
(one time), then dried (magnesium sulfate) and concentrated under vacuum to give 610 
mg (90%) of 3a as a white solid, mp 220-221 oC (lit23 mp 218-220 oC). IR: 3302, 3185, 
1652, 1611 cm-1; 1H NMR: δ 8.29 (br s, 1H), 7.61 (d, 1H, J = 7.8), 7.49 (d, 2H, J = 7.0), 
7.42-7.32 (complex, 3H), 7.24 (td, 1H, J = 7.6, 1.6), 7.11 (br s, 1H), 6.75 (d, 1H, J = 8.0),
6.67 (t, 1H, J = 7.6), 5.75 (s, 1H); 13C NMR: δ 163.6, 147.9, 141.6, 133.3, 128.4, 128.3, 
127.3, 126.8, 117.1, 114.9, 114.4, 66.5; ms (30 eV): m/z 224 (M+). 
(±)-2-(4-Methoxyphenyl)-2,3-dihydro-4(1H)-quinazolinone (3b). This compound (686 
mg, 90%) was prepared from 498 mg (3.00 mmoles) of 1 and 408 mg (3.00 mmoles) of 
4-methoxybenzaldehyde (2b), and isolated as a white solid, mp 192-193 oC (lit23 mp 193-
195 oC). IR: 3300, 3188, 1655, 1609 cm-1; 1H NMR: δ 8.17 (br s, 1H), 7.61 (d, 1H, J = 
6.6), 7.41 (d, 2H, J = 8.6), 7.23 (td, 1H, J = 7.6, 1.4), 6.99 (br s, 1H), 6.94 (d, 2H, J = 8.6), 
6.72 (d, 1H, J = 8.2), 6.67 (t, 1H, J = 7.7), 5.70 (s, 1H), 3.74 (s, 3H); 13C NMR: δ 163.4, 
159.4, 148.0, 133.4, 133.2, 128.2, 127.3, 117.0, 115.0, 114.4, 113.6, 66.3, 55.1; ms (30 
eV): m/z  254 (M+). 
(±)-2-[4-(Trifluoromethyl)phenyl]-2,3-dihydro-4(1 H)-quinazolinone (3c). This 
compound (779 mg, 89%) was prepared from 498 mg (3.00 mmoles) of 1 and 522 mg 
(3.00 mmoles) of 2-(trifluoromethyl)benzaldehyde (2c), and isolated as a white solid, mp 
194-196 oC. IR: 3285, 3187, 1648, 1618 cm-1; 1H NMR: δ 8.46 (d, 1H, J = 1.3), 7.78 (d, 
2H, J = 8.2), 7.72 (d, 2H, J = 8.2), 7.63 (dd, 1H, J = 7.7, 1.1), 7.26 (overlapping td, 1H, J 
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= 7.1, 1.1 and br s, 1H), 6.77 (d, 1 H, J = 7.7), 6.69 (t, 1H, J = 7.7), 5.88 (d, 1H, J = 1.3); 
13C NMR: δ 163.4, 147.5, 146.4, 133.5, 129.0, 128.9 (q, J = 31.7), 127.7 (2C), 127.4, 
125.3 (q, J = 3.7), 124.2 (q, J = 271.6), 117.4, 114.9, 114.5, 65.7; ms (30 eV): m/z  292 
(M+). Anal. Calcd. for C15H11F3N2O: C, 61.64; H, 3.79; N, 9.59. Found: C, 61.58; H, 
3.81; N, 9.56. 
(±)-2-(2-Chlorophenyl)-2,3-dihydro-4(1H)-quinazolinone (3d). This compound (721 
mg, 93%) was prepared from 498 mg (3.00 mmoles) of 1 and 421 mg (3.00 mmoles) of 
2-chlorobenzaldehyde (2d), and isolated as an off-white solid, mp 205-206 oC. IR: 3286, 
3192, 1645, 1614 cm-1; 1H NMR: δ 8.20 (s, 1 H), 7.65 (d, 1H, J = 6.6), 7.50 (m, 1H), 7.40 
(m, 2H), 7.26 (t, 2H, J = 7.1), 7.00 (s, 1H), 6.74 (m, 2H); 13C NMR: δ 163.6, 147.6, 
137.8, 133.4, 131.8, 130.2, 129.5, 128.7, 127.4, 127.3, 117.4, 114.6, 114.5, 63.6; ms (30 
eV): m/z 258, 260 (M+:M++2, 3:1). Anal. Calcd. for C14H11ClN2O: C, 64.99; H, 4.29; N, 
10.83. Found: C, 65.03; H, 4.28; N, 10.79. 
(±)-2-Butyl-2,3-dihydro-4(1H)-quinazolinone (3e). This compound (383 mg, 94%) was 
prepared from 332 mg (2.00 mmoles) of 1 and 172 mg (2.00 mmoles) of pentanal (2e) 
and isolated as a white solid, mp 143-144 oC (lit15 mp 144-146 oC). IR: 3293, 1651, 1614 
cm-1; 1H NMR: δ 7.90 (br s, 1H), 7.58 (d, 1H, J = 7.7), 7.23 (t, 1H, J = 7.7), 6.73 (d, 1H, J 
= 7.7), 6.65 (t, 1H, J = 7.7), 6.58 (br s, 1H), 4.69 (s, 1H), 1.62 (m, 2H), 1.40 (m, 2H), 1.30 
(m, 2H), 0.88 (t, 3H, J = 6.8); 13C NMR: δ 163.9, 148.5, 133.0, 127.3, 116.8, 115.0, 
114.3, 64.4, 34.7, 25.4, 22.1, 13.9; ms (70 eV): m/z 147 (M+-C4H9). 
(±)-2-[(1E)-2-Phenylethenyl]-2,3-dihydro-4(1H)-quinazolinone (3f). This compound 
(445 mg, 89%) was prepared from 332 mg (2.00 mmoles) of 1 and 264 mg (2.00 
mmoles) of trans-cinnamaldehyde (2f), and isolated as a yellow solid, mp 170-173 oC 
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[lit 7 mp 168-172 oC). IR: 3276, 1651, 1611 cm-1; 1H NMR: δ 8.16 (br s, 1H), 7.63 (d, 1H, 
J = 7.7), 7.46 (d, 2H, J = 8.2), 7.35 (t, 2H, J = 7.7), 7.26 (m, 2H), 6.90 (s, 1H), 6.76 (d, 
1H, J = 8.2), 6.68 (d, 1H, J = 15.9), 6.67 (d, 1H, J = 7.7,), 6.38 (dd, 1H, J = 15.9, 6.6), 
5.31 (d, 1H, J = 6.6); 13C NMR: δ 163.3, 147.8, 135.7, 133.2, 131.6, 128.7, 128.3, 128.1, 
127.4, 126.6, 117.1, 114.8, 114.5, 65.8; ms (30 eV): m/z 250 (M+). 
(±)-Ethyl 4-(4-Oxo-1,2,3,4-tetrahydroquinazolin-2-yl)butanoate (3g). This compound 
(408 mg, 78%) was prepared from 332 mg (2.00 mmoles) of 1 and 288 mg (2.00 
mmoles) of ethyl 5-oxopentanoate (2g),29 and isolated a pale pink solid, mp 105-108 oC. 
IR: 3302, 3204, 1731, 1661, 1614 cm-1; 1H NMR (CDCl3): δ 7.87 (d. 1 H, J = 7.7), 7.30 
(t, 1H, J = 7.7), 7.04 (br s, 1H), 6.84 (t, 1H, J = 7.7), 6.69 (d, 1 H, J = 8.2), 4.91 (s, 1 H), 
4.49 (br s, 1H), 4.14 (q, 2 H, J = 7.1), 2.39 (m, 2H), 1.82 (m, 4H), 1.26 (t, 3H, J = 7.1); 
13C NMR (CDCl3): δ 173.2, 165.5, 147.3, 133.8, 128.4, 119.2, 115.8, 114.8, 64.9, 60.6, 
34.7, 33.5, 19.1; ms (30 eV): m/z 262 (M+). Anal. Calcd. for C14H18N2O3: C, 64.12; H, 
6.87; N, 10.69. Found: C, 64.16; H, 6.91; N, 10.63.  Extended heating of this reaction for 
24 h failed to induce cyclization. 
(±)-Ethyl 5-(4-Oxo-1,2,3,4-tetrahydroquinazolin-2-yl)pentanoate (3h). This 
compound (402 mg, 73%) was prepared from 332 mg (2.00 mmoles) of 1 and 316 mg 
(2.00 mmoles) of ethyl 6-oxohexanoate (2h),30 and isolated as a white solid following 
flash chromatography eluted with 50% ether in hexanes containing 1% methanol, mp 
110-113 oC. IR: 3307, 3203, 1736, 1643, 1614 cm-1; 1H NMR (CDCl3): δ 7.88 (d, 1H, J = 
7.7), 7.31 (t, 1H, J = 7.7), 6.86 (t, 1H, J = 7.7), 6.69 (d, 1H, J = 8.2), 6.24 (br s, 2H), 4.91 
(t, 1H, J = 5.8), 4.14 (q, 2H, J = 7.1), 2.35 (t, 2H, J = 7.1), 1.80 (q, 2H, J = 7.1), 1.69 
(quintet, 2H, J = 7.1), 1.51 (m, 2H), 1.26 (t, 3H, J = 7.1); 13C NMR (CDCl3): δ 173.4, 
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165.4, 147.4, 133.7, 128.4, 119.2, 115.8, 114.7, 65.0, 60.4, 35.0, 33.8, 24.3, 23.4, 14.2; 
ms (30 eV): m/z 276 (M+). Anal. Calcd. for C15H20N2O3: C, 65.22; H, 7.24; N, 10.14. 
Found: C, 65.29; H, 7.27; N, 10.09. Extended heating of this reaction for 24 h failed to 
induce cyclization. 
2,2-Dimethyl-2,3-dihydro-4(1H)-quinazolinone (3i). This compound (334 mg, 95%) 
was prepared from 332 mg (2.00 mmoles) of 1 and 116 mg (2.00 mmoles) of acetone (2i)
and isolated as a white solid, mp 182-183 oC (lit31 mp 183-184 oC). IR: 3260, 3172, 1640, 
1614 cm-1; 1H NMR: δ  7.94 (br s, 1H), 7.57 (d, 1H, J = 8.2), 7.20 (t, 1H, J = 7.7), 6.63 
(br s, 1H), 6.62 (d, 1H, J = 8.2), 6.61 (t, 1H, J = 7.7), 1.36 (s, 6H); 13C NMR: δ 163.1, 
147.1, 133.2, 127.2, 116.4, 114.2, 113.8, 66.8, 29.0; ms (70 eV): m/z 161 (M+-CH3). 
(±)-2-Methyl-2-propyl-2,3-dihydro-4(1H)-quinazolinone (3j). This compound (367 
mg, 90%) was prepared from 332 mg (2.00 mmoles) of 1 and 172 mg (2.00 mmoles) of 
2-pentanone (2j), and isolated as a white solid, mp 192-195 oC.  IR: 3272, 3184, 1645, 
1613 cm-1; 1H NMR: δ 7.90 (br s, 1H), 7.56 (d, 1H, J = 7.7), 7.20 (td, 1H, J = 8.2, 1.6), 
6.64 (d, 1H, J = 8.2), 6.59 (br s, 1H),  6.59 (t, 1H, J = 7.7), 1.60 (m, 2H), 1.35 (m, 2H), 
1.34 (s, 3H), 0.84 (t, 3H, J = 7.1); 13C NMR: δ 163.1, 147.2, 133.1, 127.1, 116.0, 113.9, 
113.5, 69.0, 43.7, 27.9, 16.7, 14.1; ms (70 eV): m/z 161 (M+-C3H7). Anal. Calcd. for 
C12H16N2O: C, 70.59; H, 7.84; N, 13.73. Found: C, 70.64; H, 7.86; N, 13.70. 
(±)-2-Methyl-2-phenyl-2,3-dihydro-4(1H)-quinazolinone (3k). This compound (409 
mg, 86%) was prepared from 332 mg (2.00 mmoles) of 1 and 240 mg (2.00 mmoles) of 
acetophenone (2k), and isolated as a white solid, mp 222-224 oC. IR: 3297, 3182, 1651, 
1611 cm-1; 1H NMR: δ 8.76 (br s, 1H), 7.63 (br s, 1H), 7.48 (m, 3H), 7.28 (d, 2H, J = 
7.4), 7.19 (m, 2H), 6.77 (d, 1H, J = 8.0), 6.57 (t, 1H, J = 7.1), 1.64 (s, 3H); 13C NMR: δ 
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163.8, 147.7, 147.2, 133.3, 127.9, 127.2, 127.0, 125.1, 116.8, 115.0, 114.3, 70.1, 30.7; ms 
(70 eV): m/z 223 (M+-CH3). Anal. Calcd. for C15H14N2O: C, 75.63; H, 5.88; N, 11.76. 
Found: C, 75.61; H, 5.89; N, 11.73. 
(±)-2-Benzyl-2-methyl-2,3-dihydro-4(1H)-quinazolinone (3l). This compound (458 
mg, 91%) was prepared from 332 mg (2.00 mmoles) of 1 and 268 mg (2.00 mmoles) of 
phenyl acetone (2l), and isolated as a white solid, mp 162-165 oC. IR: 3292, 1655, 1615 
cm-1; 1H NMR: δ 7.96 (br s, 1H), 7.50 (d, 1H, J = 7.7), 7.22 (m, 3H), 7.15 (d, 2H, J = 
7.1), 6.71 (br s, 1H), 6.65 (d, 1H, J = 8.2), 6.57 (t, 1H, J = 7.7), 2.93 (d, 1H, J = 13.2), 
2.83 (d, 1H, J = 13.2), 1.37 (s, 3H); 13C NMR: δ 163.0, 146.8, 136.5, 133.2, 130.7, 127.7, 
127.0, 126.2, 116.1, 114.0, 113.6, 69.3, 46.5, 27.5; ms (70 eV): m/z 161 (M+-C7H7). Anal. 
Calcd. for C16H16N2O: C, 76.19; H, 6.35; H, 11.11. Found: C, 76.24; H, 6.36; N, 11.05. 
Spiro[cyclopentane-1,2'(1'H)-quinazolin]-4'(3'H)-one (3m). This compound (374 mg, 
93%) was prepared from 332 mg (2.00 mmoles) of 1 and 168 mg (2.00 mmoles) of 
cyclopentanone (2m), and isolated as an off-white solid, mp 258-259 oC (lit23 mp 257-
260 oC). IR: 3289, 3162, 1638, 1613 cm-1; 1H NMR: δ 8.10 (br s, 1H), 7.59  (d, 1H, J = 
7.7), 7.22 (t, 1H, J = 7.7), 6.75 (br s, 1H), 6.70 (d, 1H, J = 8.2), 6.63 (t, 1H, J = 7.7), 1.80 
(s, 4H), 1.67 (s, 4H); 13C NMR: δ 163.4, 147.5, 133.0, 127.2, 116.5, 114.6, 114.3, 77.1, 
39.3, 22.0; ms (30 eV): m/z 202 (M+).  
Spiro[cyclohexane-1,2'(1'H)-quinazolin]-4'(3'H)-one (3n). This compound (396 mg, 
92%) was prepared from 332 mg (2.00 mmoles) of  1 and 196 mg (2.00 mmoles) of 
cyclohexanone (2n), and isolated as an off-white solid, mp 216-218 oC (lit23 mp 217-219 
oC). IR: 3287, 1651, 1613 cm-1; 1H NMR: δ 7.94 (br s, 1H), 7.57 (d, 1H, J = 7.7), 7.22 
(td, 1H, J = 8.2, 1.1), 6,82 (d, 1H, J = 8.2), 6.62 (t, 1H, J = 7.1), 6.62 (br s, 1H), 1.74 (m, 
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2H), 1.61 (m, 2H), 1.58 (m, 4H), 1.42 (m, 1H), 1.25 (m, 1H); 13C NMR: δ 163.2, 146.8, 
133.1, 127.1, 116.5, 114.6, 114.4, 67.8, 37.2, 24.7, 20.9; ms (30 eV): m/z 216 (M+). 
(±)-3a-Methyl-2,3,3a,4-tetrahydropyrrolo[1,2-a]quinazolin-5(1H)-one (6). The 
reaction to prepare this compound required refluxing for 8 hours under the conditions 
described for the preparation of 3a from 415 mg (2.50 mmoles) of 1 and 301 mg (2.50 
mmoles) of 5-chloro-2-pentanone (10). The compound (368 mg, 73%) was isolated 
directly from the reaction as a white solid, mp 143-145 oC. IR: 3190, 1660, 1609 cm-1; 1H 
NMR (CDCl3): δ 7.92 (dd, 1H, J = 7.7, 1.1), 7.36 (td, 1H, J = 7.7, 1.6), 7.04 (br s, 1H), 
6.78 (t, 1H, J = 7.1), 6.59 (d, 1H, J = 8.2), 3.50 (m, 2H), 2.17 (m, 2H), 2.04 (m, 1H), 1.39 
(s, 3H); 13CNMR (CDCl3): δ 164.9, 145.3, 134.0, 128.6, 117.3, 114.9, 113.8, 74.9, 47.1, 
39.6, 25.6, 21.8; ms (30 eV): m/z  202 (M+). Anal. Calcd. for C11H14N2O: C, 71.29; H, 
6.93; N, 13.86. Found: 71.33; H, 6.94; N, 13.83. 
(±)-3a-Methyl-2,3,3a,4-tetrahydropyrrolo[1,2-a]quinazoline-1,5-dione (7a). This 
compound was prepared as described for 6 from 415 mg (2.50 mmoles) of 1 and 325 mg 
(2.50 mmoles) of methyl levulinate (11). Flash chromatography on a 30 cm x 2 cm silica 
gel column eluted with 50% ether in hexanes containing 2% methanol gave 400 mg 
(74%) of 7a as a pale yellow solid, mp 175-177 oC (lit26 mp 179-180 oC). IR: cm-1; 1H 
NMR: δ  8.25 (br s, 1H), 8.16 (d, 1H, J = 8.2), 8.06 (dd, 1H, J = 7.8, 1.4), 7.59 (td, 1H, J 
= 7.8, 1,4), 7.29 (t, 1H, J = 8.2), 2.71 (m, 2H), 2.40 (m, 2H), 1.58 s, 3H); 13C: δ 171.7, 
163.5, 135.8, 133.8, 128.2, 125.0, 120.7, 119.5, 74.5, 32.9, 30.0, 26.9; ms (30 eV): m/z 
216 (M+). 
(±)-3a-Phenyl-2,3,3a,4-tetrahydropyrrolo[1,2-a]quinazoline-1,5-dione (7b). This 
compound was prepared as described for 6 from 415 mg (2.50 mmoles) of 1 and 480 mg 
 75
(2.50 mmoles) of methyl 3-benzoylpropionate (12). Flash chromatography on a 30-cm × 
2-cm silica gel column eluted with  50% ether in hexanes containing 2% methanol gave 
536 mg (77%) of 7b as a pale yellow solid, mp 290 oC (decomposition) (lit26 mp >290 
oC). IR: 3203, 1716, 1668, 1604 cm-1; 1H NMR: δ 9.82 (br s, 1H), 8.09 (d, 1H, J = 8.2), 
7.77(dd, 1H, J = 7.7, 1.1), 7.60 (td, 1H, J = 7.7, 1.6), 7.34 (m, 4H), 7.26 (m, 2H), 2.68 (m, 
3H), 2.26 (m, 1H); 13C: δ 173.0, 161.9, 144.0, 136.3, 133.3,128.7, 128.0, 127.6, 124.9, 
124.8, 120.8, 120.7, 77.2, 34.7, 29.3; ms (30 eV): m/z 278 (M+). 
(±)-6,6a-Dihydroisoindolo[2,1-a]quinazoline-5,11-dione (8). This compound was 
prepared as described for 6 from 415 mg (2.50 mmoles) of 1 and 415 mg (2.50 mmoles) 
of methyl 2-formylbenzoate (13).27  Flash chromatography eluted with 50% ether in 
hexanes containing 5% methanol gave 450 mg (72%) of 8 as an off-white solid, mp 255-
258 oC. IR: 3154, 1715, 1681, 1605 cm-1; 1H NMR: δ 9.43 (br s, 1H), 8.30-7.55 
(complex, 7H), 7.36 (br s, 1H), 6.25 (br s, 1H); 13C: δ 164.1, 163.6, 140.7, 137.1, 133.5, 
133.2, 131.1, 130.1, 128.1, 124.7, 124.1, 123.8, 119.9, 119.5, 67.0; ms (30 eV): m/z 250 
(M+). Anal. Calcd. for C15H10N2O2: C, 72.00; H, 4.00; N, 11.20. Found: C, 72.03; H, 
3.99; N, 11.15. 
2,4(1H,3H)-Quinazolinedione (9). This compound was prepared as described for 6 rom 
415 mg (2.50 mmoles) of 1 and 495 mg (2.50 mmoles) of diphosgene (14). The product 
(348 mg, 86%) was isolated as a gray solid, mp 343-345 oC (lit [32] mp >300 oC). The 
spectral data matched those reported previously.32  
Representative Procedure from 2-Aminobenzamide: (±)-2-Phenyl-2,3-dihydro-
4(1H)-quinazolinone (3a). A 100-mL three-necked round-bottomed flask, equipped with 
magnetic stirring and a reflux condenser, was charged with 7 mL of acetic acid, 250 mg 
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(1.84 mmoles) of 4 and 195 mg (1.84 mmoles) of benzaldehyde (2a).  The resulting 
solution was stirred at room temperature for 4 hours or, alternatively, at 115 oC for 30 
minutes.  The crude reaction mixture was cooled and poured into saturated aqu ous 
sodium chloride and extracted with ether (1 × 50 mL) and ethyl acetate (1 × 50 mL). The 
combined organic layers were washed with saturated aqueous sodium bicarbonate (2 × 50 
mL) and saturated aqueous sodium chloride (1 × 50 mL), then dried (magnesium sulfate) 
and concentrated under vacuum to give 370 mg (90%) of 3a as a white solid.  The mp 
and spectral data matched those reported above. 
(±)-2-(4-Methoxyphenyl)-2,3-dihydro-4(1H)-quinazolinone (3b). This compound (420 
mg, 90%) was prepared from 250 mg (1.84 mmoles) of 4 and 250 mg (1.84 mmoles) of 
2b. The mp and spectral data matched those reported above. 
(±)-2-(2-Chlorophenyl)-2,3-dihydro-4(1H)-quinazolinone (3d). This compound (437 
mg, 92%) was prepared from 250 mg (1.84 mmoles) of 4 and 258 mg (1.84 mmoles) of 
2d. The mp and spectral data matched those reported above. 
(±)- Ethyl 4-(4-Oxo-1,2,3,4-tetrahydroquinazolin-2-yl)butanoate (3g). This compound 
(366 mg, 76%) was prepared from 250 mg (1.84 mmoles) of 4 and 265 mg (1.84 
mmoles) of 2g. The mp and spectral data matched those reported above. 
2,2-Dimethyl-2,3-dihydro-4(1H)-quinazolinone (3i). This compound (297 mg, 92%) 
was prepared from 250 mg (1.84 mmoles) of 4 and 107 mg (1.84 mmoles) of 2i. The mp 
and spectral data matched those reported above. 
(±)-2-Methyl-2-propyl-2,3-dihydroquinazolin-4(1H)-one (3j). This compound (335 
mg, 90%) was prepared from 250 mg (1.84 mmoles) of 4 and 158 mg (1.84 mmoles) of 
2j. The mp and spectral data matched those reported above. 
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(±)-2-Methyl-2-(phenylmethyl)-2,3-dihydro-4(1H)-quinazolinone (3l).  This 
compound (408 mg, 88%) was prepared from 250 mg (1.84 mmoles) of 4 and 247 mg 
(1.84 mmoles) of 2l. The mp and spectral data matched those reported above. 
Spiro[cyclohexane-1,2'(1'H)-quinazolin]-4'(3'H)-one (3n). This compound (357 mg, 
90%) was prepared from 250 mg (1.84 mmoles) of 4 and 180 mg (1.84 mmoles) of 2n. 
The mp and spectral data matched those reported above. 
(±)-Methyl 3-(2-Methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (15). 
This compound (192 mg, 70%) was prepared from 150 mg (1.10 mmoles) of 4 and 143 
mg (1.10 mmoles) of 11 by stirring in acetic acid at room temperature for 24 h, mp 141-
142 oC. IR: 3287, 1722, 1655, 1615 cm-1; 1H NMR: δ 7.85 (dd, 1H, J = 7.7, 1.6), 7.28 
(ddd, 1 H, J = 8.2, 7.7, 1.6), 6.80 (t, 1H, J = 7.7), 6.62 (br s, 1H), 6.59 (d, 1H, J = 8.2), 
4.22, (br s, 1H), 3.65 (s, 3H), 2.64 (dt, 1H, J = 17.0, 7.1), 2.52 (dt, 1H, J = 17.0, 7.1), 2.15 
(dt, 1H, J = 14.0, 7.1), 2.06 (dt, 1H, J = 14.0, 7.1), 1.55, 2, 3H); 13C NMR δ 174.2, 164.5, 
145.8, 134.0, 128.3, 118.6, 114.5, 114.0, 69.8, 51.9, 36.4, 29.0, 28.7; ms (30 eV): m/z 248 
(M+). Anal. Calcd. for C13H16N2O3: C, 62.90; H, 6.45; N, 11.29. Found: C, 62.96; H, 
6.46; N, 11.21.  Treatment of equimolar amounts of 4 and 11 in acetic acid at 115 oC for 
8 hours gave 7a in 75% yield.  Additionally, heating 15 in acetic acid at 115 oC for 8 
hours resulted in quantitative conversion to 7a. The mp and spectral data for 7a matched 
those reported above.   
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CHAPTER V 




 Compounds incorporating the 4(1H)-quinolinone ring system are commonly 
encountered in drug chemistry and express a broad spectrum of biological act vities.1-13  
Thus, they have become attractive targets for synthesis.  In this project, we wish to report 
an efficient and simple synthesis of 4(1H)-quinolinone (3), 2,4(1H,3H)-quinolinedione 
(8) and ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate (10) using an adaptation of the 
Batcho-Leimgruber reaction.14-17    
Numerous methods have been devised for the synthesis of 3.  In the most practical 
sequence, aniline was reacted with Meldrum’s acid18,19 or methyl propiolate20 to form an 
adduct that underwent thermal cyclization to give the target heterocycle.  Another useful 
approach involved the condensation of 2-nitroacetophenone with N,N-
dimethylformamide dimethyl acetal to give an enaminone, followed by cyclization in the 
presence of cyclohexene and 10% Pd/C.21  Though this reaction is similar to our 
procedure, we were not able to achieve the yield reported for the preparation of 3.  
Finally, the palladium-catalyzed coupling 2-bromoacetophenone with formamide, 
followed by intramolecular cyclization using sodium tert-butoxide, also provided access 
to this ring system.22  A disadvantage of this procedure is the expensive catalyst required.
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for the initial coupling reaction 
There are also many reported syntheses of 2,4(1H 3H)-quinolinedione (8).  In the 
classical synthesis, 2-aminobenzoic acid was condensed with urea in a high boiling 
solvent.23-27  This method appears to be the most viable approach since it is simple, 
inexpensive and scalable.  Other preparations have been reported from 2-
aminobenzamide,28 2-aminobenzonitrile,29,30 methyl 2-bromobenzoate31 and 1H-indole-
2,3-dione.32  While elegant, most of these approaches use expensive or hazardous 
reagents that would not be practical on a large scale.   
The approaches to the synthesis of ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate 
(10) are more limited.  All of the methods were based on the addition of a iline to diethyl 
2-(ethoxymethylene)propandioate7,9,33-35 and closure under high temperature conditions. 
The drawback of these processes was the high temperature conditions and the 
requirement of removing a high-boiling solvent from the product. 
Results and Discussion 
  The syntheses of 4(1H)-quinolinone (3), 2,4(1H,3H)-quinolinedione (8) and ethyl 
4-oxo-1,4-dihydroquinoline-3-carboxylate (10) are outlined in Figures 5.1 and 5.2.  The 
strategy is an adaptation of the Batcho-Leimgruber reaction, which is normally used to 
prepare indoles.14-17  The synthesis of 3 was achieved in an overall yield of 80% in a two 
step sequence.  The first step involved the addition of N,N-dimethylformamide dimethyl 
acetal to 2-nitroacetophenone (1) in DMF under hot conditions (100 ºC) to give the 3-
(dimethylamino)-1-(2-nitrophenyl)prop-2-en-1-one (2) in 95% yield.  Enaminone 2 then 
underwent ring closure via treatment with hydrazine hydrate and 10% Pd/C in ethanol at 





Figure 5.1.  Synthesis of 4(1H)-quinolinone (3) 
 
The preparations of 8 and 10 were readily achieved from 3-(2-nitrophenyl)-3-
oxopropanoate (7).  To prepare 7,23 ethyl hydrogen malonate (6) was converted to its 
dianion using 2 equivalents of n-BuLi in THF which was reacted with 1 equivalent of 2-
nitrobenzoyl chloride 5, prepared from 2- nitrobenzoic acid using oxalyl chloride.  This 
procedure gave the ketoester 7 in 87% yield.  Treatment of 7 with 85% hydrazine hydrate 
and 10% Pd/C in refluxing ethanol for 20 minutes led to dione 8 in 86% yield.  The 
conversion of 7 to 10 was analogous to the procedure used to prepare 3.  Ketoester 7 was 
converted to enaminone 9 in DMF in 98% yield by addition of N,N-dimethylformamide 
dimethyl acetal at 100 oC and continued heating for 4 hours.  Treatment of enaminone 9 
with hydrazine hydrate and 10% Pd/C in refluxing ethanol for 30 minutes then initiated a 
one-pot sequence involving the reduction of the nitro function, addition of the resulting 
amino group to the enaminone double bond, and loss of dimethylamine.  Both 8 and 10 
were easily purified by crystallization. 
 An alternative synthesis was also tried for the preparation of 10 using ethyl 3-
ethoxy-2-(2'-nitrobenzoyl)acrylate (11).  Treatment of 7 with triethyl orthoformate in 

















Figure 5.2.  Preparation of 2,4(1H,3H)-quinolinedione (8) and  
                       ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate (10)
 
conversion of 11 to 10 through the use of Fe/HCl, Fe/HOAc and hydrazine hydrate and 






Figure 5.3.  Attempted preparation of 10 from 11 
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Conclusion  
We have developed a relatively simple and efficient method for the syntheses of 
two quinolinones (3 and 10) and a quinolinedione (8) using commercially available 
starting materials.  The yields are comparatively higher than previous methods used by 
Kosinen et. al.21  These ring systems can serve as building blocks for the syntheses of a 
number of pharmaceutically active drug compounds.  
Experimental Section 
All reactions were run under dry nitrogen in oven-dried glassware.  Reactions were 
monitored by thin layer chromatography on silica gel GF plates.  Preparative separations 
were performed using flash column chromatography37 on silica gel (Grade 62, 60-200 
mesh) mixed with ultraviolet-active phosphor (Sorbent Technologies UV-5) or thin layer 
chromatography on 20-cm × 20-cm silica gel GF plates (Analtech 02015).  Band elution 
for both separation methods was monitored using a hand held UV lamp.  Melting points 
were taken on a MelTemp purchased from Laboratory Devices, Cambridge, MA 02139 
and were uncorrected.  Infrared spectra were taken on a Varian 800 FT-IR (Scimitar 
series) run as thin films on sodium chloride disks.  Unless otherwise indicated, 1H and 
13C NMR spectra were measured in deuteriochloroform using a broadband Gemini 2000 
High-Resolution NMR spectrometer operating at 300 MHz and 75 MHz respectively.  
All the NMR signals were referenced to internal tetramethylsilane; coupling constants (J) 
are reported in Hz.  Low-resolution mass spectra (electron impact/direct probe) were run 
at 70 eV.  Elemental analysis were performed by Altlantic Microlab Inc., Norcross, GA.  
N,N-Dimethylformamide, from a freshly opened bottle, was dried over 4 Å molecular 
sieves under nitrogen and was transferred by syringe into reactions where it was used.  
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Tetrahydrofuran was dried over potassium hydroxide pellets and distille  from lithium 
aluminium hydride. Commercial reagents and solvents were used as r ceived.  The NaCl, 
NaHCO3 and HCl used in various workup procedures refer to saturated aqueous 
solutions.  
(E)-3-(Dimethylamino)-1-(2-nitrophenyl)-2-propen-1-one (2). The procedure of 
Kosinen and coworkers21 was modified. In a one-necked round-bottomed flask, equipped 
with a magnetic stir bar and a nitrogen atmosphere, was placed 5.0 g (30.2 mmol) of 2-
nitroacetophenone (1) dissolved in 25 mL of dry DMF. To this was added 3.60 g (30.2 
mmoles) of dimethylformamide dimethyl acetal, and the mixture was heated for 45 
minutes at 90 oC (oil bath). The crude reaction mixture was quenched with ice watr, 
stirred for 5 minutes, and then extracted with ether (2 × 300 mL). The aqueous layer was 
saturated with NaCl and extracted one final time with ether (1 × 150 mL). The ether 
layers were combined and washed with saturated sodium chloride solution (2 × 200 mL), 
then dried (MgSO4) and concentrated under vacuum. Concentration under vacuum for 30 
minutes gave 6.30 g (95%) of 2 as a yellow solid, which was used directly in the next 
step, mp 119-121 ºC. IR: 1645, 1556, 1527, 1355 cm-1; 1H NMR: δ 7.96 (d, 1H, J = 7.0), 
7.62 (apparent t, 2H, J ≈ 7.5), 7.49 (m, 2H), 5.27(d, 1H, J = 12.5), 3.10 (s, 3H), 2.87 (s, 
3H); 13C NMR: δ 154.8, 147.1, 138.3, 133.0, 129.2 (2C), 128.7, 123.9, 85.3, 45.0, 37.0; 
ms (30 eV): m/z 220 (M+). Anal. Calcd. for C11H12N2O3: C, 60.00; H, 5.45; N, 12.72. 
Found: C, 59.93; H, 5.40; N, 12.81. 
4(1H)-Quinolinone (3).  A solution of 2.00 g (9.10 mmoles) of 2 was dissolved in 
ethanol, and 0.27 g (0.26 mL, 5.44 mmoles, 0.6 equivalents) of 85% hydrazine 
monohydrate was added to a three-necked round-bottomed flask, fitted with a condenser 
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and a nitrogen inlet, and stirred for about 5 minutes.  To this solution nder nitrogen was 
carefully added 15 mg of 10% palladium-on-charcoal and stirring was continued until 
thin layer chromatography indicated complete consumption of the starting material (ca 60 
minutes).  The crude product was refluxed at 80 ºC over a period of 60 minutes.  The 
resulting hot solution was filtered through a Celite® bed and concentrated under vacuum.  
The resulting mixture was flash chromatographed on a 20-cm × 2-cm silica gel column 
using increasing concentrations of ether in hexanes to give 99 mg (75%) of 3 as a white 
solid, mp 208-210 oC [lit20 mp 209-211 oC].  IR: 3600-2410, 1613, 1587, 1507 cm-1; 1H 
NMR: δ 11.81 (br s, 1H), 8.12 (d, 1H, J = 8.2), 7.93 (t, 1H, J = 6.3), 7.65 (td, 1H, J = 8.2, 
1.3), 7.57 (d, 1H, J = 8.4), 7.33 (td, 1H, J = 6.8, 1.3), 6.07 (d, 1H, J = 7.4); 13C NMR: δ 
176.9, 140.0, 139.4, 131.6, 125.8, 124.9, 123.1, 118.3, 108.7. 
Ethyl 3-(2-nitrophenyl)-3-oxopropanoate (7).  The procedure of Domagala and 
coworkers was modified.36  A 250-mL one-necked round-bottomed flask, equipped with 
a magnetic stir bar, a condenser and a nitrogen inlet, was charged with 3.00 g (18.0 
mmoles) of 2-nitrobenzoic acid (4) and 100 mL of dichloromethane.  The resulting 
solution was stirred for 5 minutes and 2.76 g (1.84 mL, 21.7 mmoles) of oxalyl chloride 
was added drop-wise over a period of 20 minutes, followed by 5 drops of N,N-
dimethylformamide.  The reaction was stirred for 12 hours during which time gas 
evolution subsided and the acid completely dissolved in the dichloromethane.  The crude 
mixture was then concentrated under vacuum to give 2-nitrobenzoyl chloride (5).  
 In a three-necked round-bottomed flask, equipped with a strong magnetic stirrer, 
was placed a solution of 4.17 g (31.6 mmoles) of ethyl hydrogen malonate (6) dissolved 
in 200 mL of tetrahydrofuran along and 10 mg of bipyridyl was adeed as an internal 
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indicator.  The mixture was cooled to −30 oC and 16.0 mL of 2.0 M n-butyllithium (32.0 
mmoles) was added drop-wise over 20 minutes.  The reaction mixture was then warmed 
to −5 oC, and another portion of 16.0 mL of 2.0 M n-butyllithium (32.0 mmoles) was 
added until a red color persisted for about 5-10 minutes. The mixture was cooled to −78 
oC, and a solution of 2-nitrobenzoyl chloride (from above) in 15 mL of tetrahydrofuran 
was added drop-wise over 25 minutes.  [Note: The solution became a thick yellow liquid 
and stirring was a problem with a weak magnetic stirrer].  The solution was kept at −78 
ºC for 30 minutes and then was slowly warmed to −30 ºC and stirred for 30 minutes.  The 
reaction mixture was the poured into ice water containing 20 mL (3 equivalents) of 
concentrated HCl and the resulting mixture was extracted with dichloromethane (3 × 200 
mL).  The combined organic extracts were washed with water (1 × 200 mL), 5% 
NaHCO3 solution (1 × 150 mL) and 1 N HCl (1 × 150 mL).  The dichloromethane layer 
was finally washed with saturated NaCl solution (1 × 150 mL), dried (MgSO4), and then 
concentrated under vacuum to give 3.70 g (87%) of 3 as thick yellow oil.  The keto ester 
was mostly in its keto form (with 8-10% enol) estimated from 1H NMR and was used 
directly in the next reaction.  IR: 1740, 1708, 1531, 1348 cm-1; 1H NMR (keto form): δ 
8.16 (d, 1H, J = 8.4), 7.77 (t, 1H, J = 7.6), 7.65 (td, 1H, J = 7.6, 1.2), 7.53 (dd, 1H, J = 
7.6, 1.3), 4.16 (q, 2H, J = 7.1), 3.83 (s, 2H), 1.23 (t, 3H, J = 7.1);  13C NMR: δ 194.6, 
166.5, 144.5, 134.5, 132.6, 130.9, 128.1, 124.2, 61.6, 49.0, 13.9; ms (30 eV): 237 (M+). 
Anal. Calcd. for C11H11NO5: C, 55.70; H, 4.64; N, 5.91. Found: C, 55.96; H, 4.66; N, 
5.83. 
2,4(1H,3H)-Quinolinedione (8).  To a solution of 1.00 g (4.20 mmoles) of 7 in 10 mL of 
ethanol was added 0.1 g (0.1 mL, 0.6 equivalents, 2.52 mmoles) of 85% hydrazine 
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monohydrate, and the reaction was stirred for 10 minutes.  To this solution under nitrogen 
was carefully added 15 mg of 10% palladium-on-carbon and stirring was continued until 
thin layer chromatography indicated complete consumption of the starting material (ca 20 
minutes).  The compound was filtered through Celite® and concentrated under vacuum to 
give a viscous oil.  To the crude product was added 10 mL of ether to give a solid 
precipitate.  The solid was filtered and washed with ether and chloroform to give 0.58 g 
(86%) of 10 as a white solid, mp 315-317 oC (dec) [lit29 mp 320 oC (dec)]. IR: 3620-
2360, 1657, 1630, 1508 cm-1.  The 1H and 13C NMR data matched those reported 
previously.29 
Attempted Preparation of 2,4(1H,3H)-Quinolinedione under Dissolving Metal 
Conditions. A 25-mL three-necked round-bottomed flask, equipped with a reflux 
condenser and a magnetic stir bar, was charged with 50 mg (0.21 mmoles) of 7 and 5 mL 
of acetic acid (or concentrated hydrochloric acid).  The flask was suspended in a bath 
preheated to 115 oC (for acetic acid) or 100 oC (for concentrated hydrochloric acid) for 5 
minutes prior to addition of the iron.  Heating was briefly intempted an  59 mg (1.05 
mmoles, 5 eq) of iron powder was added, and heating was resumed for 30 minutes.  The 
mixture was cooled, added to ice water and extracted with ethyl acetate (3 × 25 mL).  The 
combined extracts were washed with saturated sodium bicarbonate (thre  times), 
saturated sodium chloride (one time), and then was dried and concentrated under vacuum 
to give a dark brown oil. 1H NMR analysis indicated that none of the desired 
quinolindione was present.  
(Z)-Ethyl 3-(Dimethylamino)-2-(2-nitrobenzoyl)acrylate (9).  A 100-mL single-
necked, round-bottomed flask, equipped with a reflux condenser and a magnetic stirr r, 
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was charged with 1.00 g (4.20 moles) of 7 dissolved in 5 mL of N,N-dimethylformamide.  
To this solution was added 0.50 g (0.56 mL, 4.20 mmoles) of dimethylformamide 
dimethylacetal, and the mixture was heated at 100 ºC for 4 hours.  The crude reaction 
mixture was quenched with ice water, stirred for 5 minutes and extracted with ether (2 × 
100 mL).  The aqueous solution was saturated with sodium chloride (1 × 100 mL) and 
extracted one final time with ether (1 × 150 mL).  The combined ether layers were 
washed with saturated sodium chloride (1 × 100 mL), dried (MgSO4) and concentrated 
under vacuum.  The resulting oil solidified to give 1.10 g (89%) of 8 as a yellow solid, 
mp 122-124 oC. IR: 1682, 1633, 1570, 1526, 1377, 1349 cm-1;  1H NMR: δ 8.05 (d, 1H, J 
= 8.2), 8.00 (s, 1H), 7.62 (t, 1H, J = 7.6), 7.48 (td, 1H, J = 7.4, 0.8), 7.36 (d, 1H, J = 7.6), 
3.83 (q, 2H, J = 7.1), 3.38 (s, 3H), 3.09 (s, 3H), 0.82 (t, 3H, J = 7.1); 13C NMR: δ 166.7, 
160.0, 146.3, 140.2, 133.3, 128.6, 127.8, 123.6, 59.7, 48.2, 42.7, 13.6; ms (30 eV): m/z 
292 (M+).  Several signals in the 13C NMR spectrum were quite broad.  However, even 
with a high sample concentration, long delay time (3 seconds) and up to 5000 transients, 
it was not possible resolve all of the carbons. 
Ethyl 4-Oxo-1,4-dihydroquinoline-3-carboxylate (10).  The procedure used to prepare 
3 was followed to convert 1.00 g (3.42 mmoles) of 9 to 10.  The reaction was complete in 
30 minutes. Workup and crystallization using ether and chloroform and yielded 0.58 g 
(78%) of 10 as an off-white solid, mp 268-269 ºC [lit1 mp 270-272 oC]. IR: 3424, 1642 
cm-1; 1H NMR: δ 12.33 (br s, 1H), 8.56 (s, 1H), 8.16 (dd, 1H, J = 8.2, 1.0), 7.71 (td, 2H, J 
= 7.5, 1.4), 7.63 (d,1H, J = 8.2), 7.42 (td, 1H, J = 7.5, 1.0), 4.22 (q, 2H, J = 7.1), 1.29 (t, 
3H, J = 7.1); 13CNMR: δ 173.4, 164.8, 144.9, 138.9, 132.4, 127.2, 125.6, 124.7, 118.8, 
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109.7, 59.5, 14.3; ms (30 eV): m/z 217 (M+). Anal. Calcd. for C12H11NO3: C, 66.34; H, 
5.08; N, 6.40. Found: C, 66.36; H, 5.07; N, 6.45. 
Attempts to convert 9 to 10 using the conventional procedures with iron in acetic acid 
and iron in concentrated hydrochloric acid, as above, failed and resulted in he isolation 
of an intractable tar. 
(E)- and (Z)-Ethyl 3-Ethoxy-2-(2-nitrobenzoyl)acrylate (11). The procedure of 
Domagala and coworkers was modified.36  To a stirred solution of 0.50 g (2.11 mmoles) 
of 7 in 0.34 g (2.32 mmoles) of triethyl orthoformate was added 8 mL of acetic anhydride 
and the mixture was refluxed for 1 hour.  The mixture was concentratd under vacuum, 
added to water and extracted with ether (2 × 75 mL).  The combined eth r extracts were 
washed with water (2 × 50 mL) and saturated NaCl (2 × 50 mL), then dried (MgSO4), 
and concentrated under vacuum to give 0.56 g (90%) of product as a viscous yell w oil.  
This product was a mixture of E and Z isomers and was used directly in subsequent 
reactions.  IR: 1717, 1617, 1529, 1349 cm-1; 1H NMR: δ 8.15 (d, 1H, J = 8.2), 8.06 (d, 
1H, J = 8.2), 7.98 (s, 1H), 7.92 (s, 1H), 7.68 (m, 2H), 7.56 (m, 2H), 7.41 (dd, 1H, J = 7.4, 
1.0), 7.33 (dd, 1H, J = 7.6, 1.0), 4.36 (q, 2H, J = 7.2), 4.21 (q, 2H, J = 7.0), 4.11 (q, 2H, J 
= 7.0), 4.01 (q, 2H, J = 7.2), 1.45 (t, 3H, J = 7.2), 1.27 (t, 3H, J = 7.0), 1.13 (t, 3H, J = 
7.2), 1.01 (t, 3H, J = 7.0);  13C NMR: δ 190.6, 188.3, 169.3, 168.7, 166.3, 165.0, 146.0, 
145.9, 138.7, 138.1, 133.8, 133.6, 129.6, 129.5, 128.1, 127.2, 123.8, 123.5, 111.8, 110.4, 
74.0, 73.9, 60.6, 60.3. 15.2, 14.9, 13.9, 13.6; ms (30 eV): m/z 293 (M+). 
Attempts to convert 11 to 10 using iron powder in acetic acid, iron powder in 
concentrated hydrochloric acid, or hydrazine hydrate and 10% Pd/C in etha ol, as above, 
all failed and resulted in the isolation of an intractable tar. 
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CHAPTER VI 
(±)-3-ARYL-2,3-DIHYDRO-4(1 H)-QUINOLINONES BY A TANDEM 
REDUCTION-MICHAEL ADDITION REACTION 
 
Introduction 
 Over the past several years, we have described a number of tandem reaction 
approaches to nitrogen heterocycles whose syntheses were initiatd by dissolving metal 
reduction of nitroarenes.1  In the current project, we sought to extend this strategy to the 
synthesis of 2,3-dihydro-4(1H)-quinolinone as well as several (±)-3-aryl-2,3-dihydro-
4(1H)-quinolinones, which have demonstrated antimalarial2 and anticancer activity.3  Our 
approach involves the reductive cyclization of 1-(2-nitrophenyl)prop-2-en 1 one 
derivatives. 
 The value of the title compounds has made them common targets for synthesis 
and numerous approaches using both basic and acidic reagents have been report d.  The 
original synthesis involved treatment of 2'-aminochalcone4 with a base, and the yields 
were modest.  Work by others described the cyclization of more acidic N-acylated 2'-
aminochalcones,5 and yields improved to 50-60%.  Subsequent studies focused on 
cyclizations of 2'-aminochalcone using mixtures of acetic acid and phosphoric acid,6 
which gave the 3-arylquinolinones in 50-70% yields.  More recently, montorillonite K-
10 with microwave irradiation7 and Lewis acids on silica or alumina8 have been used to 
promote the cyclization in 60-90% yields.  Additionally, the ring closure of 2'-
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aminochalcone has been reported to occur in PEG-400 solvent at 130 oC with no 
additives in 80-90% yield.9  In another recent approach, metathesis of 2-alkynylanilines 
with aldehdyes in the presence of an antimony pentafluoride-methanol c talyst gave (±)-
2,3-disubstituted-2,3-dihydro-4(1H)-quinolinones10 as cis-trans mixtures in 25-95% 
yields.  Finally, condensation of 2-aminoacetophenone with various benzaldehydes in the 
presence of L-proline has been reported as a potential route to chiral 3-
aryldihydroquinolinones11 and, while yields were high (79-93%), asymmetric induction 
was low (< 10% ee).  To date, there have been no reports on the synthesi  of 3-
aryldihydroquinolinones from 2-'nitrochalcones. 
Results and Discussion 
 The synthesis of the cyclization substrates is shown in Figure 6.1.  To prepare the 
precursor to 2,3-dihydro-4(1H)-quinolinone, vinylmagnesium bromide was added to 2-
nitrobenzaldehyde (1) in tetrahydrofuran to give alcohol 2, and the latter further oxidized 
to deliver 1-(2-nitrophenyl)prop-2-en-1-one (3) in 71% overall yield.12  The 2'-
nitrochalcones 6a-f used for the preparation of the (±)-3-aryl-2,3-dihydro-4(1H)-
quinolinones were prepared in 92-97% from 2-nitroacetophenone (4) and a series of 
benzaldehyde derivatives (5a-f) using standard conditions of sodium hydroxide in ethanol 
(Figure 6.1). 
The cyclization of 3 to the parent 2,3-dihydro-4(1H)-quinolinone (7) was initially 
attempted in 1:1 v/v acetic acid/phosphoric acid, and the product was isol ted in 72% 
yield via chromatography.  During the course of the reaction, a heavy precipitate formed, 
which caused problems with stirring and isolation of the product.  The same 















Figure 6.1.  Synthesis of cyclization substrates 
 
hydrochloric acid at 100 oC for 30 minutes.  Critical to the success of the reaction was the 
addition of the iron to the hot solution.  This minimized the formation of side products 





Figure 6.2.  Reductive cyclization of 3 with iron in concentrated hydrochloric acid 
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We began our study on the conversion of 2'-nitrochalcone (6a) to (±)-3-phenyl-2,3-
dihydro-4(1H)-quinolinone by attempting to effect the cyclization using iron powder in 
acetic acid since these conditions have proven successful in many of our ther reactions.  
Unfortunately, this protocol yielded only mixtures of 2'-aminochalcone (8a) and its 
double bond reduction product 9a (Figure 6.3).  None of the 2,3-dihydro-3-phenyl-  





Figure 6.3.  Reduction of 6a with iron in acetic acid 
quinolinone was observed.  Similar results were obtained with substrates 6e and6f.  
We also explored the use of iron powdered in various mixtures of acetic id and 
phosphoric acid since our work with 3 suggested that this might be successful.  Under  
these conditions, the cyclization proceeded smoothly (Figure 6.4) with maximum yields 
in the 60-78% range.  Best results were achieved using a 70:30 ratio of CH3CO2H:H3PO4.  
With higher percentages of phosphoric acid, the reaction became very thick due to 
reaction between iron and phosphoric acid.  This impaired stirring, made extraction of the 
product difficult and decreased the isolated yields significantly (see Figure 6.4). 
Based on the improvement in yield noted by using stronger acid, we decide  to 
explore the use of iron powder in concentrated hydrochloric acid.  Under these 
conditions, we found that yields improved to 70-90% for all cases.  Surprisingly, no 






















Figure 6.4.  Reductive cyclization of 6a with various mixtures of acetic acid and 
phosphoric acid 
 
only substrates derived from benzaldehydes bearing resonance electron-donating 
substituents were explored.  This was due to the fact that many electron-withdrawing 
groups, such as ester and cyano, are unstable to the basic conditions used to prepare the 
chalcones and others, such as nitro, are reduced in the cyclization reaction. 
 The optimized conditions involved treating 1.00 eq (ca 500 mg) of the 2'-
nitrochalcone derivative 6 with four equivalents of iron powder in 10 mL of concentrated 
hydrochloric acid at 100 oC for 30 minutes.  Again, it was important to add the iron to the 
hot mixture to achieve optimum yields with a minimum of side products.  After 



















[a] Yield estimated from 1H NMR
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aryldihydroquinazolinones 10 were isolated in nearly pure form.  Chromatography was 
generally not necessary since all reactions went to completion and gave highly crystalline 











Figure 6.5.  Reductive cyclization of 6 with iron in concentrated HCl 
  
Following reduction of the nitro group in 6a, two mechanistic pathways can be 
envisoned for the ring closure of aminochalcone 8a.  Iron does not appear to play a 
significant role in the cyclization since 8a has been successfully cyclized to 10a using 1:1 
acetic acid/phosphoric acid6 or concentrated hydrochloric acid (this study) without iron 
present.  In the first mechanistic scenario, strong acid would protonate the carbonyl 
oxygen of 8a to give 11, which would be activated toward conjugate addition by the 
amino group.  Since the amino function in 8a is part of a vinylogous amide, it is not as 





Conc. HCl, 100 oC, 30 min
6
10









add to the activated enone system 10a.  Alternatively, strong acid conditions could also 
protonate the enone double bond to give the benzylic carbocation 12, which would then 
be attacked by the nucleophilic aniline nitrogen.  These mechanistic possibilities for the 







Figure 6.6.  Mechanisitic possibilities of ring closure of 2’-aminochalcone 
 
Conclusion 
 We have successfully developed a synthesis of  2,3-dihydro-4(1H)-quinolinone 
from 1-(2-nitrophenyl)prop-2-en-1-one and a series of (±)-3-aryl-2,3-dihydro-4(1H)-
quinolinones from  2'-nitrochalcones.  Reductive cyclization of these derivatives using 
iron powder in concentrated hydrochloric acid gave the best results, affording the target 
heterocycles in 72-88% yields.  Products were obtained in good yields without the need 
for extensive purification.  This synthetic approach is limited to chalcone substrates 
bearing electron-donating groups on the C3 aromatic ring carbon since these groups are 
most stable to the base used in the preparation and the reductive conditions in their final 
cyclization.    
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Experimental Section 
All reactions were run under dry nitrogen in oven-dried glassware. Reactions were 
monitored by thin layer chromatography on silica gel GF plates (Analtech No 21521) 
using ultraviolet or iodine vapor detection.  Preparative separations were performed using 
flash chromatography13 on silica gel (grade 62, 60-200 mesh) mixed with ultraviolet-
active phosphor (Sorbent Technologies UV-5), or thin layer chromatography on 20-cm × 
20-cm silica gel GF plates (Analtech 02015) band elution was monitored using a hand-
held ultraviolet lamp.  Melting points were taken on a MelTemp purchased from 
Laboratory Devices, Cambridge, MA 02139 and were uncorrected.  Infrared spectra were 
taken on a Varian 800 FT-IR (Scimitar series) run as thin films on sodium chloride disks 
and were referenced to polystyrene.  1H NMR and 13C spectra were obtained using a 
UNITY INOVA 400 BB NMR spectrometer operating at 400 and 100 MHz respectively; 
In addition some 1H and 13C spectra were recorded using a broadband Gemini 2000 High-
Resolution NMR (300 MHz) spectrometer operating at 300 MHz and 75 MHz, 
respectively.  All NMR signals were referenced to internal tetramethylsilane; coupling 
constants (J) are reported in Hz.  Low resolution mass spectra (direct probe/electron 
impact) were obtained at 70 electron volts or 30 electron volts as indicate .  Elemental 
analysis were obtained at Atlantic Microlabs Inc., Norcross, GA 30091.  
Tetrahydrofuran was dried over potassium hydroxide pellets and distille  from 
lithium aluminum hydride.  All other commercial reagents and solvents were used as 
received.  The ammonium chloride, sodium bicarbonate and sodium chloride used in 
various workup procedures refer to saturated aqueous solution. 
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1-(2-Nitrophenyl)prop-2-en-1-ol (2). The general procedure of Danishefsky and 
coworkers12 was used. A 250-mL three-necked round-bottomed flask, equipped with 
magnetic stirring, a rubber septum and a reflux condenser (nitrogen inlet), was charged 
with 50 mL of dry tetrahydrofuran, followed by 3.00 g (19.9 mmoles) of 2-
nitrobenzaldehyde (1).  The reaction mixture was then cooled to −78 ºC, and 29.5 mL of 
1.0 M vinylmagnesium bromide (29.5 mmoles) was added dropwise via syringe over a 
period of 20 minutes.  The reaction was stirred for 2 hours at −78 oC at which time thin 
layer chromatography indicated the reaction was complete.  The reaction mixture was 
then poured into 50 mL of 3 M HCl solution, stirred for 10 minutes and extracted with 50 
mL of ether.  The aqueous layer was then saturated with sodium chloride and extracted 
with ether (2 × 50 mL).  The combined ether layers were washed with saturated sodium 
chloride solution, dried (magnesium sulfate) and concentrated under vacuum to yield 
3.32 g (93%) of 2 as a viscous yellow liquid.  This product was spectroscopically pure 
and was used in the next step without any further purification.  IR: 3415, 1639, 1609, 
1524, 1349  cm-1; 1H NMR (400 MHz): δ 7.90 (d, 1H,  J = 7.7), 7.76 (d, 1H,  J = 7.7), 
7.64 (t, 1H,  J = 7.9), 7.44 (t, 1H,  J = 7.9), 6.07 (ddd, 1H, J = 17.2, 10.4, 5.3), 5.79 (d, 
1H,  J = 5.3), 5.41 (d, 1H, J = 17.2), 5.25 (d, 1H, J = 10.4), 2.82 (br s, 1H); 13C NMR 
(100 MHz): δ 148.2, 138.0, 137.6, 133.5, 128.8, 128.4, 124.5, 116.1, 69.9; ms (30 eV): 
m/z 179 (M+). Anal. Calcd. for C9H9NO3: C, 60.34; H, 5.03; N, 7.82.  Found: C, 60.51; H, 
5.07; N, 7.69. 
1-(2-Nitrophenyl)prop-2-en-1-one (3). A 100-mL three-necked round-bottomed flask, 
fitted with magnetic stirring, an addition funnel and a reflux condenser (nitrogen inlet), 
was charged with 3.00 g (16.7 mmoles) of 2 and 20 mL of acetone.  To the resulting 
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solution was slowly added 8.5 mL of 2.97 M Jones reagent (25.5 mmoles) over a period 
of 25 minutes at room temperature. [Note: The addition was done very slowly.  Fast 
addition led to significant heating, loss of solvent and a reduced yield.]  After 1 hour at 
room temperature, thin layer chromatography indicated that the reaction was complete.  
Excess Jones reagent was quenched with saturated sodium bisulfite solution (ca 3 mL), 
and the crude reaction mixture was extracted with 50 mL of ether.  The aqueous layer 
was then saturated with sodium chloride solution and extracted again with ether (2 × 50 
mL).  The combined ether layers were washed with saturated sodium chloride, then dried 
(magnesium sulfate) and concentrated under vacuum.  The crude product was purified by 
flash chromatography on a 20-cm × 2-cm silica gel column using increasing 
concentrations of ether in hexanes to give 2.26 g (76%) of 3 as a yellow oil.  IR: 1672, 
1613, 1527, 1347 cm-1; 1H NMR (300 MHz): δ 8.16 (dd, 1H, J = 8.2, 1.3), 7.75 (td, 1H, J 
= 7.5, 1.3), 7.65 (ddd, 1H, J = 8.2, 7.5, 1.5), 7.45 (dd, 1H, J = 7.5, 1.5), 6.65 (dd, 1H, J = 
17.6, 10.6), 6.05 (d, 1H, J = 10.6), 5.85 (d, 1H, J = 17.6); 13C NMR (75 MHz): δ 193.4, 
146.8, 136.5, 135.4, 134.1, 131.2, 130.7, 128.8, 124.4; ms: m/z 177 (M+). Anal. Calcd. for 
C9H7NO3: C, 61.01; H, 3.95; N, 7.91. Found: C, 61.12; H, 3.98; N, 7.83. 
Representative Aldol Condensation:  (2E)-1-(2-Nitrophenyl)-3-phenylprop-2-en-1-
one (6a).  A 100-mL three-necked round-bottomed flask, equipped with magnetic 
stirring, an addition funnel and a nitrogen inlet, was charged with 800 mg (4.84 mmoles) 
of 2’-nitroacetophenone (4) and 15 mL of ethanol.  The resulting solution was cooled to 0 
ºC, stirring was begun, and 232 mg (5.80 mmoles, 1.2 eq) of sodium hydroxide powder 
was added and allowed to dissolve.  To was added on a solution of 539 mg (5.08 mmoles, 
1.05 eq) of benzaldehyde (5a) in 5 mL of ethanol dropwise with continued stirring.  The 
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reaction was stirred for 3 hours at 0 ºC to give a white precipitate.  The product was 
filtered, and the crystals which formed were washed thoroughly with ice-cold ethanol to 
give 1.16 g (95%) of 4a as a white solid, mp 125-127 ºC (lit14 mp 128 ºC).  IR: 1652, 
1608, 1527, 1347 cm-1; 1H NMR (400 MHz): δ 8.18 (dd, 1H, J = 8.2, 1.1), 7.77 (td, 1H, J 
= 7.6, 1.1), 7.66 (td, 1H, J = 7.6, 1.1), 7.53-7.46 (complex, 3H), 7.42-7.34 (complex, 3H), 
7.24 (d, 1H, J = 16.2), 7.01 (d, 1H, J = 16.2); 13C NMR (100 MHz): δ 192.9, 146.7, 
146.3, 136.3, 134.0, 133.9, 131.0, 130.5, 129.0, 128.8, 128.5, 126.2, 124.5; ms: m/z 253 
(M+). 
(2E)-3-(4-Methylphenyl)-1-(2-nitrophenyl)prop-2-en-1-one (6b). This compound 
(1.25 g, 97%) was prepared from 800 mg (4.84 mmoles) of 4 and 610 mg (5.08 mmoles, 
1.05 eq) of 4-methylbenzaldehyde (5b), and isolated as a pale yellow solid, mp 133-135 
ºC (lit14 mp 134-135 ºC)  IR: 1652, 1599, 1528, 1348 cm-1; 1H NMR (300 MHz): δ 8.16 
(dd, 1H, J = 7.7, 1.1), 7.76 (td, 1H, J = 7.7, 1.1), 7.65 (td, 1H, J = 7.7, 1.1), 7.50 (dd, 1H, 
J =  7.7, 1.1), 7.39 (d, 2H, J = 8.2), 7.21 (d, 1H, J = 15.9), 7.18 (d, 2H, J = 8.2), 6.97 (d, 
1H,  J = 15.9), 2.37 (s, 3H); 13C NMR (75 MHz): δ 193.0, 146.52, 146.49, 141.7, 136.4, 
133.9, 131.2, 130.4, 129.7, 128.8, 128.6, 125.3, 124.5, 21.5; ms: m/z 267 (M+). 
(2E)-3-(4-Methoxyphenyl)-1-(2-nitrophenyl)prop-2-en-1-one (6c).  This compound 
(1.27 g, 93%) was prepared from 800 mg (4.84 mmoles) of 4 and 762 mg (5.08 mmoles, 
1.05 eq) of 4-methoxybenzaldehyde (5c), and isolated as an off-white solid, mp 96-98 ºC.  
IR: 2840, 1645, 1600, 1528, 1348 cm-1; 1H NMR (400 MHz): δ 8.16 (dd, 1H, J = 8.2, 
1.2), 7.75 (dt, 1H, J = 7.5, 1.2), 7.64 (ddd, 1H, J = 8.2, 7.5, 1.4), 7.50 (dd, 1H, J = 7.5, 
1.4), 7.45 (d, 2H, J = 8.8), 7.24 (d, 1H, J = 16.2), 6.90 (d, 1H, J = 16.2), 6.87 (d, 2H, J = 
8.8), 3.83 (s, 3H); 13C NMR (100 MHz): δ 192.9, 162.0, 146.6, 146.3, 136.5, 133.9, 
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130.40, 130.38, 128.8, 126.6, 124.5, 123.9, 114.4, 55.4; ms: m/z 283 (M+). Anal. Calcd. 
for C16H13NO4: C, 67.84; H, 4.59; N, 4.95.  Found: C, 67.88; H, 4.62; N, 4.87.  
 (2E)-3-(3,4-Dimethoxyphenyl)-1-(2-nitrophenyl)-prop-2-en-1-one (6d).  This comp-
ound (1.44 g, 95%) was prepared from 800 mg (4.84 mmoles) of 4 and 914 mg (5.08 
mmoles, 1.05 eq) of 3,4-dimethoxybenzaldehyde (5d), and isolated as a yellow solid, mp 
116-117 ºC.  IR: 2839, 1645, 1594, 1512, 1347 cm-1; 1H NMR (300 MHz): δ 8.18 (d, 1H, 
J = 7.7), 7.76 (td, 1H, J = 7.7, 1.1), 7.65 (td, 1H, J = 7.7, 1.6), 7.51 (dd, 1H, J = 7.7, 1.1), 
7.19 (d, 1H, J = 15.9), 7.10-7.01 (complex, 2H), 6.89 (d, 1H, J = 15.9), 6.85 (d, 1H, J = 
7.7), 3.91 (s, 3H), 3.90 (s, 3H); 13C NMR (75 MHz): δ 192.8, 151.8, 149.3, 146.6, 146.5, 
136.5, 133.9, 130.4, 128.8, 126.7, 124.5, 124.2, 123.6, 111.0, 109.8, 56.0, 55.9; ms: m/z
313 (M+). Anal. Calcd. for C17H15NO5: 65.18; H, 4.79; N, 4.47. Found: C, 65.23; H, 4.78; 
N, 4.44.    
(2E)-3-(1,3-Benzodioxol-5-yl)-1-(2-nitrophenyl)prop-2-en-1-one (6e).  This compound 
(1.36 g, 95%) was prepared from 800 mg (4.84 mmoles) of 4 and 762 mg (5.08 mmoles) 
of piperonal (5e), and isolated as a pale yellow solid, mp 128-130 ºC.  IR: 1650, 1599, 
1528, 1384 cm-1; 1H NMR (300 MHz): δ 8.17 (d, 1H, J = 8.2), 7.76 (td, 1H, J = 7.7, 1.1), 
7.64 (td, 1H, J = 8.2, 1.1), 7.51 (dd, 1H, J = 7.7, 1.6), 7.17 (d, 1H, J = 15.9), 7.03 (d, 1H, J 
= 1.6), 6.96 (dd, 1H, J = 7.7, 1.1), 6.84 (d, 1H, J = 15.9), 6.79 (d, 1H, J = 8.2), 6.02 (s, 
2H); 13C NMR (75 MHz): δ 192.7, 150.3, 148.5, 146.7, 146.1, 136.5, 133.9, 130.4, 128.8, 
128.4, 125.5, 124.5, 124.2, 108.6, 106.7, 101.7; ms: /z 297 (M+). Anal. Calcd. for 
C16H11NO5: C, 64.65; H, 3.70; N, 4.71.  Found: C, 64.71; H, 3.73; N, 4.66.  
(2E)-3-(2-Chlorophenyl)-1-(2-nitrophenyl)prop-2-en-1-one (6f).  This compound 
(1.28 g, 92%) was prepared from 800 mg (4.84 mmoles) of 4 and 714 mg (5.08 mmoles, 
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1.05 eq) of 2-chlorobenzaldehyde (5f), and isolated as a pale yellow solid, mp 87-88 ºC 
(lit 14 mp 88-89 ºC).  IR: 1657, 1605, 1527, 1347 cm-1; 1H NMR (300 MHz): δ 8.20 (d,  
1H, J = 7.7), 7.79 (t, 1H, J = 7.1), 7.75-7.60 (complex, 3H), 7.53 (d, 1H, J = 7.1), 7.42-
7.23 (complex, 3H), 6.97 (d, 1H, J = 16.5); 13C NMR (75 MHz): δ 192.8, 146.7, 141.8, 
136.0, 135.2, 134.1, 132.2, 131.7, 130.7, 130.2, 128.9, 128.6, 127.8, 127.2, 124.5; ms: 
m/z 287, 289 (ca 3:1, M+). 
2,3-Dihydro-4(1H)-quinolinone (7).  A 100-mL one-necked round-bottomed flask, 
equipped with magnetic stirring, and a reflux condenser (nitrogen inlet), was charged 
with 400 mg (2.26 mmoles) of 3 and 10 mL of concentrated hydrochloric acid and the 
mixture was brought to reflux in a pre-heated oil bath at 120 ºC.  The heat was briefly 
removed, 630 mg (1.13 mmoles, 5 eq) of iron powder (>100 mesh) was added, and 
heating was resumed for 1 hour.  The reaction mixture was cooled, poured into ice water, 
and extracted with 50 mL of ether.  The aqueous layer was then saturated with sodium 
chloride and extracted again with ether (1 x 50 mL) and ethyl acetate (1 x 50 mL).  The 
combined organic layers were washed with saturated sodium chloride solution, dried 
(magnesium sulfate) and concentrated under vacuum.  The resulting mixture was flash 
chromatographed on 20-cm × 2-cm silica gel column eluted with increasing 
concentrations of ether in hexane to give 276 mg (83 %) of 7 as a yellow solid, mp 42-44 
ºC (lit.15 mp 43-44.5 oC).  IR: 3347, 1659, 1611 cm-1; 1H NMR (300 MHz): δ 7.84 (dd, 
1H, J = 8.2, 1.1), 7.29 (td, 1H, J = 7.7, 1.1), 6.74 (t, 1H, J = 7.7), 6.67 (d, 1H, J = 8.2), 
4.43 (br s, 1H), 3.58 (t, 2H, J = 6.6), 2.70 (t, 2H, J = 6.6); 13C NMR (75 MHz): δ 193.7, 
152.0, 135.1, 127.6, 119.4, 117.9, 115.8, 42.3, 38.1; ms: m/z 147 (M+).  Anal. Calcd. for 
C9H9NO: C, 73.47; H, 6.12;  N, 9.52. Found: C, 73.51; H, 6.11; N, 9.47. 
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This same reaction was carried out using 5 eq of iron powder in 1:1 v/v acetic 
acid/phosphoric acid, but the product yield was only 72%.  This reaction was more 
difficult to perform due to the formation of a heavy insoluble preciitate during the 
heating period. 
Attempted Reductive Cyclization of 6a with Iron Powder in Acetic Acid: (2E)-1-(2-
Aminophenyl)prop-2-en-1-one (8a) and 1-(2-aminophenyl)propan-1-one (9a).  A 
100-mL one-necked round-bottomed flask was charged with 500 mg (1.98 mmoles) of 6a 
in 10 mL of acetic acid and the solution was brought to reflux in a preheated oil bath at 
120 ºC.  The heat was briefly removed, 440 mg (7.88 mmoles) of iron powder (>100 
mesh) was added heating was resumed for 10 minutes.  The reaction mixture was cooled, 
poured into ice-cold water and extracted with ether (3 × 25 mL).  Thecombined ether 
layers were washed with saturated sodium bicarbonate (three tim s) and saturated sodium 
chloride (one time), then dried (magnesium sulfate) and concentrated under vacuum.  The 
crude product was purified on a 40-cm × 2-cm silica gel column eluted with increasing 
concentrations of ether in hexanes to give 220 mg (50%) of 8a as a yellow solid, mp 70-
71 ºC (lit4 mp 72 ºC) and 169 mg (38%) of 9a as a yellow solid, mp 85-86 oC.  The 
spectral data for 8a were: IR: 3471, 3334, 1645, 1614 cm-1; 1H NMR (400 MHz): δ 7.85 
(dd, 1H, J = 8.4, 1.4), 7.74 (d, 1H, J = 15.6), 7.62 (d, 1H, J = 15.6). 7.60 (obscured, 1H), 
7.43-7.33 (complex, 4H), 7.28 (ddd, 1H, J = 8.4, 7.2, 1.6), 6.69 (overlapping d and t, 2H, 
J ≈ 8.0) 6.34 (br s, 2H); 13C NMR (100 MHz): δ 191.6, 150.9, 142.8, 135.2, 134.3, 130.9, 
130.0, 128.8, 128.2, 123.0, 118.9, 117.2, 115.8; ms: m/z 223 (M+). 
The spectral data for 9a were: IR: 3475, 3346, 1647, 1614 cm-1; 1H NMR (400 
MHz): δ 7.73 (dd, 1H, J = 6.6, 8.2), 7.33-7.16 (complex, 6H), 6.65 (d, 1H, J = 7.2), 6.63 
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(td, 1H, J = 7.7, 1.0), 6.26 (br s, 2H), 3.28 (t, 2H, J = 7.4), 3.04 (t, 2H, J = 7.4); 13C NMR 
(100 MHz): δ 201.5, 150.3, 141.5, 134.3, 131.0, 128.5, 128.4, 126.0, 117.8, 117.3, 115.8, 
41.0, 30.6; ms: m/z 225 (M+).  Anal. Calcd. for C15H15NO: C, 80.00; H, 6.67; N, 6.22. 
Found: C, 79.93; H, 6.69; N, 6.17.  
(2E)-1-(2-Aminophenyl)-3-(1,3-benzodioxol-5-yl)prop-2-en-1-one (8e) and 1-(2-
aminophenyl)-3-(1,3-benzodioxol-5-yl)propan-1-one (9e).  Reduction of 500 mg (1.68 
mmoles) of 6e using 375 mg (6.72 mmoles) of iron powder gave 207 mg (46%) of 8e as a 
yellow solid, mp 110-112 ºC, and 171 mg (40%) of 9e as a yellow solid, mp 85-87 oC.  
The spectral data for 8e were: IR: 3468, 3339, 1643, 1614 cm-1; 1H NMR (300 MHz): δ 
7.85 (dd, 1H, J = 8.2, 1.1), 7.67 (d, 1H, J = 15.4), 7.45 (d, 1H, J = 15.4), 7.29 (dt, 1H, J = 
8.2, 1.6), 7.16 (d, 1H, J = 1.6), 7.11 (dd, 1H, J = 8.2, 1.6), 6.84 (d, 1H, J = 8.2), 6.70 (m, 
2H), 6.31 (br s, 2H), 6.02 (s, 2H); 13C NMR (75 MHz): δ 191.6, 150.9, 149.5, 148.3, 
142.8, 134.1, 130.9, 129.7, 124.7, 121.1, 119.2, 117.3, 115.8, 108.6, 106.6, 101.5; ms: 
m/z 267 (M+).  Anal. Calcd. for C16H13NO3: C, 71.91; H, 4.87; N, 5.24. Found: C, 71.98; 
H, 4.89; N, 5.15.  
The spectral data for 9e were: IR: 3468, 3352, 1645, 1614 cm-1; 1H NMR (300 
MHz): δ 7.72 (d, 1H, J = 7.7), 7.26 (t, 1H, J = 7.7), 6.78-6.59 (complex, 5H), 6.27 (br s, 
2H), 5.92 (s, 2H), 3.23 (t, 2H, J = 7.6), 2.96 (t, 2H, J = 7.6); 13C NMR (75 MHz): δ 201.4, 
150.3, 147.6, 146.3 135.3, 134.2, 131.0, 121.1, 117.8, 117.3, 115.8, 108.9, 108.2, 100.8, 
41.2, 30.3; ms: m/z 269 (M+).  Anal. Calcd. for C16H15NO3: C, 71.38; H, 5.58; N, 5.20.  
Found: C, 71.44; H, 5.61; N, 5.14. 
(2E)-1-(2-Aminophenyl)-3-(2-chlorophenyl)prop-2-en-1-one (8f) and 1-(2-
aminophenyl)-3-(2-chlorophenyl)propan-1-one (9f).  Reduction of 500 mg (1.74 
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mmoles) of 6f using 389 mg (6.96 mmoles) of iron gave 235 mg (53%) of 8f as a yellow 
solid, mp 87-89 oC, and 156 mg (34%) of 9f as a yellow solid, mp 86-87 oC.  The spectral 
data for 8f were: IR: 3464, 3338, 1644, 1615 cm-1; 1H NMR (300 MHz): δ 8.11 (d, 1H, J 
= 15.4), 7.84 (d, 1H, J = 8.2), 7.73 (m, 1H), 7.59 (d, 1H, J = 15.4), 7.43 (m, 1H), 7.36-
7.25 (complex, 3H), 6.70 (d, 1H, J = 7.7), 6.69 (t, 1H, J = 7.7), 6.37 (br s, 2H); 13C NMR 
(75 MHz): δ 191.3, 151.1, 138.7, 135.2, 134.5, 133.6, 131.1, 130.7, 130.2, 127.7, 127.0, 
125.8, 118.8, 117.3, 115.8; ms: m/z 257, 259 (ca 3:1, M+).  Anal. Calcd for C15H12ClNO: 
C, 69.90; H, 4.66; N, 5.44. Found: C, 69.97; H, 4.67; N, 5.39. 
The spectral data for 9f were: IR: 3478, 3348, 1647, 1615 cm-1; 1H NMR (300 
MHz): δ 7.73 (d, 1H, J = 8.2), 7.38-7.12 (complex, 5H), 6.64 (d, 1H, J = 8.2), 6.62 (t, 1H, 
J = 7.7), 6.28 (br s, 2H), 3.27 (m, 2H), 3.14 (m, 2H); 13C NMR (75 MHz): δ 201.2, 150.3, 
139.0, 134.3, 133.9, 131.0, 130.6, 129.5, 127.6, 126.9, 117.7, 117.3, 115.8, 39.0, 28.7; 
ms: m/z 259, 261 (ca 3:1, M+).  Anal. Calcd. for C15H14ClNO: C, 69.36; H, 5.39; N, 5.39. 
Found: C, 69.45; H, 5.44; N, 5.30. 
Attempted Reductive Ring Closure with Iron Powder in Acetic Acid/Phosphoric 
Acid Mixtures : (±)-2-Phenyl-2,3-dihydro-4(1H)-quinolinone (10a).  Using the 
procedure given for the preparation of 3 (with various ratios of acetic acid:phosphoric 
acid), 500 mg (1.97 mmoles) of 6a and 440 mg (7.88 mmoles) of iron were reacted for 30 
minutes at 120 oC.  Product 10a was formed, but the maximum yields were generally not 
as high as the procedure using iron and concentrated HCl.  Yields for different acid 
mixtures are given in Figure 6.4. 
Representative Reductive Ring Closure using Iron Powder in Concentrated 
Hydrochloric Acid: (±)-2-Phenyl-2,3-dihydro-4(1H)-quinolinone (10a).  A 100-mL 
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one-necked round-bottomed flask, equipped with magnetic stirring and a reflux 
condenser (nitrogen inlet), was charged with 500 mg (1.97 mmoles) of 6a and 10 mL of 
concentrated hydrochloric acid and heated to 80-85 ºC (oil bath).  The heat was briefly 
removed, and 440 mg (7.88 mmoles, 4 eq) of iron powder (>100 mesh) was added.  
[Caution! The addition is sufficiently exothermic to boil the mixture.  The reaction froths 
while adding the iron powder.]  Heating was resumed at 100 ºC until thin layer 
chromatography indicated complete consumption of the starting material (ca 30 minutes).  
The reaction was cooled, added to 50 mL of water and extracted with ether (2 × 25 mL) 
and ethyl acetate (1 × 25 mL).  The combined organic layers were ashed with saturated 
sodium chloride, dried (magnesium sulfate) and concentrated under vacuum.  The 
resulting mixture was flash chromatographed on 20-cm × 2-cm silica gel column eluted 
with increasing concentrations of ether in hexanes to give 386 mg (88%) of 10a as a pale 
yellow solid, mp 149-151 ºC (lit3 mp 149-150 oC).  IR: 3326, 1661, 1608, 1482 cm-1; 1H 
NMR (400 MHz): δ 7.87 (dd, 1H, J = 8.0, 1.5), 7.45 (dd, 2H, J = 7.6, 1.5), 7.42-7.31 
(complex, 4H), 6.78 (t, 1H, J = 7.6), 6.71 (d, 1H, J = 8.2), 4.74 (dd, 1H, J = 13.8, 3.7), 
4.55 (br s, 1H), 2.87 (dd, 1H, J = 16.2, 13.8), 2.77 (dm, 1H, J = 16.2); 13C NMR (100 
MHz): δ 193.3, 151.5, 141.0, 135.4, 128.9, 128.4, 127.6, 126.6, 119.0, 118.4, 115.9, 58.4, 
46.4; ms: m/z 223 (M+). 
(±)-2-(4-Methylphenyl)-2,3-dihydro-4(1H)-quinolinone (10b).  Reductive cyclization 
of 415 mg (1.87 mmoles) of 6b with 417 mg (7.48 mmoles, 4 eq) of iron gave 378 mg 
(85%) of 10b as an off-white solid, mp 147-149 ºC (lit3 mp 148-149 ºC).  IR: 3331, 1655, 
1608 cm-1; 1H NMR (300 MHz): δ 7.87 (d, 1H, J = 7.7), 7.35 (d, 2H, J = 7.7), 7.34 
(obscured signal, 1H),  7.21 (d, 2H, J = 7.7),  6.79 (t, 1H, J = 7.7),  6.70 (d, 1H, J = 8.2), 
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4.72 (dd, 1H,  J = 13.7, 3.7),  4.47 (br s, 1H), 2.88 (dd, 1H, J = 16.2, 13.7), 2.75 (dd, 1H, J 
= 16.2, 3.7), 2.37 (s, 3H); 13C NMR (75 MHz): δ 193.4, 151.6, 138.3, 138.0, 135.3, 
129.6, 127.6, 126.5, 119.0, 118.4, 115.9, 58.2, 46.5, 21.1; ms: m/z 237 (M+).  Anal. 
Calcd. for C16H15NO: C, 81.01; H, 6.33; N, 5.91.  Found: 80.94; H, 6.32; N, 5.85.  
(±)-2-(4-Methoxyphenyl)-2,3-dihydro-4(1H)-quinolinone (10c).  Reductive cyclization 
of 415 mg (1.76 mmoles) of 6c with 393 mg (7.04 mmoles, 4 eq) of iron gave 365 mg 
(82%) of 10c as a yellow solid, mp 147-148 ºC (lit8c mp 147 ºC).  IR: 3329, 2836, 1660, 
1608 cm-1; 1H NMR (400 MHz): δ 7.87 (dd, 1H, J = 8.0, 1.6), 7.37 (d, 2H, J = 8.6), 7.33 
(td, 1H, J = 7.7, 1.2), 6.92 (d, 2H, J = 8.6), 6.78 (t, 1H, J = 7.7),  6.70 (d, 1H, J = 8.2),  
4.69 (dd, 1H, J = 13.8, 3.7), 4.48 (br s, 1H), 3.82 (s, 3H), 2.87 (dd, 1H, J = 16.2, 13.8), 
2.74 (dd, 1H, J = 16.2, 3.7); 13C NMR (75 MHz): δ 193.5, 159.6, 151.6, 135.3, 133.0, 
127.8, 127.6, 119.0, 118.3, 115.9, 114.2, 57.9, 55.3, 46.5; ms: m/z 253 (M+).  Anal. 
Calcd. for C16H15NO2: C, 75.89; H, 5.93; N, 5.53.  Found: C, 75.83; H, 5.94; N, 5.49. 
(±)-2-(3,4-Dimethoxyphenyl)-2,3-dihydro-4(1H)-quinolinone (10d).  Reductive 
cyclization of 426 mg (1.59 mmoles) of 6d and 355 mg (6.36 mmoles, 4 eq) of iron gave 
326 mg (72%) of 10d as a white solid, mp 145-147 ºC. IR: 3348, 2836, 1660, 1611 cm-1. 
1H NMR (300 MHz): δ 7.87 (d, 1H, J = 7.7), 7.35 (t, 1H, J = 7.1), 7.00 (s, 1H), 6.99 (d, 
1H, J = 7.7), 6.87 (d, 1H, J = 8.2), 6.80 (t, 1H, J = 7.7), 6.72 (d, 1H, J = 8.2), 4.70 (dd, 
1H, J = 13.7, 3.7), 4.51 (br s, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 2.88 (dd, 1H, J = 15.9, 
13.7), 2.75 (dd, 1H, J = 15.9, 3.7); 13C NMR (75 MHz): δ 193.4, 151.5, 149.3, 149.0, 
135.3, 133.5, 127.6, 119.0, 118.9, 118.4, 115.9, 111.2, 109.4, 58.3, 55.97, 55.94, 46.7; 
ms: m/z 283 (M+).  Anal. Calcd. for C17H17NO3: C, 72.08; H, 6.01; N, 4.95.  Found: C, 
72.11; H, 6.02; N, 4.91. 
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(±)-2-(1,3-Benzodioxol-5-yl)-2,3,dihydro-4(1H)-quinolinone (10e).  Reductive 
cyclization of 423 mg (1.68 mmoles) of 6e and 375 mg (6.72 mmoles, 4 eq) of iron gave 
374 mg (83%) of 10e as an off-white solid, mp 145-147 ºC. IR: 3328, 1663, 1610 cm-1; 
1H NMR (300 MHz):  δ 7.86 (d, 1H, J = 7.7), 7.34 (td, 1H, J = 7.7, 1.6), 6.97 (d, 1H, J = 
1.1), 6.89 (dd, 1H, J = 8.0, 1.6), 6.79 (overlapping d and t, 2H,  J ≈ 8.2), 6.71 (d, 1H, J = 
8.2), 5.98 (s, 2H), 4.65 (dd,1H, J = 13.4, 3.7), 4.49 (br s, 1H), 2.83 (dd, 1H, J = 16.2, 
13.4), 2.71 (dd, 1H, J = 16.2, 3.7); 13C NMR (75 MHz): δ 193.3, 151.5, 148.0, 147.6, 
135.4, 134.9, 127.6, 120.1, 119.0, 118.4, 115.9, 108.5, 106.9, 101.2, 58.3, 46.6; ms: m/z
267 (M+).  Anal. Calcd. for C16H13NO3: C, 71.91; H, 4.87; N, 5.24.  Found: C, 71.92; H, 
4.89; N, 5.22. 
(±)-2-(2-Chlorophenyl)-2,3-dihydro-4(1H)-quinolinone (10f).  Reductive cyclization 
of 399 mg (1.73 mmoles) of 6f and 386 mg (6.92 mmoles, 4 eq) of iron gave 357 mg 
(80%) of 10f as a yellow solid, mp 126-128 ºC. IR: 3429, 1659, 1609 cm-1. 1H NMR (300 
MHz): δ 7.88 (d, 1H, J = 7.7), 7.68 (dd, 1H, J = 7.1, 1.6), 7.44-7.23 (complex, 4H), 6.81 
(t, 1H, J = 7.1), 6.74 (d, 1H, J = 8.2), 5.27 (dd, 1H, J = 12.1, 3.7), 4.52 (br s, 1H), 2.96 
(ddd, 1H, J = 16.2, 3.7, 1.5), 2.78 (dd, 1H, J = 16.2, 12.1); 13C NMR (75 MHz): δ 192.7, 
151.5, 138.3, 135.4, 132.8, 130.0, 129.3, 127.6, 127.5, 127.4, 119.1, 118.7, 116.0, 54.2, 
44.0; ms: m/z 257, 259 (ca 3:1, M+).  Anal. Calcd. for C15H12ClNO: C, 69.90; H, 4.66; N, 
5.44.  Found: C, 69.97; H, 4.69; N, 5.39. 
Cyclization of 8a Using Concentrated Hydrochloric Acid: (±)-2-Phenyl-2,3-dihydro-
4(1H)-quinolinone (10a).  Using the procedure for the reductive cyclization of 6a to 10a 
above, 150 mg (0.67 mmoles) of 8a and 6 mL of concentrated hydrochloric acid were 
treated with 150 mg (2.69 mmoles, 4 eq) of iron powder at 100 oC for 3 hours.  Workup 
 114
and purification on a 20 cm x 20 cm preparative thin layer chromatography plate, eluted 
with 30% ether in hexanes, yielded 128 mg (85%) of 10a as a pale yellow solid.  The 
physical properties and spectral data matched those reported above.   
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CHAPTER VII 




 Kidney cancer is known to have a high mortality rate due to a lack of treatment 
options.1   The incidence of renal cancer appears to have increased over the last 50  
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years.2  Preliminary evidence is available which demonstrates that certain 
heteroarotinoids can be effective in the treatment of such cancers.3  Heteroarotinoids 1 
have been known for more than a decade with much of the early chemistry being 
reviewed in 2002.4    
The basic structural unit 1 was originally designed for heteroarotinoids as illustrated 
above and was based, in part, on a partial structural relationship with trans-retinoic acid 
(2) (see Figure 7.1).  Studies of the biological activity of 2 and isomers thereof revealed 
them to possess high toxicity and therefore limited utility.5  Pioneering work in which 
heteroatoms were inserted into strategic positions, as shown in 1, within the molecular 
framework reduced the toxicity significantly.4,6  Since an aryl ring was also present, the 
term heteroarotinoids was established to identify such systems.4,6  The toxicity associated 
with acid 2 has been presumed to arise from metabolites the major members of which are 
shown as 3-6.7  An initial objective was to ascertain if heteroarotinoids with a heteroatom 
at C-4 had reduced toxicity and to avoid oxidation at the C-4 position which could lead to 
derivatives reminiscent of those from 2, such as 4 and 5 which are toxic.  The hypothesis 
that heteroatoms reduce toxicity has been validated.4,6,8,9  Moreover, the addition of the 
benzene ring fused to the cyclohexyl unit in 1 would also prevent epoxidation as found in 
3 derived from 2.  Variations in the linking group also produced marked changes in 
biological responses.6,8-21  A second benzene ring with a functional group Z in 1 locked 
the double bonds into a cis-arrangement at the terminus which was deemed important for 
activity.  Consequently, strong activity against cancers for the breast, head/neck, kidney, 
and lung has been observed.8-23 
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The long term objective of the current research is to provide the foundation N-(3,4-
dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-6-yl)-N’-(4-nitrophenyl) thiourea 7 to 
be acceptable to the FDA as an agent to treat or prevent kidney cacer and possibly other 
cancers.3,32-33  The identification and importance in meeting the MIST (human 
metabolites in safety testing) standards for metabolites of potential drugs are well 
documented.36-39  The synthetic work outlined in this chapter was needed before 
biological evaluations of the metabolites could be made.  However, as sm ll samples of 
the metabolites become available, they will be sent to NCI as for preliminary screening. 
The most recent discovery is that the thiourea derivative 7 has enhanced inhibitory 
properties with respect to cancers of the breast, head-neck, kidneys, lung and certain 
ovarian cancers.3,12-15,17-23  The urea derivative 8 has also displayed strong activity against 
ovarian cancer cells18 and especially against kidney cancers.3  Of prime significance was 
the observation that no inhibitory activity against benign cells has been detected with 7
and related urea and thiourea analogs.15,19  Preclinical pharmacokinetic studies have 
revealed that plasma protein binding by 7 is 99.3-99.5% at low micromolar 
concentrations which is a useful clinical range.23  An interesting observation is that 8 
forms co-crystals to a large extent in the solid state while 7 forms them to a lesser extent.  
The area of co-crystals, as correlated to drug discovery, has now been established and 
includes a number of substituted ureas and derivatives.38 
A need to obtain metabolites from 7 is imperative to satisfy federal requirements prior 
to filing a request for FDA approval of the agent for human use.  Although the 
metabolities are known,2,39 an appraisal of biological activity and toxicity will be required 
in the near future.  A determination of the major metabolites of 7 has been accomplished 
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Figure 7.2.  Various heteroarotinoid metabolites 
 
with compound 9-13 being identified (see Figure 7.2).41  The metabolites 9-13 from 7 are 
somewhat reminiscent of alcohol 5 which arose from 2.  Oxidation of the cyclohexyl unit 
to give a secondary alcohol 13 is surprising since the position is hindered by flanking 
methyl groups.  Agent 7 regulates, growth, differentiation, and apotosis in cancer cells,3 
but it is not known if the metabolites are involved.  Consequently, it is important to 


































































comparison of activities with those of 7.   This work will aid in eventual identification of 
the location of hydroxymethyl groups which initiate the greatest apoptosis action.13   It is 
important to recognize that 7 induces apoptosis in cancer cells and not benign cells.15    
The need for an improved synthesis of 7 is apparent.  Preclinical trials of 7 are 
nearly complete by the National Cancer Institute (NCI) of the National Institutes of 
Health (NIH).  A second toxicity study is underway and will be complete by March, 
2010, with human clinical trials to begin in the early summer of 2010.  If 7 is to be 
approved by the FDA and brought to market, a high yielding synthetic procedure to 
obtain the compound must be available to minimize costs.   Consequently, this part of the 
thesis has been directed to the development of a preparative methodology to obtain 7 in 
the highest yield possible. 
Results and Discussion 
 The goal of this project was to develop improved methodology for the synthesis 
of SHetA2 (7) potentially applicable to a commercial scaleup with few steps and high 
yields for all intermediates and the final product.  The synthetic pathways for the 
prepartion of SHetA2 are outlined in Figure 7.3.  Methyl ketone 18 was prepared from 
acetamidothiophenol (16) by a Michael addition with mesityl oxide (17) in chloroform 
with triethylamine at reflux to give 18 (89%).  In this case, it was found that an addition 
of 0.6 equivalent excess of mesityl oxide and triethylamine at regular intervals (~ every 4 
h) ensured completion of the reaction.  In this manner a 5% increase in th yield of 18 
(83%) was realized compared to that reported.40 
 Treatment of methyl ketone 18 with excess methyllithium (3 equivalents) gave 
alcohol 19.  The addition protocol and temperature played vital roles in the conversion of 
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ketone 18 to alcohol 19.  Initially the reaction was cooled to -50 ºC, and 1.5 equivalents 
of methyllithium was added quickly over a period of 20 minutes.   The remaining 1.5 
equivalents of methyllithium was added slowly and dropwise over a period of 1 hour.  
When the addition was complete, the reaction was stirred at -5 ºC for 1 hour and finally at 
room temperature for 1 hour.  Stirring at room temperature ensured a high yield (82%) of 
19.  
   
Figure 7.3.  Synthetic scheme for the prepartion of SHetA2 
 
Cyclodehydration of 19 was accomplished by the use of anhydrous AlCl3 in benzene.  
changes in anhydrous AlCl3 and the reaction solvent from chlorobenzene to benzene 
markedly improved the yield (82%) of the cyclization product 20.   This process had an 
advantage in that few impurities were formed which made for easyseparation of the 
product 20 from the crude mixture by column chromatography.  The ease of removal of 
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solvent from the reaction mixture becomes simpler due to the lower boiling point of 
benzene compared to chlorobenzene. 
Final hydrolysis of the amide group in 20 was accomplished by refluxing the 
acetamidothiochroman (20) in 90% HCl for a period of 9 hours which gave pure 6-
aminothiochroman (21) in a yield of 96%.   The 6-aminothiochroman (21) was coupled 
by stirring with 4-nitrophenylisothiocyanate in dry THF.  The crude product was 
recrystallized using chloroform:pentane (1:3) as solvent to provide the desired compound 
7 in a yield of 87%.  The overall yield obtained was about 75% compared to 50% by the 
previously developed method.40 
Conclusion 
 An optimized synthesis of 7 has been accomplished, straightforward, efficient, 
and more cost effective than the methods currently available for the synthesis of this 
drug.  This improved procedure should be feasible on an industrial scale for the bulk 
preparation of the thiourea heteroarotinoid 7.  The synthesis gives an overall increase of 
25% higher yield compared to the original route40 and also avoids the use of excesses of 
expensive solvents and reagents.   
Experimental Section 
 All reactions were run under dry nitrogen in an oven-dried glasswre.  All 
reactions were carried out under argon unless otherwise noted.  Commercial reagents and 
solvents were used as received.  Tetrahydrofuran was dried over potassium hydroxide 
pellets and distilled from lithium aluminium hydride prior to use.  The hydrochloric acid 
(1 M), ammonium chloride (saturated), sodium bicarbonate (saturated) and sodium 
chloride (saturated) used in workup procedures refer to aqueous solutions.     
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Evaporation of solvents was accomplished in vacuo via the use of a Buchi 
Rotovapor® RE-111 and a Brinkman B-169 water aspirator unless otherwise specified.  
For those intermediates that were liquids and required distillation for purificat on, 
vacuum distillation was employed using a Welch® ChemstarTM 1402N vacuum pump.  
Final compounds or intermediates that were solids were also dried using the same 
vacuum pump.  Solid intermediates and compounds were purified by flash column 
chromatography on silica gel (Grade 62, 60-200 mesh).  Reactions were monitored by 
thin layer chromatography on silica gel GF plates (Analtech 21521).  Preparative 
separations were performed using flash chromatography on silica ge (grade 62, 60-200 
mesh) mixed with ultraviolet-active phosphor (Sorbent Technologies UV-5); band elution 
was monitored using a hand held ultraviolet lamp.  In addition to the synthesis and 
purification techniques, each product was analyzed for structure and purity using IR 
spectroscopy, 1H NMR spectroscopy, 13C NMR spectroscopy, and TLC.  Melting points 
of all solids were uncorrected and taken on a MelTemp purchased from Laboratory 
Devices, Cambridge, MA 02139.   Infrared spectroscopy were taken on a Varian 800 FT-
IR (Scimitar series) run on a thin films on sodium chloride disks.  1H and 13C Nuclear 
magnetic resonance spectra were measured in deuteriochloroform at 300 MHz and 75 
MHz, respectively, on a Varian Gemini 300 MHz unit and were referenc d to internal 
tetramethylsilane; coupling constants (J) are reported in Hertz. 
4-Methyl-4-(4-acetamidophenylthio)-2-pentanone (18). A 1-L three-necked round-
bottomed flask, equipped with an addition funnel, a reflux condenser, a magnetic stir bar 
and an argon inlet was charged with 25.0 g (149.7 mmol) of acetamidothiophenol (16), 
200 mL of dry chloroform and 7.0 mL of triethylamine.  Stirring was initiated and 17.0 
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mL (50.3 mmol) of freshly distilled mesityl oxide (17) was added dropwise over a period 
of 15 min.  The resulting grey slurry was heated to reflux in an oil bath preheated to 70 
ºC.  After refluxing for 3 h the grey slurry slowly changed into a dark brown solution. 
Following this initial period, two portions of triethylamine (1.1 g, 1.5 mL, 10.9 mmol) 
and mesityl oxide (2.6 g, 3.0 mL, 26.2 mmol) were added twice at regula intervals of 4 h 
and the solution was allowed to reflux for 24 h.  A TLC analysis at this point indicated 
product formation with only a trace of starting material.  The reaction mixture was cooled 
to room temperature, filtered through Celite® and concentrated under vacuum.  The 
resulting crude product was purified by flash chromatography on a 55-cm × 5-cm silica 
gel column.  Elution with 1.5 L of dichloromethane removed the unreacted mesityl oxide 
and this was followed by 3.5 L of dichloromethane:ethyl acetate (1:1) to elute the 
product.  The solvent was evaporated, and the resulting residue was dried under high 
vacuum for 4 h to give ketone 18 as a viscous dark yellow liquid.  The dark liquid was 
placed in the freezer at −20 oC where it slowly solidified into a pale yellow solid.  The 
solid was crushed into a fine powder and dried under high vacuum (5 h) before being 
used in the next step.  The final yield was 35.3 g (89%), mp 50-51 ºC [Lit40 46-49 oC].  
IR: 3311, 1699, 1675 cm-1; 1H NMR (CDCl3): δ 7.90 (br s, 1H), 7.53 (d, J = 8.8 Hz, 2 H), 
7.45 (d, J = 8.8 Hz, 2 H), 2.65 (s, 2 H), 2.19 (s, 3 H), 2.15 (s, 3 H), 1.36 (s, 6 H); 13C 
NMR: δ 206.9, 168.6, 139.0, 138.3, 126.2, 119.6, 54.3, 47.0, 32.1, 28.0, 24.5.  
2,4-Dimethyl-4-(4-acetamidophenylthio)-2-pentanol (19). A 2-L three-necked round-
bottomed flask, fitted with a mechanical stirrer, an addition funnel a d an argon inlet, 
was charged with a solution of 20.0 g (75.5 mmol) of ketone 18 in 1 L of dry THF.  As 
the solution was cooled to −50 oC (dry ice-acetone), 142 mL of 1.6 M methyllithium in 
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ether (227.2 mmol) was transferred by cannula into a 250-mL graduated addition funnel.  
Approximately 70 mL of the methyllithium solution was added dropwise to the solution 
of 3 over a period of 20 min.  A white precipitate started to form after the addition.  After 
10 min, the remaining 72 mL of the methyllithium solution was added dropwise over a 
period of 1 h.   The reaction mixture was allowed to warm slowly to −5 to −10 ºC during 
1 h, and maintained at −5 oC (salt-ice bath) for a period of 3 h.  Finally, the reaction 
mixture was stirred at room temperature for 1 h.  The crude reaction mixture was 
cautiously quenched by slow dropwise addition of 25 mL of ice water.  When the initial 
reaction subsided, an additional 175 mL of ice water was added portionwise to the 
mixture.  The aqueous layer was adjusted to pH 7 using 1 N HCl and the crude mixture 
was transferred to a separatory funnel.  The two phases were sepaated, nd the aqueous 
phase was further extracted with ethyl acetate (2 × 300 mL).  The combined organic 
layers were washed with saturated aqueous sodium chloride (1 × 200 mL) and dried 
(magnesium sulfate).  Evaporation of the solvent yielded a crude, white solid which was 
purified by chromatography on a packed silica gel column (50 cm × 5 cm, grade 62, 60-
120 mesh) via elution with 7:3 of ethyl acetate:hexanes.  The solvent was evaporated to 
give 17.3 g (82%) of alcohol 19 as a white solid, mp 140-142 ºC [lit40 yield 65%, mp 
138-144 ºC].  IR: 3400, 3303, 1676 cm-1; 1H NMR (CDCl3): δ 7.68 (br s 1 H), 7.52 (s, 4 
H), 3.50 (br s, 1 H), 2.19 (s, 3 H), 1.77 (s, 2 H), 1.34 (s, 6 H), 1.33 (s, 6 H); 13C NMR 
(CDCl3): δ 168.4, 138.8, 138.1, 126.3, 119.6, 72.0, 52.0, 49.2, 32.2, 30.8, 24.6. 
2,2,4,4-Tetramethyl-6-acetamidothiochroman (20).  A 500-mL three-necked round-
bottomed flask, fitted with a condenser, a magnetic stir bar and a itrogen inlet, was 
charged with 150 mL of dry benzene and 15.0 g (53.4 mmol) of the dry alcohol 19.  The 
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mixture was stirred for 10 min to partially dissolve the alcohol.  To this mixture as added 
11.4 g (85.3 mmol) of dry aluminum chloride and the mixture was stirred for 5 min.  The 
reaction was then placed in an oil bath preheated to 70 ºC and stirring was continued for 
90 min at which time TLC analysis confirmed that the reaction was complete.  The 
reaction mixture was cooled to room temperature and added to a 1-L Erlenmeyer flask 
containing 200 mL of ice-cold water.  The resulting white, turbid mixture was transferred 
to a separatory funnel and extracted with ethyl acetate:ether (1:1, 2 × 200 mL).  The 
combined organic layers were washed with saturated aqueous sodium chloride (1 × 400 
mL), dried (MgSO4) and concentrated under vacuum to give a yellow liquid.  The crude 
product was purified by chromatography on a packed silica gel column (40 ×  4 cm, 
grade 62, 60-200 mesh) and eluted with 7:3 hexanes:ethyl acetate to giv 11.5 g (82%) of 
20 as a  white solid, mp 107-109 ºC [lit40 mp 104-107 ºC].  IR: 3294, 1660 cm-1; 1H NMR 
(CDCl3): δ 7.60 (br s, 1 H), 7.57 (d, J = 2.2 Hz, 1 H), 7.20 (dd, J = 8.2, 2.2 Hz, 1 H), 7.04 
(d, J = 8.2 Hz, 1 H), 2.1 (s, 3 H), 1.92 (s, 2 H), 1.39 (s, 6 H), 1.35 (s, 6 H); 13C NMR 
(CDCl3): δ 168.3, 143.4, 135.1, 128.4, 128.2, 118.7, 118.2, 54.4, 42.0, 35.7, 32.4, 31.4, 
24.4.  
2,2,4,4-Tetramethyl-6-aminothiochroman (21). A 250-mL one-necked round- 
bottomed flask, equipped with a condenser, a magnetic stir bar, a condenser and a 
nitrogen inlet, was charged with 8.0 g (30.4 mmol) of amide 20 and 100 mL of 10:90 
water/concentrated HCl at room temperature.  The resulting slurry was stirred for 10 min 
and the flask was then suspended in an oil bath preheated to 100 ºC.  The brown slu ry 
became a clear solution after 2 h and on continued heating once again bec me a half 
white suspension.  After 7 h, TLC analysis indicated the reaction was complete.  The 
 127
reaction was cooled to room temperature and carefully poured into 200 mL of ice-cold 
water.  The compound was then extracted with 1:1 ethyl acetate:ether ( 2 × 150 mL).  The 
combined organic layers were washed with saturated aqueous sodium bicarbonate (1 × 
200 mL) and saturated aqueous sodium chloride (1 × 250 mL), then dried (MgSO4) and 
concentrated under vacuum to give 6.4 g (96%) of amine 21 as a pale brown shiny solid, 
mp 57-59 ºC.  [lit40 mp 35-65 ºC; the HCl derivative of 21 has been prepared42 in a yield 
of 91% with a mp of 165 ºC; the melt then re-solidified and melted at 275-290 ºC]; IR: 
2863 cm-1; 1H NMR (CDCl3): δ 9-10 (br s, 2 H), 7.47 (s, 1 H), 7.16 (m, 2 H), 1.92 (s, 2 
H), 1.39 (s, 6 H), 1.37 (s, 6 H); 13C NMR (CDCl3): δ 144.8, 133.7, 129.3, 127.8, 121.0, 
120.2, 53.9, 42.3, 35.8, 32.2, 31.5. 
N-(3,4-Dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-6-yl)-N'-(4-nitrophen-
yl)thiourea (7).  A one-necked round-bottomed flask, equipped with a magnetic stir bar 
and a nitrogen atmosphere was charged with 5.0 g (22.8 mmol) of amine 21 and 
dissolved in 100 mL of dry THF.  To the stirred solution was added 4.1 g (22.8 mmol) of 
4-nitrophenylisothiocyanate and stirring was continued for 24 h.  The reaction mixture 
was then concentrated under vacuum to give a crude yellow solid.  Chromatography of 
the solid on a  25-cm × 4 cm column of silica gel (grade 62, 60-200 mesh) eluted with 7:3 
ethyl acetate:hexanes gave a yellow solid. The compound was further purified by 
recrystallization from 1:3 chloroform:pentane to give 7.9 g (95%) of 7 as a bright yellow 
solid, mp 154-155 ºC [lit41 mp 153-155 ºC].  IR: 3307, 3192 cm-1; 1H NMR (CDCl3): δ 
8.37 (br s, 1 H), 8.19 (d, J = 8.8 Hz, 2 H), 7.91 (br s, 1 H), 7.74 (d, J = 9.3 Hz, 2 H), 7.33 
(d, J = 2.2 Hz, 1 H), 7.20 (d, J = 8.2 Hz, 1 H), 7.02 (dd, J = 8.2, 2.2 Hz, 1 H), 1.97 (s, 2 
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H), 1.44 (s, 6 H), 1.39 (s, 6 H); 13C NMR (CDCl3): δ 178.8, 145.0, 144.4, 143.8, 133.9, 
132.1, 129.5, 124.5, 124.1, 122.9, 122.8, 53.6, 42.4, 35.8, 32.4, 31.5. 
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SYNTHESIS OF METABOLITES OF SHetA2 HETEROAROTINOID 
Introduction  
The development of useful drugs has often required an improvement in 
hydrophilicity which increases aqueous solubility and frequently biological activity as 
well.1  Noted Examples include certain diaryl urea multikinase inhibitors which inhibit 







Figure 8.1.  Structure of Sorafenib and ABT-86 
 
by increasing the hydrophilicity of its precursor, which led to increased in vivo potency.  
The ability to prolong progression free survival in recurrent kidney cancer patients with 
manageable toxicity led to its FDA approval.  However, the toxicity of Sorafenib remains 
a problem.3  Since 3 has not shown any significant toxicity in the studies by NCI, it is
predictable that the metabolites may not be toxic.  The increased polarity of the 
metabolites could provide a number of pharmaceutical and pharmokinetic advantages 
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with increased aqueous solubility.  Higher hydrophilicity correlates w ll with reduced 
lipid tissue uptake, typically resulting in higher blood or plasma concentrations available 
for delivery to target tumor cells.  Compound 3 has shown interaction with the kinase 
KIT [Ambit Biosciences Corporation, 4215 Sorrento Valley Blvd, San Diego, CA] at 5 
nM concentration.  Recognition of the significance of ureas and derivatives for the 
inhibition of kinases is acknowledged by the American Custom Chemicals Corporation 
[P. O. Box 910574, San Diego, CA 92191-0574] who market such agents as ABT-869 (2) 
above.4 
 In view of the fact that N-(3,4-dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-
6-yl)-N'-(4-nitrophenyl)thiourea (3) has not displayed any toxicity in animal studies and 
yet is active against breast, head-neck, kidney, ovarian and lung cancers, it is highly 
possible that a metabolite elicits the biological response and is not toxic.5  Consequently, 
it is imperative that the metabolites be synthesized and screened for biological activity.  
The objective of this project was to obtain major metabolites such as 4 whose structure is 
illustrated below and its acetate derivative 5. The second objective was to prepare a 
derivative of  4, namely 6, for eventual linking to a magnetic nanobead.  The latter is to 
be done by scientists at SoluLink Biosciences, 9853 Pacific Heights Blvd, Suite H, San 
Diego, CA 92121 under the direction of Dr. David Schwartz, Chief Science Officer.  The 
attached metabolite on the magnetic bead will be submitted to Dr. Doris M. Benbrook of 
the University  of Oklahoma Health Sciences Center who will use it d termine which 
proteins interact with the attached metabolite.  The identified protein(s) will serve as 










                  Figure 8.2.  Structures of heteroarotinoid metabolites 
 
Results and Dicussion 
 Due to the reduced toxicity reports available on SHetA2 (3) from the National 
Cancer Institute (NCI) and its ability to inhibit various cancer lls, we have developed 
methodology to obtain the sulfur-containing heteroarotinoid metabolites.  The syntheses 
of the metabolites are outlined in Figure 8.3.  Based on earlier work,6 the core  
thiochroman 10 was built using benzenethiol (7) and methyl-2-butenoic acid (8) along 
with piperdine in sealed tube which was heated at 130 ºC for 24 hours to afford the acid 9 
in a yield of 83%.  Cyclodehydration of 9 was accomplished by stirring it in 
polyphosphoric acid at 70 ºC which afforded thiochroman 10.  Treatment of 10 with 
trimethylsilyl cyanide and a catalytic amount of ZnI2 gave an unstable trimethylsilyl 
cyanohydrin 11.  Thus, 11 was converted immediately to 12 by dissolving it in benzene 
and refluxing the solution with triethylamine and POCl3.  The unsaturated nitrile 12 was 
converted to the saturated nitrile 13 by treatment with NaBH4 in refluxing ethanol.  
Compound 13 was methylated at the position alpha to the cyanide group by 
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deprotonation using NaH in anhydrous N,N-dimethylformamide, followed by the addition 
of methyl iodide, to produced 14 (90%).  Hydrolysis of nitrile 14 occurred with 50% 
H2SO4 at 90 ºC to yield 15 (90%).  Reduction of acid 15 with LiAlH 4 gave alcohol 16 
(87%).  Acylation of 16 with acetic anhydride in the presence of DMAP in methylene 
chloride generated acetate 17 (98%). 
The amine 19 was envisioned to be the key intermediate in the synthesis of these 
metabolites 20 and 22.  To accomplish the goal, nitration step of (17) was initiated.  The 
nitration was effected by dissolving the compound in acetic anhydride, followed by 
addition of HNO3/Ac2O mixture at -5 ºC and stirring for 3.5 hours.  The reaction mixtures 
afforded a mixture of isomers along with a variety of other products as evidenced by TLC 
analysis.  However, a complete separation of the 6-isomer was done by flash 
chromatography to afford the nitrothiochroman acetate 18 in a modest yield of 20%.   
Earlier nitrations were performed on similar molecules in yields as high as 26%.5  The 
acetate group in the thiochroman reduces the yield of the compound by about 7%.   
 A search for a clean, straightforward reduction procedure to accmplish the 
conversion of nitrothiochroman acetate 18 to aminothiochroman acetate 19 was initiated.  
A previous method6 in the synthesis of the heteroarotinoid drug SHetA2 involved the use 
of Fe/AcOH/EtOH which afforded a yield of 45%.  To overcome the problem, compound 
18 was refluxed in glacial acetic acid, Fe powder (3 eq) was added under hot conditions 
and continued stirring at reflux for 30 minutes afforded 19 in a yield of 95%.  By 
avoiding the use of EtOH and by avoiding overheating, the yield of the compound is 
increased by 50% over that reported 45%.16  Furthemore, acetate 19 could be hydrolyzed 
with 10% NaOH to give the aminothiochroman alcohol 20 (94%).  The advantage of the 
 137
procedure was that, after neutralization of the reaction mixture with 6 M HCl, 20 was 


















      











Figure 8.3.  Synthentic scheme for SHetA2 arotinoid metabolites 
 
Generation of the desired heteroarotinoid metabolite 4 and its acetate derivative 5, 
was accomplished by coupling of 4-nitrophenylisothiocyanate with the respective amines 
20 and 19 to give the corresponding thiourea derivatives 4 and 5 (Scheme 1).  The crude 
products were crystallized from chloroform:pentane (1:3) to afford 4 (82%) and 5 (88%) 
in good yields.  
Conclusion  
 We have developed a new route for the sytheses of the SHetA2 heteroaro inoid 
metabolites using a 15 step sequence.   Except for the nitration step all other steps in this 
synthesis are high yielding.  In view of the importance of the SHetA2 as a effective drug 
against kidney and ovarian cancer cells, the metabolites might also prove active against 
these cancer cells.  Testing of these metabolites against various other cancer cells will 




All reactions were run under dry nitrogen (unless otherwise stated) in oven-dried 
glassware.  Tetrahydrofuran (THF) was dried over potassium hydroxide pellets and 
distilled from lithium aluminium hydride.  Anhydrous N,N-dimethylformamide (DMF) 
was purchased commercially and transferred by syringe into reactions where it was used. 
All other commercial reagents and solvents were used as received.  Solutions of HCl, 
NaOH, NH4Cl, NaHCO3 and NaCl used in work-up procedures were all aqueous. 
  Evaporation of solvents was accomplished in vacuo via the use of a Buchi 
Rotovapor® R-3000 and a Brinkman B-169 water aspirator unless otherwise specified.  
For those intermediates and final compounds which required drying were dri d using a 
Welch® ChemstarTM 1402N vacuum pump.  For those intermediates and compounds that 
were solids and required purification, in addition to recrystallization, flash column 
chromatography was used.  Chromatography was performed on silica gel p cking (grade 
62, 60-200 mesh).  Reactions were monitored by thin layer chromatography on silica gel 
GF plates (Analtech No. 21521) using ultraviolet detection.  Preparative separations were 
performed by flash column chromatography on silica gel (grade 62, 60- 00 mesh) mixed 
with ultraviolet-active phosphor (Sorbent Technologies UV-5); band elution was 
monitored using a hand-held ultraviolet lamp.  Elemental analyses were performed by 
Atlantic Microlab, Inc., Norcross, GA 30091.  
Melting points were taken on a MelTemp purchased from Laboratory Devices, 
Cambridge, MA 02139 and were uncorrected.  Infrared spectra were taken on a Varian 
800 FT-IR (Scimitar series) run as thin films on sodium chloride disks.  Unless otherwise 
indicated, 1H and 13C NMR spectra were measured in CDCl3 at 300 MHz and 75 MHz, 
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respectively, on a Varian Gemini 300 MHz unit and were referenced to internal 
tetramethylsilane; coupling constants (J) are reported in Hz. 
3-(Phenylthio)-3-methylbutanoic Acid (9). The procedure of Comasseto and coworkers 
was modified6.  A 200-mL pressure tube reactor was charged with 30.0g (0.30 mol) of 3-
methyl-2-butenoic acid 8 along with 27.0 g (0.32 mol, 1.5 eq) of piperidine and 33.0 g 
(0.30 mol) of thiophenol 7.  The pressure tube was then sealed and heated at 130 ºC in a 
oil bath (silicone oil) for 24 h.  The resulting mixture dark brown thick liquid was cooled 
to room temperature and diluted with 1 L of ether. The ether layer was washed with 1 M 
HCl  (3 × 200 mL), water (1 × 200 mL) and saturated NaCl (1 × 200 mL), then dried 
(Na2SO4, 15 min ) and concentrated under vacuum to give a pale yellow solid. The 
compound was further purified by recrystallization from benzene and petroleum ether 
(1:3) to give 52.3 g (83%) of acid 9 as an off-white solid, mp 70-72 ºC [lit1 mp 69-71 ºC 
].  IR: 3700-2350, 1707 cm-1; 1H NMR: δ 10-11 (br s, 1 H), 7.57 (dd, J = 7.7, 1.6 Hz, 2 
H), 7.36 (m, 3 H), 2.56 (s, 2 H), 1.41 (s, 6 H); 13C NMR: δ 177.0, 137.7, 131.1, 129.2, 
128.7, 46.7, 46.4, 28.4. 
2,2-Dimethylthiochroman-4-one (10). A 1000-mL three-necked round-bottomed flask, 
fitted with a mechanical stirrer, a condenser and a nitrogen inlet, was charged with 400 
mL of polyphosphoric acid and the acid was heated for 20 minutes to 70 ºC using an oil 
bath.  To the stirred polyphosphoric acid was added 50 g (0.24 mol) of 9 over a period of 
5 minutes, and the resulting dark mixture was stirred at 70 oC for 45 min.  TLC analysis 
was performed after 45 minutes confirmed that the reaction was complete.  [Note:  
Higher temperature or prolonged stirring in polyphosphoric acid led to an increased 
number of impurities].  The reaction mixture was cooled to 0 oC using an ice bath and 
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was carefully added into ice-cold water (1 L). [Caution! This process is extremely 
exothermic.].  The resulting solution was extracted with ether (3 × 600 mL), and the 
combined organic layers were washed with 1 N NaOH (1 × 200 mL) and saturated NaCl 
(1 × 200 mL), then dried (MgSO4, 20 min) and concentrated under vacuum to afford a 
white solid. The compound was recrystallized from ethyl acetate and petroleum ether 
(1:3) to give 36.5 g (80%) of ketone 10 as a white solid, mp 67-68 oC [lit1 mp 66-68 ºC ]. 
IR: 1686 cm-1; 1H NMR: δ 8.10 (dd, J = 7.7, 1.1 Hz, 1 H), 7.39 (td, J = 8.0, 1.6 Hz, 1 H), 
7.22 (d, J = 7.7 Hz, 1 H), 7.16 (td, J = 7.7, 1.1 Hz, 1 H), 2.87 (s, 2 H), 1.47 (s, 6 H); 13C
NMR: δ 194.8, 141.3, 133.6, 129.6, 128.6, 127.5, 124.6, 53.8, 44.6, 28.5.    
2,2-Dimethyl-2H-thiochromene-4-carbonitrile (12). The general procedure Johnson 
and coworkers7 was used. A 250-mL one-necked round-bottomed flask, equipped with a 
magnetic stirrer, a condenser and a nitrogen inlet, was charged with 32.0 g (0.17 mol) of 
ketone 10, along with 19.8 g (25 mL, 0.20 mol, 1.2 eq) of trimethylsilyl cyanide and 40 
mg of anhydrous zinc iodide.  The resulting reaction mixture was stirred at room 
temperature for 24 h under nitrogen at which time TLC analysis indicated the reaction 
was complete.  Trimethylsilyl cyanohydrin 11 was unstable to purification and was used 
directly in the next step.  Spectral data for the crude product were: IR: 2210 (weak) cm-1; 
1H NMR: δ 7.70 (dd, J = 7.7, 1.6 Hz, 1 H), 7.28-7.10 (complex, 3 H), 2.53 (d, J = 14.0 
Hz, 1 H), 2.47 (d, J = 14.0 Hz, 1 H), 1.54 (s, 3 H), 1.49 (s, 3 H), 0.22 (s, 9 H); 13C NMR: 
133.4, 132.0, 129.5, 129.3, 127.8, 125.3, 121.6, 69.9, 51.5, 41.4, 31.3, 31.0, 1.2.   
In a 500-mL, three-necked, round-bottomed flask, fitted with a magnetic stirrer, a 
reflux condenser, an addition funnel and a drying tube was placed crude trimethylsilyl 
cyanohydrin 11 dissolved in 200 mL of benzene containing 10 mL of pyridine.  Then 
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33.5 g (20 mL, 0.22 mol) of phosphorus oxychloride was cautiously added dropwise with 
stirring.  The reaction mixture was refluxed for 4 h at which time TLC analysis indicated 
the reaction was complete. The reaction mixture was carefully poured into 500 g of ice 
and extracted with ether (3 × 300 mL). The organic layer was washed with water (1 × 
200 mL) and saturated NaCl (1 × 150 mL), then dried (MgSO4, 10 min) and concentrated 
under vacuum. The crude product was further purified by flash chromatography on a 55 × 
5 cm silica gel column using increasing concentrations of ether [5%, 10%, 15%, 25%, 
30%] in hexanes to give 27.5 g (82%) of unsaturated nitrile 12 as a white solid, mp 62-63 
oC.  IR: 2224 cm-1; 1H NMR: δ 7.59 (dd, J = 6.0, 2.7 Hz, 1 H), 7.36-7.18 (complex, 3 H), 
6.56 (s, 1 H), 1.46 (s, 6 H); 13C NMR: δ 146.8, 131.6, 129.7, 127.8, 126.9, 126.7, 126.0, 
117.1, 113.5, 40.9, 28.2.  
2,2-Dimethylthiochroman-4-carbonitrile (13).  Exactly 24.0 g (0.12 mol) of 
unsaturated nitrile 12, dissolved in dry ethanol (150 mL), was placed in a 500-mL three-
necked round-bottomed flask, fitted with magnetic stirring, a reflux condenser and a 
nitrogen inlet.  The reaction mixture was heated for 10 min to effect solution.  To the 
warm solution 2.25 g (0.06 mol) of sodium borohydride was slowly added in small
portions, and refluxing was continued for 45 min. The reaction mixture was evaporated 
under vacuum and purified by flash chromatography on a 25-cm × 4-cm silica gel olumn 
using ether:hexanes (1:1) to give 22.3 g (92%) of  saturated nitrile 13 as a white solid, mp 
62-63 oC. IR: 2243 cm-1; 1H NMR: δ 7.51 (d, J = 7.1 Hz, 1 H), 7.24-7.10 (complex, 3 H), 
4.12 (dd, J = 11.0, 5.2 Hz, 1 H), 2.35 (dd, J = 13.7, 5.2 Hz, 1 H), 2.21 (dd, J = 13.7, 11.0 
Hz, 1 H), 1.47 (s, 3 H), 1.44 (s, 3 H); 13C NMR: δ 133.5, 128.6, 128.4, 127.7, 126.4, 
125.1, 120.7, 41.9, 41.7, 30.9, 29.9, 29.4.  
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2,2,4-Trimethylthiochroman-4-carbonitrile (14). A 500-mL three-necked round-
bottomed flask, equipped with magnetic stirring, a reflux condenser ad a nitrogen inlet, 
was charged with 5.19 g of NaH (60% mineral oil suspension).  The solid was washed 
with hexane (3 × 50 mL) to remove the mineral oil, and the remaining 3.11 g (0.13 mol) 
of NaH was suspended in 50 mL of dry DMF.  The resulting suspension was chilled to 0 
ºC (ice bath), and 22.0 g (0.11 mol) of nitrile 13, in dry DMF (50 mL) was added 
dropwise (10 min). The ice bath was removed, and the resulting dark brown mixture was 
stirred at room temperature for 30 min.  To the stirred solution was added dropwise 16.9 
g (7.4 mL, 0.12 mol) of methyl iodide over a period of 15 min.  The resulting pale white 
reaction mixture was stirred for an additional 30 min, and was then carefully quenched by 
addition of 25 mL of saturated NH4Cl.  The mixture was extracted  with ether (3 × 200 
mL).  The combined organic layers were washed with saturated NaCl (1 × 200 mL), dried 
(MgSO4, 10 min) and concentrated under vacuum to give 21.1 g (90%) of 13 as a pale 
yellow solid, mp 64-65 oC. IR: 2231 cm-1; 1H NMR: δ 7.56 (m, 1 H), 7.20-7.14 (complex, 
3 H), 2.52 (d, J = 14.5 Hz, 1 H), 2.14 (d, J = 14.5 Hz, 1 H), 1.80 (s, 3 H), 1.59 (s, 3 H), 
1.44 (s, 3 H); 13C NMR: δ 132.8, 131.7, 128.7, 128.5, 128.2, 125.6, 124.5, 51.3, 41.4, 
34.8, 30.8, 30.6, 28.2. 
2,2,4-Trimethylthiochroman-4-carboxylic acid (15). A 500-mL one-necked round-
bottomed flask, equipped with magnetic stirring, a reflux condenser ad a nitrogen inlet, 
was charged with 20.0 g (0.09 mol) of nitrile 14, along with 200 mL of 50% aqueous 
H2SO4.  The solution was heated at 100 ºC and, after approximately 60 minutes, the 
reaction mixture turned from a turbid solution to a completely clear solution.  Heating 
was continued for an additional 60 minutes during which time the reaction mixture once 
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again became a turbid suspension.  TLC analysis indicates that the reaction was 
complete.  The reaction mixture was then cooled to room temperature, slowly poured into 
a 600-mL beaker containing 250 g of ice and extracted with ether:ethyl acetate (1:1, 3 × 
200 mL). The combined organic layers were washed with water (1 × 150 mL) and 
saturated NaCl (1 × 200 mL), then dried (MgSO4, 10 min) and concentrated under 
vacuum to give 19.5 g (90%) of 15 as a pale yellow solid, mp 136-137 ºC. The solid was 
spectroscopically pure and was used in the next step without additional purification. IR: 
3680-2360, 1699 cm-1; 1H NMR: δ 10.29 (br s, 1 H), 7.41 (m, 1 H), 7.22-7.14 (complex, 
3 H), 2.82 (d, J = 14.3 Hz, 1 H), 1.81 (d, J = 14.3 Hz, 1 H), 1.66 (s, 3 H), 1.43 (s, 3 H), 
1.31 (s, 3 H); 13C NMR: δ 183.2, 136.6, 134.2, 128.7, 128.4, 127.3, 125.2, 50.5, 47.4, 
42.6, 32.6, 29.4, 27.8.   
(2,2,4-Trimethylthiochroman-4-yl)methanol (16). A 500-mL three-necked round- 
bottomed flask, fitted with magnetic stirring, a reflux condenser and a nitrogen inlet, was 
charged with 18.0 g (0.08 mol) of acid 15 along with 150 mL of dry THF and the mixture 
was stirred at room temperature to dissolve the acid.  To the resulting solution, 5.78 g 
(0.15 mol, 2 eq) of lithium aluminium hydride was slowly added in small portions with 
stirring, and the reaction was allowed to stir for 4 h.  [Caution! Frothing is a problem if 
the added portions of lithium aluminium hydride are too large].  The resulting gray 
suspension was slowly quenched with 20 mL of 10% sodium hydroxide solution. The 
reaction mixture turned into a turbid white solution, which slowly became a white 
precipitate. The solid was removed by filtration through Celite® and the filtrate was 
concentrated under vacuum. The crude product was purified by flash chromatography on 
a 20-cm × 4-cm silica gel column using 40% ethyl acetate in hexanes to give 14.7 g 
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(87%) of  16 as a pale yellow oil.  IR: 3378 cm-1; 1H NMR: δ 7.36 (m, 1 H), 7.16-7.08 
(complex, 3 H), 3.60 (d, J = 10.8 Hz, 1 H), 3.56 (d, J = 10.8 Hz, 1 H), 2.38 (d, J = 14.0 
Hz, 1 H), 1.78 (d, J = 14.0 Hz, 1 H), 1.43 (s, 3 H), 1.41 (s, 3 H), 1.40 (s, 3 H), 1.40 (br s, 
1 H); 13C NMR: δ 138.2, 134.6, 128.6, 127.2, 126.5, 125.1, 72.0, 49.3, 41.8, 40.7, 31.3, 
30.6, 27.2.    
(2,2,4-Trimethylthiochroman-4-yl)methyl acetate (17). A 250-mL one-necked round-
bottomed flask was charged with 14.0 g (0.06 mol) of alcohol 16, along with 7.7 g (0.06 
mol) of 4-dimethylaminopyridine dissolved in 100 mL of dichloromethane.  Then 7.0 g 
(6.5 mL, 0.07 mol) of acetic anhydride dissolved in 5 mL of dichloromethane w s added 
slowly to the solution over a period of 5 min at room temperature. The reaction mixture 
was stirred at room temperature for 3 h at which time TLC analysis confirmed that the 
reaction was completel.  The reaction mixture was diluted with dic loromethane (1 × 100 
mL) and washed with 2 M HCl (1 × 150 mL), water (1 × 200 mL) and saturated NaCl (1 
× 175 mL) then dried (MgSO4, 10 min) and concentrated under vacuum to give 16.3 g 
(98%) of 17 as a dark yellow oil.  IR: 1742 cm-1; 1H NMR: δ 7.35 (m, 1 H), 7.17-7.07 
(complex, 3 H), 4.18 (d, J = 11.0 Hz, 1 H), 4.14 (d, J = 11.0 Hz, 1 H), 2.23 (d, J = 14.3 
Hz, 1 H), 2.03 (s, 3 H), 1.86 (d, J = 14.3 Hz, 1 H), 1.42 (2 s, 6 H), 1.41 (s, 3 H); 13C 
NMR: δ 171.0, 138.0, 133.9, 128.5, 127.2, 126.7, 125.1, 71.9, 49.6, 41.6, 38.9, 31.3, 
31.2, 27.3, 20.9. 
(2,2,4-Trimethyl-6-nitrochroman-4-yl)methyl acetate (18). A 250-mL three-necked 
round-bottomed flask, equipped with magnetic stirring, an addition funnel and a nitrogen 
inlet was charged with 10.0 g (0.04 mol) of acetate 17 dissolved in 25 mL of freshly 
distilled acetic anhydride. The solution was cooled to −5 ºC (ice/salt bath) and a cold 
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solution of 3.4 mL of concentrated nitric acid in 8.1 mL of acetic anhydride was added 
drop-wise over 10 min.  The reaction was stirred at −5 ºC for 90 min, then diluted with 
250 mL of ether and washed with saturated NaHCO3 (1 × 100 mL).  The NaHCO3 wash 
was back extracted with 50 mL of dichloromethane, and the combined organic layers 
were washed with water (1 × 150 mL) and saturated NaCl (1 × 100 mL) then dried 
(MgSO4, 10 min) and concentrated under vacuum. The crude product was purified by 
flash chromatography on a 40-cm × 2-cm silica gel column using increasing 
concentrations of ethyl acetate [5%, 10%, 25%, 50%] in hexanes to give 2.3 g ( 0%) of 
18 as a viscous yellow oil.  IR: 1743, 1516, 1340 cm-1; 1H NMR: δ 8.29 (d, J = 2.2 Hz, 1 
H), 7.95 (dd, J = 8.2, 2.2 Hz, 1 H), 7.28 (d, J = 8.2 Hz, 1 H), 4.20 (d, J = 11.0 Hz, 1 H), 
4.11 (d, J = 11.0 Hz, 1 H), 2.23 (d, J = 14.3 Hz, 1 H), 2.05 (s, 3 H), 1.92 (d, J = 14.3 Hz, 
1 H), 1.52 (s, 3 H), 1.47 (s, 3 H), 1.44 (s, 3 H); 13C NMR: δ 170.7, 145.1, 144.1, 138.9, 
128.6, 122.8, 121.6, 71.3, 48.9, 42.6, 39.1, 31.3, 31.2, 27.3, 20.8.  
(6-Amino-2,2,4-trimethylthiochroman-4-yl)methyl acetate (19).  The procedure of 
Bunce and co-workers was used.8  In a 25-mL three-necked round-bottomed flask, 
equipped with magnetic stirring, a reflux condenser and a nitrogen inlet, was placed a 
mixture of  0.50 g (1.62 mmol) of nitro acetate 18, 8 mL of acetic acid, acetic acid (8 mL) 
and 0.27 g (4.85 mmol, 3 eq) of iron powder (>100 mesh) which was added under reflux 
and stirred at 115 ºC (oil bath) until TLC analysis indicated complete consumption of 
starting material (ca 15 min).  The crude reaction was cooled, transferred to a separatory 
funnel containing 50 mL of water and extracted with ether (3 × 25 mL).  The combined 
ether layers were washed with water (1 × 50 mL), saturated NaHCO3 (3 × 100 mL) and 
saturated NaCl (1 × 75 mL) then dried (MgSO4) and concentrated under vacuum to give 
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0.43 g (95%) of 19 as pale brown liquid.  IR: 3451, 3365, 3224, 1734 cm-1; 1H NMR: δ 
6.97 (d, J = 8.2 Hz, 1 H), 6.73 (d, J = 2.2 Hz, 1 H), 6.51 (dd, J = 8.2, 2.2 Hz, 1 H), 4.19 
(d, J = 11.0 Hz, 1 H), 4.14 (d, J = 11.0 Hz, 1 H), 3.61 (br s, 2 H), 2.19 (d, J = 14.3 Hz, 1 
H), 2.06 (s, 3 H), 1.80 (d, J = 14.3 Hz, 1 H), 1.39 (s, 3 H), 1.38 (s, 3 H), 1.37 (s, 3 H); 13C 
NMR: δ 171.1, 144.1, 139.4, 129.6, 122.2, 114.4, 114.2, 71.8, 49.8, 41.6, 39.1, 31.1, 
29.6, 27.1, 20.9. 
(6-Amino-2,2,4-trimethylthiochroman-4-yl)methanol (20). A 25-mL three-necked 
round-bottomed flask, equipped with magnetic stirring, a reflux condenser a d a nitrogen 
inlet, was charged with 150 mg (0.54 mol) of amino acetate 19 along with 2 mL of 10% 
NaOH.   The flask was suspended in an oil bath at 90 ºC for 30 min.  After 30 minutes, 
TLC analysis indicated the reaction was complete.  The reaction m xture was cooled to 
room temperature, adjusted to pH 9 with 1 M HCl and extracted with ether (2 × 25 mL). 
The combined ether layers were washed with water (1 × 25 mL) and saturated NaCl (1 × 
25 mL), then dried (MgSO4, 10 min) and concentrated under vacuum to give 120 mg 
(94%) of 20 as a viscous brown oil.  IR: 3344 cm-1; 1H NMR: δ 6.96 (d, J = 8.2 Hz, 1 H), 
6.73 (d, J = 2.2 Hz, 1 H), 6.49 (dd, J = 8.2, 2.2 Hz, 1 H), 3.60 (d, J = 11.0 Hz, 1 H), 3.55 
(d, J = 11.0 Hz, 1 H), 2.90 (br s, 2 H), 2.30 (d, J = 14.3 Hz, 1 H), 1.72 (d, J = 14.3 Hz, 1 
H), 1.39 (s, 3 H), 1.36 (s, 3 H), 1.34 (s, 3 H) 1.25 (br s, 1 H); 13C NMR: δ 144.0, 139.7, 
129.7, 123.1, 114.4, 114.3, 71.9, 49.9, 41.8, 41.0, 31.2, 30.4, 27.1. 
General Procedure for Preparation of the Thiourea. N-[3,4-Dihydro-(4-
methylacetate)2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-N’ -(4-nitrophenyl) 
thiourea (4).     The general procedure of Berlin and coworkers5 was used.  A 25-mL 
one-necked round-bottomed flask, equipped with magnetic stirring, an addition funnel 
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and a nitrogen inlet, was charged with a solution 79 mg (0.28 mmol) of amino acetate 19 
in 3 mL of dry THF, and the flask was cooled to 0 ºC (ice bath).  To this was added a 
solution of 54 mg (0.30 mmol) of 4-nitrophenylisothiocyanate in 3 mL of dry THF over 5 
min.  After the addition, the reaction mixture was allowed to warm to room temperature 
and stirring was continued for 24 h. The solvent was evaporated and the residue was 
purified using flash chromatography on a 10-cm × 2-cm silica gel column using 70% 
ether in hexanes to give 4 as pale yellow solid.  The yellow solid was further 
recrystallized using dichloromethane:pentane (1:3) to give 114 mg (88%) of 4 as a yellow 
solid, mp 155-156 ºC.  IR: 3291, 1727 cm-1; 1H NMR: δ 8.35 (br s, 1 H), 8.20 (d, J = 9.0 
Hz, 2 H), 7.95 (br s, 1 H), 7.83 (d, J = 9.0 Hz, 2 H), 7.41 (d, J = 2.2 Hz, 1 H), 7.18 (d, J = 
8.2 Hz, 1 H), 6.99 (dd, J = 8.2, 2.2 Hz, 1 H), 4.53 (d, J = 11.0 Hz, 1 H), 3.74 (d, J = 11.0 
Hz, 1 H), 2.48 (d, J = 14.3 Hz, 1 H), 1.87 (s, 3 H), 1.86 (d, J = 14.3 Hz, 1 H), 1.45 (s, 6 
H), 1.40 (s, 3 H); 13C NMR: δ 179.6, 170.9, 144.6, 144.5, 139.3, 135.4, 132.2, 129.7, 
126.0, 124.2, 124.1, 123.9, 72.6, 49.5, 42.1, 39.9, 30.9, 29.5, 27.3, 20.8.  Anal. Calcd. for 
C22H25N3O4S2: C, 57.49; H, 5.48; N, 9.14; S, 13.95.  Found: C, 57.63; H, 5.48; N, 9.09; 
S, 13.83. 
N-[3,4-Dihydro-(4-hydroxymethyl)2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-N’ -(4-
nitrophenyl)thiourea (5).  This compound (97 mg, 82%) was prepared as above from 66 
mg (0.28 mmol) of 20 and 54 mg (0.30 mmol) of 4-nitrophenylisothiocyanate. The 
product was purified by recrystallization from methanol, mp 154-155 ºC.  IR: 3435 cm-1; 
1H NMR (CD3OD): δ 8.24 (d, J = 9.0 Hz, 2 H), 7.83 (d, J = 9.0 Hz, 2 H), 7.56 (d, J = 2.2 
Hz, 1 H), 7.18 (dd, J = 8.2, 2.2 Hz, 1 H), 7.13 (d, J = 8.2 Hz, 1 H), 3.63 (d, J = 11.0 Hz, 1 
H), 3.57 (d, J = 11.0 Hz, 1 H), 2.36 (d, J = 14.3 Hz, 1 H), 1.82 (d, J = 14.3 Hz, 1 H), 1.44 
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(s, 3 H), 1.40 (s, 6 H), the 2 NH and 1 OH were exchanged; 13C NMR (CD3OD): δ 181.5, 
147.2, 144.9, 141.5, 136.8, 133.2, 129.7, 125.3, 125.2, 123.7, 123.6, 72.2, 50.2, 42.9, 
42.0, 31.6, 31.1, 27.7.  Anal. Calcd for C20H23N3O3S2: C, 57.53; H, 5.55; N, 10.06; S, 
15.36.  Found C, 57.45; H, 5.52; N, 10.05; S, 15.23. 
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